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ABSTARCT 
 Agents that exert their effects in the central nervous system are among the most 
important in medicinal practice.  One in three Americans will have a disease affecting the 
nervous system in their lifetime exceeding $600 billion dollars per year in cost.  Side effects, 
lack of efficacy, and lack of selectivity hamper their clinical use.  Thus, additional agents need to 
be developed and new chemical tools are needed to further elucidate the mechanisms of CNS 
disorders.  
 Salvinorin A, the main component of the hallucinogenic mint Salvia divinorum is a novel 
and potent κ opioid (KOP) receptor agonist that is the first naturally occurring opioid ligand that 
lacks a basic nitrogen atom.  In efforts to attain a greater understating for the interatctions of the 
furan ring binding pocket within the KOP receptor, several modifications were made at the C-13 
position of the salvinoirn A scaffold.  Pharmacological evaluations of the synthesized analogues 
indicated that there is a prefferred orientation of the furan O-atom in that the cis alkene analogue 
(236) had a greater binding affinity than the trans alkene analogue (235).  However, despite its 
similar binding affinity to that of salvinorin A the cis analogue showed to 34-fold less active than 
salvinorin A.   
 It was also hypothesized that a combination of the salvinorin A scaffold with a similar 
terpene based family of marine natural products, namely the nakijiquinones, will alter the 
biological activity of salvinorin A and yield a useful biological probe.  With this hypothesis in 
mind, several quinone containing salvinoirn A analogues were synthesized and upon 
pharmacological evaluation it was determined that these analogues did not exhibit any significant 
KOP receptor activity, indicative of a change in the biological activity of the salvinorin A 
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scaffold.  Furthermore, these analogues proved to be the first salvinorin A based analogues that 
exhibit antiproliferative activity. 
 In the search for novel CNS biological probes, the aminoalkylindole class of synthetic 
cannabinoids was also investigated.  Due to its cannabinoid 1 receptor (CB1R) antagonist 
activity, JWH-073-M4 was shown to be a valuable lead molecule.  The hypothesis was that the 
design and synthesis of JWH-073-M4 based analogues would lead to compounds with dual 
CB1R antagonist/CB2R agonist activity that may have potential as alcohol abuse therapies.  
Upon in vitro pharmacological investigation, two analogues 461 and 444 were shown to have the 
most promise and were further subjected to in vivo pharmacological evaluation in animal models 
of alcohol abuse, namely ethanol self-administration and ethanol conditioned place preference.  
From these studies it was determined that analogues 461 and 444 exhibit dual CB1R 
antagonist/CB2R agonist activity and represent potential leads in the ongoing search for novel 
alcohol abuse therapies.   
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CHAPTER 1: INTRODUCTION 
 
Drug Development for CNS Disorders 
 Disorders of the central nervous system (CNS) represent some of the most devastating 
and widespread disorders worldwide.  Presently over 1.5 billion people worldwide are affected 
by disorders of the CNS.1  This accounts for a third of the global disease burden.1  It has been 
projected that within the first 50 years of this millennium, the worldwide population of persons 
older than 65 years will raise from 6.9% of the total population to a staggering 15.9%.2  This 
increase will equal to an extra billion elderly individuals worldwide, thus increasing the need for 
CNS pharmaceuticals for the treatment of chronic neurological disorders.  It was estimated by 
the Pharmaceutical Research and Manufacturers of America Foundation (PhRMA) that the cost 
of serious mental illnesses has reached $317 billion annually in the Unites States alone, which 
includes health care expenses, disability benefits and lost wages.3  The numbers are expected to 
increase considerably over the next few decades.  For instance, the occurrence of Alzheimer’s 
disease (AD) will increase by over 100% in the United States and Western Europe and by more 
than 300% in Latin America, China, and India.3, 4   
Despite the growing need for CNS therapeutics, the success rate for CNS drug candidates 
in the clinic is relatively low compared to the industry average across other therapeutic areas.  
Only 8% of CNS drugs that enter clinical trials are approved by the Food and Drug 
Administration (FDA).5  Some of the reasons for the poor representation of CNS therapeutics on 
the market are the immense complexity of the CNS itself, as well as the longer development time 
needed for the candidates to reach the drug market.4, 6  The extended period needed for the 
development of a CNS drug candidates is due to the utter complexity of the brain; the 
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predisposition of CNS drugs to cause unwanted CNS-mediated side effects, and the presence of 
the blood-brain barrier (BBB).4 
 One of the greatest challenges that CNS researches face in the development of CNS 
therapeutics is the vast complexity of the human brain.  An inter-connected network of circuits 
and subcircuits connects over 100 billion neurons and a trillion glial cells whose actions are 
mediated through electrochemical transmission across 1014 synapses.6  Additional factor to the 
decreased success of CNS therapeutics is the challenge of penetration through the BBB in order 
to reach their therapeutic target.  Only about 2% of CNS drug therapeutics can cross the BBB 
and reach their target within the CNS, which greatly constrains their potential of becoming 
successful in the clinic.7   
 
Challenges in CNS Drug Discovery 
 There are several protective barriers around the CNS that shield the brain from foreign 
xenobiotics, while maintaining homeostasis.  Two of those include the BBB and the blood-
cerebrospinal-fluid barrier (BCSFB).8  The brain requires a vast amount of energy that comes in 
the form of oxygen and glucose and is delivered by a great network of blood vessels.  These 
blood vessels are comprised of endothelial cells that contain tight intercellular junctions that 
control any passage of foreign substances through the BBB making it very difficult for CNS 
therapeutics to reach their intended target.  The presence of these tight junctions leads to minimal 
paracellular transport and negligible pinocytosis making it very challenging for small molecules 
to pass through.9, 10  As a second line of defense aside from the tight junctions, these cells are 
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also equipped with uptake and efflux transporters.8  The most prevalent efflux transporter is the 
P-glycoprotein (P-gp) transporter.  Pgp, a 170 kDa protein, is a member of the adenosine  
	  
triphosphate (ATP)-binding cassette (ABC) superfamily and it represents an additional obstacle 
to small molecules attempting to enter the CNS and obtain appreciable concentration at their 
target site (Figure 1).11 
 There are several concepts that have to be taken into account for successful brain 
penetration and CNS drug discovery.  One of the essential concepts in in vivo pharmacology is 
the free drug hypothesis, which consists of two parts.12  The first part of the hypothesis 
conditions that pharmacological activity is directly correlated to the free (unbound) drug 
concentration at the site of action, and the second part states that when no drug transporters are 
present, the free drug concentration at state is equal across all biomembranes.7, 12  Because of the 
difficulty of measuring free drug concentrations in the brain, several surrogate measures have 
been employed to estimate the free drug concentration and use it to elucidate the 
pharmacological effect.13  The second concept of importance to brain penetration is the unbound 
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brain-to-plasma ratio (Kp,uu).  This parameter is of importance because with it one can evaluate 
the presence of distribution equilibrium between blood and brain compartments and because it is 
also reflective of the collective influence of BBB passive permeability and transporters.7  When a 
compound is at a distribution equilibrium between plasma and brain compartments, the Kp,uu 
value is near 1 and this is indicative of a compound that has good passive permeability and is not 
a substrate for transporters.7  If a compound has a value that is significantly less than 1 that 
indicates that the compound in question is a substrate for efflux transporters.  On the other hand, 
when a compound has a Kp,uu value that is higher than 1 it is suggestive of a compound that is 
involved in active process and is a substrate for influx transporters.7  When evaluating the 
unbound brain-to-plasma ratio, one should refrain from using total brain-to-plasma ratio because 
this ratio is mainly directed by nonspecific binding to lipids and/or proteins in the plasma and 
brain and it can lead to misleading conclusions regarding the biological activity.9  The third 
concept of importance to brain penetration is the fraction unbound (fu).  This measurement is 
valuable in CNS drug discovery because it allows for the conversion of total drug concentration 
to unbound concentration in plasma or brain and it does not modify the unbound drug 
concentration in vivo for orally administered drugs.7  BBB passive permeability (Papp) is the 
fourth concept of importance to brain penetration in CNS drug discovery.  It is characterized by 
the rate across the BBB due to passive diffusion but not the extent of brain penetration.7  Rapid 
establishment of distribution equilibrium between plasma and brain compartments is anticipated 
when BBB passive permeability is high; however this high BBB permeability is not indicative of 
a high unbound drug concentration within the brain.7  In contrast, a low BBB passive 
permeability reduces the extent of brain penetration, which is due to limited diffusion absorption 
into the brain.  However, when the Papp is extreme, that could be detrimental for CNS drugs 
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because a high BBB permeability is indicative of high lipophilicity, which could lead to non-
specific binding, toxicity, rapid metabolism and low unbound drug concentration in the brain.12, 
14  Efflux ratio (ER) is the fifth and last concept of importance to brain penetration and CNS drug 
discovery.  It is reflective of the potential of a compound to be pumped out of the brain by BBB 
efflux transporters like P-gp.  It is very difficult to predict the unbound drug concentration of an 
efflux transporter substrate in the brain, thus making it dangerous for the advancement of such 
compound further in the drug discovery process.7   
 Understanding the challenges that are present in CNS drug development and discovery 
will allow us to better design molecules that will have a higher degree of success in the clinic.  In 
addition, the concepts discussed represent critical parameters that may not be overlooked when 
designing CNS active molecules.  
 
Target Product Profile of a CNS Drug Candidate 
 In order for successful CNS drug discovery, several physicochemical properties have to 
be taken into account when designing molecules.  The physicochemical and biological properties 
of a molecule play a fundamental role in the successful absorption, distribution, metabolism, and 
excretion (ADME) profile of a molecule.  Table 1 lists the various physicochemical properties 
that should be considered in CNS drug development and are based on CNS orally active drugs. 
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Table 1.  List of physicochemical properties for a CNS drug candidate.6 
Physicochemical properties of a CNS drug 
candidate 
Target profile 
Desired potency at molecular target (nM) <10 
Selectivity over other targets >30 
Molecular weight (D) <450 
Aqueous solubility >60µg/mL 
pKa Neutral or basic (7.5-10.5) 
Lipophilicity clogP < 4 
Presence of N-atoms At least one 
Number of linear chains <7 
Volume of molecule 740-940 Å3 
Polar surface area <70 Å2 
H-bond donors <3 
H-bond acceptors <7 
Molecular flexibility <8 rotatable bonds 
Protein binding KD for serum albumin binding <30 µM 
Metabolic stability >80% remaining after one hour 
Solvent accessible surface area 460-580 Å2 
CYP 450 enzyme inhibition <30% at 30 µM 
CYP2D6 metabolism Minimal 
CYP3A4 induction No induction 
P-gp activity No substrate activity 
BBB passive permeability High: Papp >10 x 10-6 cm/s 
Moderate: Papp 2-10 x 10-6 cm/s 
Pharmacokinetics %F/Clp/MRT 
Excellent: >50/<25% QH/2-4 hours 
 Viable: %F 10-50/25-75% QH/0.5-2 hours 
hERG inhibition (hERG IC50 and effective 
unbound plasma concentration) 
>30 fold 
 
The molecular weight (MW) of CNS drugs was seen to be significantly reduced as 
compared to the MW of non-CNS therapeutics.  It has been suggested that the MW should be 
below 450 Da with the objective of achieving acceptable brain penetration and to facilitate oral 
absorption.15, 16  Lipophilicity is an important characteristic of a drug molecule and it directly 
relates to the ability of a molecule to cross the BBB and reach its target.  Hansch and coworkers 
found that for several classes of CNS drugs, optimal BBB penetration is achieved when the 
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clogP is in the range of 1.5-2.7.17  Hydrogen-bond (H-bond) acceptors are defined as 
heteroatoms that possess one or more lone pairs of electrons and that the ideal number of H-bond 
acceptors is less than 7.6, 18  On the other hand, H-bond donors are defined as heteroatoms with 
one or more hydrogen atoms and the ideal number of H-bond donors for viable BBB penetration 
is less than 3.6, 18  It was reported that a sum of all heteroatoms in a molecule should be less than 
10 for suitable CNS penetration.19  Increased hydrogen bonding both through H-bond donors and 
H-bond acceptors such as the hydrogen bonding seen in larger peptides is detrimental to CNS 
penetration and decreases BBB passive diffusion.20  The degree of polarity of a given molecule 
can also be predicted through polar surface area (PSA) calculations and it has been used as a 
predictor of BBB penetration by many CNS drug discovery programs.  Generally, CNS active 
drugs tend to have lower PSA (60-70 Å2) when compared to other classes of therapeutics.16, 21  
The flexibility of a drug molecule refers to the number of rotatable bonds present and it goes 
along with another parameter, namely the molecular volume, which takes into account all of the 
accessible conformations available under physiological conditions.15  The ideal molecular 
volume for a CNS active compound is in the range of 740-970 Å3 and the ultimate number for 
rotatable bonds in a molecule is less than 8.6, 15  There is a well acknowledged fact regarding pKa 
of CNS active compounds, which is that CNS active molecules have a basic center.22  From an 
analysis of 119 marketed CNS drugs and 108 Pfizer CNS drug candidates, it was determined by 
Wager and coworkers that the mean pKa for a CNS active compound is 8.4.22  As mentioned 
above, P-gp efflux transporters represent one of the challenges in BBB penetration and delivery 
of drug to target.  Because of its role as a gatekeeper, P-gp is very promiscuous against numerous 
chemical structures.  It has been very difficult to foresee whether a compound will be a P-gp 
substrate; however a rule of 4 was formulated to predict P-gp efflux liability.23  The rule of 4 
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suggests that a compound with MW of less than 400 Da, total number of nitrogen and oxygen 
atoms less than 4, and whose pKa is less than 8 will not be a P-gp substrate.23  Although some 
molecules that are CNS active may exceed one of these criteria, the rule of 4 may be used as an 
indicator of approaches that can be applied to decrease efflux by P-gp.   
Rapid metabolism by the liver and intestines represents one of the main reasons for 
compounds not achieving satisfactory systemic levels.  Low metabolic stability of a compound is 
indicative of high clearance rates and short half-life.  The ideal metabolic stability is considered 
to be greater than 80% remaining at 60 minutes when evalated in a microsome test system.15  
The major metabolizing family of enzymes responsible for biotransformation of drugs and their 
pharmacological and toxicological effects is the cytochrome P450 superfamily.  There are 
several isoforms that are responsible for the majoring of xenobiotic metabolism and they include 
CYP3A4, CYP2C9, CYP2D6, CYP1A2, and CYP2C19.24  Concentration between 10 and 30 µM 
of drug that inhibits the metabolic activity by less than 50% is considered an acceptable level of 
CYP inhibition.6, 15  In order for a compound to be a successful CNS drug and to maximize oral 
absorption it must have no significant CYP2D6 metabolism and not be an inducer of CYP3A4.15  
Being highly protein bound is unfavorable for a CNS drug because high protein binding will 
likely affect efficacy.  Human serum albumin (HSA) and α1-acid glycoprotein (AGP) are the 
plasma proteins most often bound by weakly basic molecules.15  A successful CNS molecule 
should exhibit Kd lower than 30 µM.6  A critical property for the unsuccessful drug discovery of 
any compound is the interference with the human ether-a-go-go related gene (hERG).  This gene 
encodes for a cardiac potassium channel and upon inhibition there is a risk of ventricular 
tachyarrhythmia also known as prolongation of the QT interval or torsade de pointes (TdP).25  In 
order for a compound to avoid interactions with the hERG channel, a greater than 30-fold margin 
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between hERG IC50 and the drugs effective plasma concentration must be achieved.25  Passive 
apparent permeability (Papp) is a measure of the permeability across the BBB and it is usually 
attained using the MDCK cell line, which is an epithelial cell line that spontaneously forms 
confluent polarized monolayer of cells.22  A highly permeable molecule is considered to have 
Papp >10 x 10-6 cm/s, whereas a moderately permeable molecule has a passive apparent 
permeability of 2.5 <Papp ≤ 10 x 10-6 cm/s.22 
The target product profile for a CNS drug candidate consists of complex parameters all of 
which can be applied in the modification and SAR of drug candidates with the intention of 
enhancing the successful development of future CNS therapeutics.  
 
Central Nervous System Disorders and Treatments 
 The quality of life for those affected by CNS disorders is profoundly reduced.1  It has 
been projected than by year 2020, the total global burden of CNS disorders will rise from 11% 
seen in 1990 to 15%, a value that represents a proportionally larger increase than that projected 
for cardiovascular disease.26  CNS disorders can be divided into two broader categories: CNS 
disorders that cause neurodegeneration and CNS disorders that do not cause neurodegeneration.1  
 Neurodegeneration causing CNS disorders are characterized by the gradual and 
progressive loss of cells from the spinal cord and brain and include chronic neurodegenerative 
disorders that cause dementia, Alzheimer’s disease, multi-infarct dementia, frontotemporal lobar 
degeneration, Lewy body dementia, Parkinson’s disease, amyotrophic lateral sclerosis and 
Huntington’s disease.1  In this group of CNS disorders are also demyelinating disorders such as 
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multiple sclerosis.  Additionally, acute neurodegenerative disorders of the CNS are furthermore 
part of this group and include stroke, traumatic brain and spinal cord injury, as well as infectious 
meningitis and meningoencephalitis.1   
 CNS disorders that do not cause prominent neurodegeneration represent a diverse group 
of disorders and include obesity, neuropathic pain, as well as acute and chronic pain, migraine, 
anxiety, depression, bipolar disorder, schizophrenia, epilepsy, drug abuse, substance abuse, 
attention deficit hyperactivity disorder (ADHD), insomnia, and autism.1 
 
Neurodegenerative CNS disorders 
Alzheimer’s disease 
  The International Alzheimer’s Disease Society has reported that approximately 36 
million people worldwide were living with dementia in 2010.27  Dementia is detrimental to the 
people that suffer from it as well as their caregivers and families.  It represents one of the major 
causes of disability and dependence among the aging population worldwide.28  This number of 
people suffering is expected to increase to 66 million by the year 2030 and staggering 115 
million people by the year 2050.27  One of the most common causes of dementia is Alzheimer’s 
disease.  Alzheimer’s disease (AD) was first described by Dr. Alois Alzheimer in 1907.29  This 
form of dementia is characterized by several pathological markers in the brain such as formation 
of amyloid plaques, neurofibrillary tangles, and neuronal cell loss.30  Hardy and Higgins 
suggested the amyloid cascade hypothesis that states that the deposition of amyloid plaques is the 
causative agent of Alzheimer’s pathology.30  The neurofibrillary tangles, cell loss, dementia 
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follow as a direct consequence of the amyloid plaque deposition.30  Several treatments for AD 
are currently available on the market.  Table 2 includes the current treatments for AD and their 
mechanism of action and Figure 2 contains the structures of the current AD treatments.31   
Table 2.  Current Alzheimer’s disease treatments 
Compound Commercial 
name 
Mechanism of 
action 
Effect 
Donepezil Aricept® Acetylcholinesterase 
inhibitor 
Increases cortical acetylcholine (ACh) 
through selective reversible inhibition 
of hydrolysis of acetylcholine by 
acetylcholinesterase (AChE) 
Galanthamine Reminyl® Acetylcholinesterase 
inhibitor 
Increases ACh by reversible, 
competitive inhibition of AChE.  Also, 
acts as an allosteric modulator of 
nicotinic acetylcholine receptors 
Rivastigmine Exelon® Acetylcholinesterase 
inhibitor 
Increases Ach by reversible inhibition 
of AChE. Inhibitor of 
butylcholineserase 
Memantine Ebixa® NMDA glutamate 
receptor inhibitor 
Reduces activity of glutamergic 
system through non-competitive 
inhibition of glutamergic NMDA 
receptors 
 
As represented in Table 2, three out of the four treatments currently available on the 
market are acetylcholinesterase (AChE) inhibitors and they do not specifically target the 
underlying pathology of the disease.  The reason for this is that cholinergic function is 
compromised in AD patients following early damage of basal forebrain cholinergic neurons.32  
Several disease-modifying candidates are currently ongoing clinical trials, however the need for 
novel approaches in treating AD is on the rise.32  
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Parkinson’s disease 
Parkinson’s disease (PD) was first described as a neurological illness by James Parkinson 
in 1817.33  Today, it is the second most common neurodegenerative disease affecting 1% of 
people over 60 years in developed countries.34  Parkinson’s disease employs debilitating 
symptoms that include resting tremors, rigidity, bradykinesia, and postural problems in younger 
patients.35  Degeneration of dopamine neurons in the substantia nigra, as well as alterations to the 
striatum and frontal cortex are believed to be the underlying causes for the symptoms seen in PD 
patients.35  The neurodegeneration observed has been linked to oxidative stress, excitotoxicity, 
apoptosis, inflammation, and mitochondrial dysfunction.33  Manifestation of motor symptoms is 
seen with the degeneration of 60-80% of dopaminergic neurons and is considered a late stage 
diagnosis because the damage of the neurons has already occurred.  There are several treatments 
available on the market for the treatment of PD, however the need for early detection of PD 
development in patients before pronounced loss of neurons still persists.35   
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Table 3.  Currently available representative PD therapies6 
Compound Commercial 
Name 
Mechanism of action Effect 
Levodopa (L-
Dopa)/Carbidopa 
Sinemet® DA precursor/aromatic 
L-amino acid 
decarboxylase 
inhibitor 
Increase dopamine (DA) 
concentration/decrease 
peripheral DA side effects 
Apomorphine Apokyn® Non-selective D1, D2 
receptor agonist 
Increase DA concentration and 
reduction of L-Dopa induced 
dyskinesia 
Trihexyphenidyl Artane® Antimuscarinic  Muscarinic receptor antagonist 
Rasagiline Azilect® MAO-B irreversible 
inhibitor 
Inhibition of the breakdown of 
DA in the mitochondria 
Pramipexole Mirapex® D2, D3, D4 receptor 
agonist 
Restoring DA signals by 
stimulation of underfunctioning 
DA receptors in the striatum 
Tolcapone Tasmar® Cathechol-O-metyl 
transferase inhibitor 
Strengthen dopaminergic 
neurotransmission 
Bromocriptine Parlodel® D2 receptor agonist Activation of DA receptors 
 
Treatments currently (Table 3) present on the market employ several mechanisms of 
action the most common being the use of dopamine (DA) receptor agonists to counteract the 
seen DA loss in PD patients.   
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The most effective treatment in controlling the motor symptoms presented with PD is the drug 
combination Sinimet®, which contains the DA precursor Levodopa (5) and the aromatic-amino 
acid decarboxylase inhibitor Carbidopa (5, Figure 3).35  Other treatments include monoamine 
oxidase inhibitors, such as rasagiline (8).  These inhibitors can be recognized as useful disease-
modifying agents, because of the effect that they have on the stabilization of mitochondria, as 
well as the induction of the expression of neurotrophic factors.36  The present treatments offer 
some comfort and provide symptom relief for patients suffering from PD, nonetheless early 
diagnosis that identifies the development of PD before degeneration arises is necessary.  
 
Amyothrophic Lateral Sclerosis 
 Alongside Alzheimer’s and Parkinson’s disease, Amyothrophic lateral sclerosis (ALS), 
also known as Lou Gehrig’s disease, is one of the major neurodegenerative CNS disorders.37  
ALS is very progressive neurodegenerative disease that leads to the dysfunction and death of 
15 
	  
motor neurons in both the motor cortex and spinal cord.38  One in every 100,000 individuals 
worldwide has been affected by ALS.38  Of those affected, 90% of the cases are classified as 
sporadic (sALS) and the other 10% are classified as familial (fALS).38  ALS is an extremely 
progressive disease with 50% of affected patents dying within 3 years of onset.37  Currently, only 
one drug, riluzole (13, Figure 4) is available on the market for the treatment of ALS (Table 4). 
Table 4.  Currently available treatments for ALS 
Compound Commercial 
Name 
Mechanism of action Effect 
Riluzole Rilutek® Sodium channel blocker Reduction of Ca2+ influx which 
indirectly prevents stimulation of 
glutamate receptors 
 
Riluzole is a neuroprotective drug that slows down the progression of ALS with the 
blockade of voltage-gated sodium channels and NMDA-receptor mediated responses, thus 
preventing excess calcium ion influx into neurons.39, 40  Mutations of the superoxide dismutase 
(SOD) protein have been shown to be the cause of 10-20% of all familial ALS cases.41  
Arimoclomol has shown to delay disease progression and extend the lifespan of mice with a 
SOD mutation, a model for ALS.41  Arimoclomol  (13) is currently in phase III clinical trials as a 
heat-shock protein coinducer.38  Another compound, edaravone (16) a free radical scavenger, is 
also currently in phase III clinical trials.  It was demonstrated that in ALS mouse models it 
slowed disease progression, motor neuron degeneration and reduced abnormal SOD1 
deposition.42  Ceftriaxone (15), a β–lactam antibiotic was shown to increase brain expression of 
the glutamate transporter, GLT1 and its biochemical and functional activity, important features 
because these transporters are important in preventing glutamate neurotoxicity.43  In addition to 
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the agents already discussed cholesterol like compound olesoxime (14), is also currently in 
clinical trials for the treatment of ALS and spinal muscular atrophy.  It was determined that this 
compound targets proteins of the mitochondrial membrane, which in turn prevents permeability 
transition pore opening mediated by oxidative stress.44  Progress has been made and there are 
several agents currently in phase III clinical trials, however further research into the palliative 
care and symptom control is still of significance for the enhancement of the quality of life for 
those patients suffering from ALS.37 
	  
	  
Huntington’s Disease 
 Huntington’s disease (HD) is an autosomal, dominant neurodegenerative disorder that is 
caused by the expression of the anomalous Huntingtin protein.  Huntingtin is a protein that is 
expressed in all humans; however in HD patients this protein contains an atypically lengthened 
polyglutamine region near its N-terminus.45, 46  HD is characterized by very devastating set of 
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symptoms which include progressive motor dysfunction, emotional disturbance, dementia, and 
weight loss.47  The incidence of HD worldwide is 5 to 10 cases per every 100,000 individuals.48  
The symptoms of HD are such that treatment is personalized for each patient and cannot be 
generalized for all individuals affected by HD.49  Currently, there is no cure for HD, but there are 
several agents that can be used to relieve the severity of the symptoms presented with HD (Table 
5).   
Table 5.  Agents used to treat symptoms of HD 
Compound Commercial 
Name 
Mechanism of action Symptom 
Adamantine Symmetrel® NMDA antagonist/DA reuptake 
blocker 
Chorea 
Remacemide Acovia® NMDA antagonist Chorea 
Tetrabenazine Xenazine® VMAT inhibitor Chorea 
Mirtazapine Remeron® α2 adrenergic receptor antagonist Depression 
Selisistat Clinical trials SIRT1 inhibitor Neuroprotection 
Cysteamine 
bitartrate 
RP103/Clinical 
trial 
– – 
 
Chorea is part of a group of neurological disorders, known as dyskinesia, and is 
characterized by uncontrolled involuntary movements of the body and is a symptom of HD.  
Several agents, adamantine (17), ramacemide (18), and tetrabenazine (19) are currently available 
for the treatment of HD chorea as seen in Table 5 and as represented in Figure 5.  Currently, 
there are several agents in clinical trials for the relief of the symptoms of HD.  AMR101 is 
currently in phase III clinical trials and is a pro drug of eicosapantenoic acid.50  Its mechanism of 
action for the treatment of HD is currently unknown.50  Sirtuin1 (SIRT1) is a NAD-dependent 
deacetylase that has been implicated in the deacetylation of huntingtin.51  Selisistat, a candidate 
in phase II clinical trials has been reported to be the first-in-class inhibitor of the SIRT1 
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deacetylase and was demonstrated to possess protective effects against HD in cellular and animal 
models of HD and has also been suggested to increase mutant huntingtin clearance.52  The 
progress with animal models and present symptomatic treatments provide for optimism for 
patients and families affected by HD. 
	  
	  
Non-neurodegenerative CNS Disorders 
Schizophrenia 
 Schizophrenia, a non-neurodegenerative CNS disorder is among the world’s top ten 
causes of long-term disability.53  The incidence of schizophrenia is 0.2-0.4 per every 1000 
individuals, with and onset of the disease in the early adulthood in both men and women.54  
Psychosis, apathy, social withdrawal, and cognitive impairment, hallucinations, delusions 
represent several of the characteristics of this disorder.53  These characteristics lead to impaired 
functioning in everyday life for patents affected by schizophrenia.  Schizophrenia is the most 
incapacitating disorder among all of the psychiatric disorders and it necessitates an unbalanced 
share of mental health service.53  For instance, it was estimated that that the total cost of 
schizophrenia in the United States alone is $62.7 billion, which includes $22.7 billion focused on 
direct healthcare costs.55  Additionally, in the United States the total cost of schizophrenia 
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exceeds the cost of all cancers combined.56  Great advances have been made in the treatment of 
schizophrenia and there are several drugs on the market that are used to treat the symptoms of 
the disease permitting patients to lead more fruitful lives (Table 6). 
Table 6.  Currently available treatments for schizophrenia6 
Compound Commercial 
Name 
Class Mechanism of action 
Quetiapine Seroquel® Atypical antipsychotic DA, 5-HT1A, adrenergic, histamine 
and muscarinic receptor antagonist 
Clozapine Clozaril® Atypical antipsychotic 5-HT and DA receptor antagonist 
Risperidone Riserdal® Atypical antipsychotic DA, 5-HT, adrenaline and 
histamine (H1) receptor antagonist 
Olanzapine Zyprexa® Atypical antipsychotic 5-HT and DA receptor antagonist 
Aripiprazole Abilify® Atypical antipsychotic Partial agonist at DA and 5-HT1A 
receptors and 5-HT2A receptor 
antagonist 
Ziprasidone Geodon® Atypical antipsychotic Non-selective DA, 5-HT receptor, 
and adrenergic receptor antagonist 
Perphenazine – Typical antipsychotic Non-selective D1, D2 receptor 
antagonist 
 
The most widely used drugs for the treatment of schizophrenia are antipsychotic drugs, 
because they decrease the hallucinations and delusions of patient suffering from schizophrenia 
and other neuropsychiatric disorders.57  There are two main classes of antipsychotic drugs, 
typical and atypical.  There are several ways to distinguish and classify the two classes of 
antipsychotic drugs but the most commonly used is the functional classification based on liability 
to cause extrapyramidal side effects (EPS).  The extrapyramidal system is part of the motor 
system and is involved in involuntary reflexes and movement as well as modulation of 
movement.58  With the use of antipsychotic drug, this system becomes affected and leads to the 
development of EPS, which were documented immediately after the introduction of 
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antipsychotic drugs as clinically used agents.59  Four common EPS syndromes are recognized 
and the include: tardive dyskinesia, dystonia, akathisisa, and parkinsonism.60  The atypical 
antipsychotic agents produce a markedly lower incidence of EPS and are now more widely used 
in the clinic.  However, treatment with atypical antipsychotics has been associated with increase 
in body mass index and development of metabolic syndrome.61  In addition to the treatments 
available on the market some of which include: quetiapine (20), clozapine (21), risperidone (22), 
olanzapine (23), aripiprazole (24), perphenazine (25), and ziprasidone (26), numerous novel 
atypical antipsychotic agents are in various stages of development (Figure 6).  Consequently, 
efforts toward designing improved treatments for individuals suffering from this neurological 
disorder have markedly increased.  
	  
 
21 
	  
Epilepsy 
 Epilepsy is a brain disorder categorized by an lasting tendency to generate epileptic 
seizures.62  This family of neurologic disorders arises with a projected frequency of around 50 
per 100,000 individuals a year, mainly seen in infants and elderly people.63, 64  If not treated 
timely, epilepsy leads to progressively impaired cognition and function, brain damage, and other 
neurologic deficits.65   
Table 7.  Currently available representative treatments for epilepsy6 
Compound Commercial 
Name 
Class Mechanism of action 
Phenytoin Dilantin® Antiepileptic Na+ channel blocker 
Gabapentin Neurontin® Antiepileptic Neuronal Ca2+ channel 
blocker 
Valproic acid Depakote® Anticonvulsant Indirect agonist of GABAA 
receptor 
Pregabalin Lyrica® Anticonvulsant Neuronal Ca2+ channel 
blocker 
Levetiracetam Keppra® Anticonvulsant Indirect agonist of GABAA 
receptor  
Topiramate Topamax® Anticonvulsant Na+ channel blocker 
Carbamazepine Tegretol® Anticonvulsant Na+ channel blocker 
 
Excessive and synchronous neuronal activity in the brain is the cause for an epileptic 
seizure.66  Epileptic seizures are normally treated with antiepileptic drugs, which continue to be 
the main treatments for epilepsy.  Despite their wide use, antiepileptic drugs are only effective in 
60-70% of patients and their objective is to regulate seizures as quickly as possible without any 
adverse effects.67  
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Antiepileptic drugs are used to prevent burst-firing of neurons, decrease excitation, and 
increase inhibition.  Antiepileptics (Figure 7) widely used in the clinic include: phenytoin (27), 
valproic acid (28), carbamazepine (29), gabapentin (30), lamotrigine (31), pregabalin (32), 
levetiracetam (33), and topiramate (34).  These currently used treatments for epilepsy involve 
compounds with various mechanisms of action, affecting different systems such as the 
GABAergic system, sodium and calcium ion channels.62  Despite the fact that more than 20 
antiepileptic drugs are licensed worldwide, about a third of patients suffering from epilepsy 
continue to experience seizures.68  For these individuals, the only hope for improving seizure 
control is to be exposed to antiepileptic drugs that they haven’t been exposed to before.  
Development of new agents is underway and great efforts are being focused at disease 
modification and symptom control. 
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Depression 
 The World Health Organization projected that by 2020, major depressive disorder 
(MDD) will become the second leading cause of disability worldwide.69  Depression is a 
debilitating and life-threating mood disorder and it has been estimated that the burden for 
depression and related mood disorders is over $100 billion in the United States and €105 billion 
in the European Union (EU).70  The prevalence rates of depression amount to 16% in the United 
States and around 30 million people in the EU.71, 72  MDD is clinically characterized as 
heterogeneous mental illness with varying symptoms such as: anhedonia, feelings of 
helplessness, sadness and despair which can be caused from a combination of genetic and 
environmental factors.73  Current treatments mainly target the reuptake and breakdown of 
monoamines (Table 8, Figure 8).  This treatment strategy is based on the monoamine hypothesis 
of depression, which indicates that neurochemical imbalance directly causes the core of the 
symptoms seen in patients suffering from MDD.74 
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Table 8.  Currently available treatments for MDD6 
Compound Commercial 
Name 
Class Mechanism of action 
Bupropion Wellbutrin® Atypical 
antidepressant 
Norepinephrine (NE) and DA 
uptake inhibitor 
Fluoxetine Prozac® Antidepressant Selective serotonin reuptake 
inhibitor (SSRI) 
Venlafaxine Effexor® Antidepressant Serotonin and norepinephrine 
reuptake inhibitor (SNRI) 
Nortriptyline Pamelor® Tricyclic 
antidepressant 
Norepinephrine inhibitor 
Mirtazapine Remeron® Antidepressant Adrenergic (α2) receptor 
inhibitor 
Trazadone Desyrel® Antidepressant Serotonin antagonist and 
reuptake inhibitor 
Sertaline Zoloft® Antidepressant SSRI 
Duloxetine Cymbalta® Antidepressant SNRI 
Since the development of the presently available antidepressant, the therapy for MDD has been 
revolutionized, however not all patients can benefit from the present treatments, especially those  
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those that suffer from treatment-resistant depression.  Several additional drawbacks have been 
described for the antidepressants currently used in the clinic mainly bupropion (35), fluoxetine 
(36), venlafaxine (37), nortriptyline (38), mirtazapine (39), trazodone (40), sertraline (41), and 
duloxetine (42).  They are characterized with a very slow onset of action requiring more then 3-4 
weeks of treatment in order for mood improvements to be observed.  Additionally, only about 
30-50% of patients respond to the initial regimen indicating poor efficacy, 30% of patients are 
resistant to a series of treatments currently available, and many adverse effects have been 
reported from the use of the currently available antidepressants.75-77  There is a growing effort in 
the discovery and development of agents that do not affect the monoaminergic system; in 
particular recent reports have introduced the glytaminergic system as a prominent target for the 
development of faster acting antidepressants.70, 78 
 
Pain Management 
 One of the greatest medical challenges worldwide is pain management.  For instance, in 
the United States alone, pain affects 116 million people, reducing quality of life with a burden of 
at least $636 billion annually.79  Furthermore, pain affects more Americans than diabetes, heart 
disease and cancer combined; making it the most common reason for access to the health 
system.80  Pain can be classified in four major categories: acute nociception, neuropathic pain, 
dysfunctional pain, and postoperative pain.81  Acute, postoperative pain and several types of 
chronic pain are caused by the activation of the nociceptor, sensory receptor mainly found in the 
periphery that responds to noxious stimuli.82  Being present in all tissues, nociceptors can be 
affected and can respond to several stimuli, such as mechanical, thermal, or chemical mediators 
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that are released from the surrounding tissue.82  Taken together, these facts identify that the 
manifestation of pain is not only affected by the CNS, but can also stem from factors such as the 
environment, various life experiences, and gender.82   
 Non-steroidal anti-inflammatory drugs (NSAIDs) have been an important class of 
analgesic agents whose use has spanned for several centuries since the introduction of aspirin on 
the market in 1860.83  The main use for NSAIDs has been for the treatment against inflammatory 
diseases, rheumatoid arthritis, osteoarthritis, dysmenorrhea, ischemic cerebrovascular disorders, 
and pain resulting from certain types of cancer.84  In the early 1970s, John Vale reported the 
mechanism by which ‘aspirin-like drugs’ act, listing the inhibition of prostaglandin synthesis as 
their mechanism of action, a system believed to be involved with inflammation and pain.85  In 
particular, the traditional NSAID agents were shown to be nonselective inhibitors of 
cyclooxygenase (COX) activity (Table 9, Figure 9).   
Table 9.  NSAIDs used in the clinic 
Compound Commercial 
name 
Class Mechanism of action 
Acetylsalicylic 
acid 
Aspirin® Salicylate Non-selective COX-1/2 inhibitor 
Diclofenac Aclonac® Arylacetic acid Non-selective COX-1/2 inhibitor 
Ibuprofen Advil® Aryl proprionic 
acid 
Non-selective COX-1/2 inhibitor 
Indomethacin Indocin® Heteroarylacetic 
acid 
Non-selective COX-1/2 inhibitor 
Celecoxib Celebrex® Coxib Selective COX-2 inhibitor 
Etoricoxib Arcoxia® Coxib Selective COX-2 inhibitor 
Lumiracoxib Prexige® Coxib Selective COX-2 inhibitor 
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There are three main types of COX enzymes, COX-1 which is constitutively expressed 
throughout the body, COX-2, which is induced in response to inflammation and the recently  
 
described COX-3, which is represented as an alternate splice variant of COX-1.86-88  Because the 
traditional NSAIDs such as aspirin (43), diclofenac (44), ibuprofen (45), and indomethacin (46) 
are nonselective inhibitors of COX-1/2, long term use of these agents leads to severe 
gastrointestinal side effects.89  The discovery of the inflammation inducible COX-2 isoform of 
cyclooxygenase has led to the development of selective COX-2 NSAIDs that have limiting 
gastrointestinal side effects.  Members of the COX-2 selective class of NSAIDs currently 
available on markets worldwide include celecoxib (47), etoricoxib (48), and lumiracoxib (49).90  
Despite the better gastrointestinal adverse effect profile seen with the use of COX-2 selective 
agents, the use of these agents has been associated with cardiovascular side effects, thus 
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increasing the need for novel NSAIDs with more site-specific mechanism and reduced 
occurrence of unwanted side effects.84, 91   
Opioid analgesics, in particular morphine and its derivatives, have been considered the 
“gold standard” for the treatment of severe acute or chronic pain and are generally used once 
primary treatment with NSAIDs does not lead to better pain management.92  The use of 
morphine (51, Table 10), the principal agent responsible for the effects of the opium poppy, for 
the treatment of pain has been known for millennia.93, 94  Despite its popularity, the structure of 
morphine, the active component of Papaver somniferum L. (Papaveraceae) was not proposed 
until 1923 by Gulland and Robinson.95, 96  The structure of morphine was later confirmed with a 
total synthesis published by Gates and Tschudi in 1953.97, 98 
Table 10.  Examples of clinically used opioids 
Compound Commercial 
name 
Class Mechanism of action 
Morphine Contin® Analgesic MOP receptor agonist 
Codeine  Analgesic/Antitussive MOP receptor agonist 
Hydromorphone Dilaudid® Analgesic MOP receptor agonist 
Oxycodone OxyContin® Analgesic Non-selective opioid 
receptor agonist 
Meperidine Demerol® Analgesic MOP receptor agonist 
Fentanyl Sublimaze® Analgesic/Anesthetic Highly potent MOP 
receptor agonist 
Methadone Methadose® Analgesic MOP receptor agonist 
Pentazocine Fortral® Analgesic MOP antagonist/KOP 
agonist 
Tapentadol Nucynta® Atypical analgesic MOP agonist/NE and 5-HT 
reuptake inhibitor 
 
Opioid ligands act at opioid receptors, which are G-protein-coupled receptors.  There are 
three main types of opioid receptors: µ opioid (MOP) receptors, κ opioid (KOP) receptors, and δ 
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opioid (DOP) receptors.99, 100  In general, the opioid receptors have been shown to couple to Gi/o 
proteins, which results in a decrease in cAMP production resulting from inhibition of adenylate 
cyclase and decrease in intracellular calcium.101, 102  It has been shown that in addition to various 
biological responses, each opioid receptor subtype has an effect on antinociception.103  Each 
receptor differs in their density, distribution, and endogenous ligands.104  Conversely, despite 
being the gold standard for pain management, physicians have become disinclined to prescribe 
opioids because of concerns concerning the serious and potentially life threatening adverse 
effects produced from long term opioid treatment.92   
Alterations of the nervous, respiratory and gastrointestinal systems are among the most 
common side effects.105  The most serious adverse effects seen with opioid analgesics use 
include constipation, respiratory depression, tolerance, and dependence and are thought to be 
associated with their agonist activity at the MOP receptors.94  Nonetheless, opioids such as 
morphine (50), codeine (51), hydromorphone (52), oxycodone (53), fentanyl (54), methadone 
(55), and meperidine (56) still continue to be used as main prescription drug therapy for the 
treatment of pain and as antitussive agents (Figure 10).  As seen in Table 10, most of the 
clinically used opioids exert their analgesic effect mainly through interactions with the MOP 
receptor.  Thus, mixed agonist/antagonist ligands active at two distinct receptors can be thought 
to have a reduced risk for serious side effects such as those seen with MOP receptor agonist 
treatment.  Pentazocine (57) is an opioid ligand exhibiting mixed agonist/antagonist activity 
interacting as an antagonist for the MOP receptors and an KOP receptor agonist that has a better 
side effect profile due to its antagonist activity at MOP receptors.106  Tapentadol (58) is another 
mixed activity ligand that was recently approved for use in the clinic for the treatment for 
moderate to severe pain.  It exerts its effects through MOP agonism and through the reuptake 
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inhibition of monoamines serotonin and norepinephrine.107  With the intention of producing 
analgesics less attractive for non-oral abuse, pharmaceutical companies are investing in abuse 
deterrent of tamper-resistant formulations.108  Such preparations include barriers to tampering 
that comprise of agonist-antagonists formulations, preparations that became increasingly viscous 
upon tampering, or modifying-release formulations.108, 109  In addition to such formulations, 
antagonists can be used to reverse the effects of an drug overdose or to reverse the effects of 
postoperative sedation, an example of which is naloxone (59).94  Moreover, peripherally active 
opioid antagonists are currently undergoing evaluation for treatment of constipation and other 
gastrointestinal effects associated with the use of opioid receptor agonists.94 
	  
	  
Substance Addiction 
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 Addiction represents a chronic, often relapsing brain disorder that causes compulsive 
drug seeking and affects all aspects of one’s life.  In the United States alone, the cost of drug and 
substance abuse, which includes health, crime related cost as well as productivity, is estimated at 
more than $600 billion annually, where $386 billion are attributed to illicit drugs and tobacco 
and $235 billion are attributed to alcohol abuse.110-113   
The production of positive reinforcing effects that results from neurochemical actions 
after repeated drug use gradually lead to neurological changes in the brain reward circuits and 
behaviors characteristic of addiction: tolerance, sensitization, dependence, withdrawal and 
craving.114  Tolerance and dependence often result from chronic use of opioids.94  When 
continuous drug exposure leads to decreased effectiveness, a larger dose is required to achieve 
the same effect, thus leading to tolerance.115  Physical dependence on the other hand, is a 
physiologically active state and its characterized by the presence of withdrawal symptoms upon 
abrupt cessation or significant reduction in dose.115  Physical dependence and addiction should 
not be confused and interchanged.  While physical dependence is defined by the appearance of 
withdrawal symptoms, addiction is defined as a chronic, compulsive and/or uncontrolled drug 
use despite significant harm to one’s health and well-being.115  Aside from alcohol, nicotine, and 
caffeine the most widely abused substances worldwide are the CNS stimulants cocaine and 
methamphetamine.116  The use of these substances usually leads to considerable social decline, 
increase in crime rates as well as emergency room visit, and elevated rates of HIV, hepatitis B 
and C infections.117   
Several treatments for drug and substance abuse are currently available on the market.  
These include nicotine replacement therapy, bupropion, and varenicline as treatments for 
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nicotine abuse; naltrexone, acamprosate, and disulfiram as therapy for alcohol abuse; and 
buprenorphine, methadone (55, Figure 10), naltrexone, and naloxone (59, Figure 10) as therapy 
for opioid abuse (Table 11, Figure 11).118  Prominent efforts are being made in the discovery 
and development of novel treatments for substance abuse.  Recent studies have explored the use 
of KOP ligands, in particular KOP receptor agonist as potential stimulant abuse therapeutics.119  
In addition to the KOP receptors as a target for the development of substance abuse therapy, 
research into sigma-1 receptors as potential target for substance abuse treatment has been on the 
rise.120   Evidence has shown that the endocannabinoid system may play a role in the drug-
seeking behaviors as well as in the mechanism that involves relapse, thus the endocannabinoid 
system represents another promising target for development of novel drug addiction therapy.121, 
122 
Table 11.  Medications currently approved for substance abuse 
Compound Commercial 
name 
Class Mechanism of action 
Bupropion Wellbutrin®/ 
® 
Antidepressant/smoking 
cessation aid 
DA reuptake inhibitor 
Varenicline Chantix® Smoking cessation Nicotinic receptor partial 
agonist 
Naltrexone Revia® Alcohol dependence Nonselective opioid 
antagonist 
Acamprosate Campral® Alcohol dependence NMDA receptor inhibitor and 
GABAA receptor agonist 
Disulfiram Antabuse® Alcohol dependence Aldehyde dehydrogenase 
Buprenorphine Buprenex® Opioid addiction MOP/KOP partial agonist, 
DOP antagonist 
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 CNS disorders affect the lives of many individuals worldwide and can have devastating 
consequences to those affected and their families.  Great efforts are being made in the discovery 
and development of novel CNS active agents that have potential to be utilized as CNS 
therapeutics.  One area of research that offers great scaffold diversity is the area of natural 
products chemistry.  Natural products have been used for centuries for their medicinal and 
spiritual purposes and evidence of their use as medicines dates back to the Mesopotamian 
pharmacopeia in 668-628 B.C.123  Recent research has implicated salvinorin A, a KOP receptor 
agonist as a promising natural product for the development of CNS therapeutics for the treatment 
of pain and drug abuse.124 
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CHAPTER 2:  SALVINORIN A 
PART I:  DESIGN AND SYNTHESIS OF STERICALLY CHALLENGED 
SALVINORIN A ANALOGUES 
 
Natural Products as Traditional Medicines 
Records indicate that humans have been using natural products for their medicinal, 
spiritual, and recreational purposes since ancient times.125  The earliest records for the use of 
natural products in ethnomedicinal traditions date back to the ancient Mesopotamian 
civilizations.126  Several of the Mesopotamian civilizations, namely the Babylonians and 
Assyrians were known to have outside pharmacies where clay-like tablets from natural product 
infusions and extracts were being dispersed to the ailing.126  Evidence of trade dating back to 
3000 B.C.E. linking Mesopotamia, Egypt, and southern Arabia involves aromatic woods, spices, 
aromatic gums, and myrrh all of which were used as medicines.126  Additional evidence from 
other ancient cultures, such as China and India supports the notion that natural products had wide 
spread use in the ethnomedicinal traditions of many cultures.  For instance, there are numerous 
references to a plant called soma that was used in rituals in ancient India.127  Furthermore, 
ginseng and ephedra are the most well-known ethnobotanicals used in ancient Chinese medicinal 
practices and are still currently used to treat a variety of illnesses.128  One of the most recognized 
medical documents is the materia medica, a text that was originally composed by a military 
physician under the Roman Empire in the 1st century AD, which contained the medicinal use of 
hundreds of plants was well preserved and copied with minor variations for centuries.129  Lastly, 
the native aboriginal residents of the territories now known as Mexico recorded their use of 
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mind-altering natural substances from the dried leaves of the peyote cactus in their spiritual 
practices.130  Evidence that natural products are still being used as ethnomedicines today lies in 
the fact that more than 80% of people worldwide still depend on traditional medicines.131 
 
Natural Products and Modern Medicine 
Plant species have been well documented for their medicinal use for thousands of years.  
Prior to the advent of pharmaceuticals, clay tablets and oils from various species such as 
Cupressus sempervirens (Cypress), Commiphora (myrrh), and Glycyrrhiza glabra (licorice) 
were used to treat coughs, colds, infections, and inflammation.132  Natural products are 
secondary metabolites synthesized by many organisms in response to external stimuli such as 
stress, temperature, nutritional changes, infection and competition.133  Natural products have 
played an important role in early drug discovery.  For instance, the value of natural products as 
pharmaceuticals was originally realized with the discovery of penicillin (68) in 1928 (Figure 
12).133   
 
Additionally, the isolation of the natural product salicin from the willow tree bark, 
eventually granted us with the discovery of aspirin (69), an anti-inflammatory agent that is still 
36 
	  
widely used in the clinic.134  Another example of the importance of natural products in current 
medicine was the isolation of the alkaloid morphine (50, Figure 10) from the opium poppy 
(Papaver somniferum L.), a natural product currently used for the treatment of severe pain.135  
Furthermore, the 1820 isolation of quinine from the Cinchona bark led to the development of 
additional antimalarial agents that together with quinine (70) are still used in the clinic to treat 
malaria.136   
Natural products have greatly influenced modern medicine and the discovery and 
development of novel agents.  In a study done by Newman and Cragg it was reported that out of 
the 1073 small molecule new chemical entities described from 1981-2010, 709 were natural 
products, natural product derived or influenced by natural products.137  In 2008 alone, 225 
natural products and natural product derivatives were in various stages of development, 
including preclinical, clinical and preregistration.138  Natural products have also significantly 
assisted with our understanding for biologic pathways and therapeutic targets and they continue 
to further influence the pharmaceutical industry.  The biosynthesis of natural products which can 
be produced by a variety of terrestrial and marine organisms is the key to the diversity of the 
chemical structures represented in natural products most of which possess an array of biological 
activities.135  Natural products research has had an influence on the development of various 
biological agents including: (1) antimicrobials; (2) anti-cancer agents; (3) antimalarial; and (4) 
agents for pain management.   
The discovery of penicillin G (68, Figure 12) by Alexander Fleming in 1928, initiated 
the golden age for antibacterial agents.139  The discovery of penicillin’s and sulfonamides in the 
1930s led to dramatically reduced mortality rates related to bacterial infections, thus 
37 
	  
revolutionizing medical practices.140, 141  Despite the marvelous discovery, penicillin wasn’t 
introduced in the clinic until 1941, followed by a large number of antibacterial agents such as 
various other penicillin derivatives, cephalosporins (71), aminoglycosides (72), macrolides (73), 
and glycopeptides (Figure 13).139, 142  The discovery of antibiotics has greatly improved the fight 
against infectious diseases as well as the quality of life of those affected and continuous efforts 
are being made in the future development of antibacterial agents that will overcome the 
drawbacks of the currently available treatments, namely resistance.143   
 
Another area of medicine where natural products research has had an immense role is the 
area of anti-cancer therapeutics.  Cancer relates to a group of devastating diseases with an 
estimated 1.7 million new cases to be reported in 2013 alone.144  It was reported that 
approximately 80% of the cancer drugs on the market from 1981-2006 were natural products or 
natural product derivatives.145  Anticancer compounds can act by several mechanisms such as 
induction of apoptosis, topoisomerase inhibition, tubulin polymerization and by alkylation.138, 146  
They belong to several structural classes of natural products some of which include: 
anthracyclines, polyketide macrolides, enediynes, isoprenoids, etc.138  Examples include 
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paclitaxel (74), vinblastine (75), doxorubicin (76), camptothecin (77), and various others (Figure 
14).147  In addition to being highly potent anticancer agents, these natural products have helped 
our understanding of various cancer pathologies as well as unknown biological pathways that 
can be explored for discovery and development of novel and improved anticancer therapeutics.  
A different area of medicine where natural products have played a great role is malaria 
research.  Malaria is caused by Plasmodium parasites and it was estimated in 2010 that there 
were more than 219 million cases of malaria and over 660,000 deaths.148  Furthermore, over 3.3 
billion people worldwide were at risk of contracting malaria in 2011 as estimated by the World  
 
Health Organization.149  Use of the Cinchona bark to treat malaria was first reported in the 1800s 
when the British began cultivating the plant.134  Quinine (70, Figure 12) isolated from the 
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Cinchona succirubra Pav. Ex Klotsch, was approved as an antimalarial agent in the United 
States in 2004.135 Efforts to synthesize quinine led to the discovery and development of 
chloroquine (78), which has been the mainstay for the treatment of malaria for the last 50 years 
(Figure 15).150  Its great success in treating malaria and heavy use worldwide gave rise to 
resistance in the species responsible for malaria in humans.151  Natural sources have helped in the 
discovery of novel antimalarial agents with diverse scaffolds such as artemisinin (79), and will 
continue to aid in the fight against malaria resistance.152   
	  
Natural products can be divided into groups depending on their biosynthetic pathway in 
such a way that the acetate pathway gives rise to fatty acids and polyketides; the shikimate 
pathway gives rise to amino acids and phenylpropanoids; and the mevalonate pathway gives rise 
to terpenoids and steroids.153  In addition to the natural products biosynthesized by the mentioned 
pathways, natural products can also be divided into alkaloids and carbohydrates.153   
 
Terpenes 
 Terpenes are a class of natural products that possess great structural and stereochemical 
diversity and are found in all forms of life.154  More than 55,000 terpenoids have been isolated to 
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date.154, 155  Terpenes are of interest to many researchers because of their structural complexity, 
structural diversity as well as their unique biological profiles.  In fact, several therapeutic agents 
currently available on the market are members of the terpene class of natural products, for 
instance the antimalarial agent artemisinin and the anticancer agent paclitaxel.138  Terpenes are 
secondary metabolites that are composed of isoprene units, a 5 carbon unit, whose biosynthesis 
stems from the mevalonate pathway.156, 157  Classification of the terpene class of natural products 
is founded on the number of isoprene units present in the carbon skeleton.156  There are several 
classes of terpenes that possess from one to six isoprene units and are classified into 
hemiterpenes, monoterpenes, sesquiterpenes, diterpenes, sesterterpenes, and triterpenes, 
respectively.158  Terpenes containing more than six isoprene units are also known as tetraterpenes 
and they comprise of eight isoprene units.156  Furthermore, terpenes composed of isoprene chains 
have also been isolated and are known as polyterpenes.156  There are several subclasses that 
follow in this classification system.156 
 Specifically concentrating on the diterpene class, the classification system is further 
divided and there are over 50 subclasses of diterpenes, many of which are known to have 
biological activity.158  Some of the best known are labdanes, kauranesa, gibberellins, taxanes, 
beyeranes, aphidicolins, cembranes, and abietanes.158  For instance, natural products research on 
the Turrheantus species resulted in the isolation of labdanes that have anti-plasmodial activity; 
research on Boswellia serrate yielded an cembrane diterpene with anti-protozoal activity; studies 
done on Podocarpus macrophyllus afforded an abietane with cytotoxic activity; research on the 
South American plant Smallanthus sonchifolius has afforded an kaurane with anti-diabetic 
activity are just a few examples of the structural diversity and pronounced biological activity 
seen with the diterpene class of natural products.159-162   
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 Another diterpene subclass that is abundant throughout Nature in a variety of plants, 
microorganisms and fungi is the clerodane class, a subclass also known for its biological 
activity.163  For a diterpene to be considered a clerodane it has to be composed of four isoprene 
units and have four contiguous stereocenters that are present on a cis or trans decalin fused 
system.163  A larger portion of clerodene diterpenes, 75%, contain the trans ring fusion and the 
natural product clerodin (80) is an example (Figure 16).   
 
This natural product was originally isolated in 1936 from Clerodendrum infortunatum L. 
(Lamiaceae), has shown activity as an antifeedant that can potentially be used as a pesticide.164  
The other 25% of clerodanes have the cis ring fusion as seen in columbin (81).  Columbin was 
isolated from Tinspora bakis (Menispermaceae), a Sudanese native species that was traditionally 
used for the treatment of headache and rheumatism and is currently being investigated as a 
potential anti-inflammatory agent.165  Alongside with the relative configuration of the cis/trans 
decalin ring fusion, the clerodanes are further classified by the relative stereochemistry at the C-8 
and C-9 carbons (82, Figure 16).163  This added classification produces additional four types of 
clerodane skeletons which are defined with respect to their ring fusion and their stereochemistry 
at the C-8 and C-9 carbons: cis-cis (CC), trans-trans (TT), cis-trans (CT), and trans-cis (TC).163  
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They can be also be classified by their absolute stereochemistry; compounds that have  the same 
absolute stereochemistry as clerodin are named neoclerodanes and compounds that are 
enantiomers of clerodin are referred to as ent-neoclerodanes.166, 167 
 Their intriguing scaffolds and extensive biological profiles have led many researchers to 
focus on the neoclerodane subclass of diterpenes.  This interest has yielded many total synthesis 
efforts, which have led to structure-activity relationships (SAR) studies and pharmacological 
evaluations.  Despite the great interest in this subclass, however, the high structural complexity 
that these natural products possess has shown to be the cause for complications for completion of 
SAR studies.168  Additionally, these molecules are often polyfunctionalized and contain many 
stereocenters making it difficult for reaction development and analogues synthesis.  Despite 
these challenges, pronounced interest has been focused on several neoclerodane diterpenes, in 
particular salvinorin A. 
 
Salvia divinorum and Salvinorin A 
 Salvia divinorum Epling & Jativa-M. (Lamiaceae) is a psychoactive mint originally 
discovered in 1962 by Wasson and Hofmann.169  This plant was also locally known as “ska 
Maria Pastora” because of a belief that S. divinorum represents a reincarnation of the Virgin 
Mary.170  Its psychoactive properties were utilized in divination practices by the Mazatec Indian 
shamans of Oaxaca, Mexico.171  Aside from its spiritual traditions, S. divinorum was also used to 
treat a variety of illnesses such as anemia, headache, rheumatism, and diarrhea.  There are 
several traditional ways for administration of S. divinorum: chewing and swallowing of the 
leaves; smoking the leaves, and pulverizing the leaves into a juice and then consuming the 
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liquid.172, 173  Because of the rapid onset of hallucinations and vivid “out-of-body” experiences, 
S. divinorum has become very popular among recreational users, which administer S. divinorum 
by smoking inhalation or by chewing on the leaves.174, 175  Salvia has been labeled as a “drug of 
concern” by the Drug Enforcement Agency (FDA); however it is not a controlled substance 
under the Controlled Substance Act of 1970.176   
 The principal active component of S. divinorum is the neoclerodane diterpene salvinorin 
A (83, Figure 17).  Salvinorin A is a trans-cis tricyclic neoclerodane that was originally isolated 
in 1984 by Valdes.171  Salvinorin A is a potent hallucinogen that exhibits similar potency to that 
of known hallucinogens LSD (84) and DOB (85).172, 177  Salvinorin A was shown not to exert its 
activity through the serotonin 5-HT2A receptor system, the mechanism of action of many of the 
known hallucinogens.172, 178  In fact, in 2002 salvinorin A was shown to exert its actions as a 
potent agonist of the KOP receptor.124  With its unique non-nitrogenous structure, salvinorin A 
was identified as the first natural product that has high affinity and efficacy for the KOP 
receptors with a scaffold structurally different than that the known hallucinogens and other KOP 
receptor ligands like JDTic (86), U-50,488 (87), or bremazocine (88).124   
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It was originally believed that a basic nitrogen atom was required for opioid receptor 
activity because of a binding hypothesis that suggested that the nitrogen atom interacts with an 
aspartate residue of the third transmembrane domain of the receptor.179-181  The elucidation of the 
X-ray crystal structures for the opioid receptors eloquently accomplished by Granier and 
coworkers (DOP receptor), Manglik and coworkers (MOP receptor), Wu and coworkers (KOP 
receptor), and Thompson and coworkers (NOP/ORL-1) will allow for further exploration and 
validation of the N-atom binding hypothesis at the opioid receptors.182-185  Furthermore, the 
outstanding efforts made into the elucidation of the X-ray crystal structures of the opioid 
receptors could be further utilized in molecular modeling studies that will aid in the development 
of SAR studies for further evaluation of the interactions between opioids and their receptors.182-
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185  Due to its unique structure and activity, salvinorin A has become a primary target for further 
SAR development and pharmacological evaluation. 
 
Opioid Receptors 
 Opioids exert their activity through the opioid receptors. With the use of radiolabeled 
opioid ligands, study reported by Martin and coworkers, the presence of opioid receptors was 
observed in the human brain.  There are three main types of opioid receptors: µ (MOP), κ (KOP), 
and δ (DOP) receptors.186, 187  The basis for the nomenclature of the opioid receptors lies in 
several observations: the ligands used for characterization, ketocyclazocine (95) (KOP receptor); 
the best known agonist, morphine (50, Figure 10) (MOP receptors), and a high affinity 
enkephalin receptor found in the mouse vas deferens (DOP receptors) (Figure 19).100, 188 It has 
been proposed that a there is a possibility of receptor subtypes, however genomal evidence has 
not supported this notion and is now believed that receptor subtypes are actually posttranslational 
modifications of the opioid receptors.189  
 Opioid receptors are members of the G-protein coupled receptor (GPCR) superfamily.  In 
in vitro models, it has been demonstrated that opioid receptors couple to Gi/o proteins, but there is 
additional evidence that suggest that they may couple to the Gs proteins as well.190, 191  In 
general, coupling to the Gi/o proteins leads to inhibition of adenylyl cyclase, event that is the 
result of the decrease in the cAMP production and intracellular calcium levels.101, 102  Additional 
effects are caused with the dissociation of the βγ complex, whose interaction with potassium 
causes additional intracellular effects.102  
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Despite the 60% amino acid sequence identity between the opioid receptors, they differ in 
their body distribution, receptor density and their respective endogenous ligands.104, 192  Shortly 
after the discovery of the opioid receptors, endogenous ligands for each of the receptors were 
reported.  Two pentapeptides that differ only in one amino acid were the first isolated peptides 
from brain tissue and were determined to be DOP receptor agonist.193  The activity of 
methionine-enkephalin (89, Met-enkephalin) and leucine-enkephalin (90, Leu-enkephalin) was 
determined thorough a naloxone (59, Figure 10) antagonism study (Figure 18).193  In 1981, the 
endogenous ligand for KOP receptors, dynorphin A (91) was isolated from porcine pituitary 
glands by Goldstein and colleagues.194  Finally, the endogeneous ligand for the MOP receptors, 
β-endorphin (92), was characterized from camel pituitary glands in1976 by Li and coworkers.195   
The three different opioid receptors were characterized in the early 1970s; however it 
wasn’t until twenty years later that they were cloned and purified.196  The first opioid receptor to 
be cloned was the DOP receptor, which was simultaneously achieved by two groups in 1992.196, 
197  The cloning and purification of the other two opioid receptors was also accomplished; for 
KOP receptors by Meng and coworkers in 1993 and for MOP receptor by Wang and coworkers 
in 1994.198, 199  
 
KOP Receptor Ligands and Therapeutic Potential 
47 
	  
 Opioids have been used for centuries for the treatment of various ailments.  However, 
specifically focusing on MOP receptor active ligands, the risk of serious side-effects has 
encouraged the search for structurally diverse opioid ligands that are selective for the other 
opioid receptors.  The identification of such ligands would lessen the risk for a negative side 
effect profile and would limit drug abuse liability.  One example of such ligands includes KOP 
receptor selective compounds, which have been implicated in the treatment of various diseases, 
such as drug abuse, mood regulation, and pain management.94, 200-202  KOP ligands are not 
without drawbacks, the biggest one of which is occurrence of dysphoria upon activation of the 
receptors.203  However, efforts are being made in the development of KOP ligands that will have 
antinociceptive effects without the occurrence of dysphoria.  
 Available treatments for moderate to severe pain management are mainly based on 
opioids, in particular opioids that exert their activity through the MOP receptors.  However, 
despite the use of opioids for the treatment of pain for centuries, these ligands come with a 
severe set of negative side effects among which respiratory depression and drug abuse liability 
are the most life threatening.202  As previously stated, KOP receptor selective ligands with 
analgesic properties would be a great replacement for MOP based pain therapy, however these 
ligands are not without drawbacks.124, 203-205  Nevertheless, KOP receptor selective ligands still 
represent a great target for pain management because of the presence of KOP receptors in the 
periphery.201, 202  For the stimulation of pain, several animal models have been established that 
study various types of pain; thermal, chemical, electrical, and mechanical.202  KOP receptor 
agonists have shown great promise in several of these models of pain.  For instance, in the 
inflammatory model of pain, where inflammatory agents are injected into the animal paw, KOP 
receptor agonists were shown to significantly diminish the antinociceptive actions and decrease 
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formalin-induced edema.206  Additionally, in the sciatic nerve ligation model, a model for 
neuropathic pain, Xu and coworkers demonstrated that endogenous dynorphin produces both 
antinociceptive and pronociceptive effects in mice.207  Furthermore, in the visceral pain model, 
where visceral pain is stimulated by stretching or distension of the visceral muscle, KOP receptor 
agonists have been shown to be effective.202, 208  As demonstrated above, KOP ligands were 
shown to be a promising target for the treatment of various types of pain.  Further investigations 
into the KOP receptor system will help us gain a better understanding of the relationship between 
KOP receptor system and the mechanisms of pain.   
 Evidence proposes that KOP receptor agonists and antagonists may modulate the activity 
of dopaminergic neurons and modify the neurochemical and behavioral effects of cocaine.209  
Drug and stimulant abuse represents a major problem worldwide.  It is characterized by 
compulsive drug-seeking, and continued drug abuse despite of the socioeconomic and health 
consequences.121, 210  Currently there are no FDA approved agents for the treatment of drug 
abuse.  Stimulation of the brain’s reward system, which originates in the ventral tegmental area 
(VTA) area and extends to the nucleus accumbens (NAc) is the primary mechanism that drives 
most forms of drug addiction.211  It has been demonstrated that the KOP receptor system has an 
inhibitory effect on the rewarding function of the brain through the suppression of dopamine 
release from the mesolimbic and nigrostriatal pathways.212-214   
 It has been demonstrated that KOP receptor agonists have an effects on cocaine self-
administration, place preference and behavioral sensitization.215  Dynorphin A, the endogenous 
KOP receptor ligand, blocked the formation of conditioned place preference; decreased basal 
dopamine levels, and diminished locomotion induced by 15 mg/kg of cocaine in mice.216  It was 
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demonstrated by Koob and coworkers as well as by Xi and coworkers that KOP receptor agonist 
U-50,488 (87) failed to substitute for heroin self-administration in rats, unlike with MOP 
receptor agonists (Figure 18).217, 218  Rather, KOP receptor agonists U-50,488 and spiradoline 
dose-dependently decreased morphine and cocaine self-administration in mice and rats.219, 220  
On the other hand, administration of an KOP receptor antagonist nor-BNI (102), had no effect on 
morphine and cocaine self-administration in monkeys and rats (Figure 20).218, 219, 221  Moreover, 
intravenous cocaine (60) and morphine (50) administration in rats was significantly reduced with 
the administration of U-50,488 (Figure 10, 11).222  Another KOP receptor agonist, U-69,593 
(93) decreased cocaine self-administration and also inhibited the reinstatement of extinguished 
drug-taking behavior in response to experimenter administered cocaine (Figure 17).223  Schenk 
and coworkers also reported that U-69,593 was able to reduce the ability of a high dose of 
cocaine (20 mg/kg) in the production of drug-seeking behaviors.223  Moreover, they observed 
that U-69,593 was able to have an effect in the decrease of cocaine self-administration when the 
doses of cocaine were administered in a descending order as opposed to ascending order.223    
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Validation studies of the effects of KOP receptor agonists on cocaine self-administration 
were also completed in non-human primates.224, 225  It has also been reported that higher efficacy 
KOP receptor agonists such as U-50,488, U-69,593, ethylketocyclazocine (96), and bremazocine 
(88) may be more effective in decreasing cocaine-seeking behavior than lower efficacy KOP 
receptor agonists such as cyclazocine (97), PD117302 (98), and spiradoline (94) (Figure 19).209   
In addition to the self-administration studies, KOP receptor agonists have been strongly 
investigated in conditioned place preference studies, and results suggest that agonists such as U-
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50,488, U-69,593 and salvinorin A induce conditioned place aversion in rodents.214  This effect 
was blocked by the KOP receptor antagonist nor-BNI.226  In a study done by Suzuki and 
coworkers, it was reported that U-50,488, a selective KOP receptor agonist and naltrexone, a 
non-selective opioid receptor antagonist both produced conditioned place aversion.227, 228  In a 
combination study completed by Suzuki and coworkers, it was identified that both U-50,488 and 
naltrexone blocked cocaine conditioned place preference.  In addition to U-50,488, U-69,593 
was similarly shown to prevent the development of sensitization to the conditioned rewarding 
effects of cocaine, a study completed by Shippenberg and coworkers.229  Moreover, 0.1mg/kg of 
the arylacetamide R-84760 (99) displayed the ability to block cocaine-induced conditioned place 
preference and to significantly decrease cocaine-induced locomotion.230  Unlike the other 
arylacetamides U-50,488 and U-69,593, R-84760 did not produce conditioned place aversion.230  
Nalfurafine (100) is an epoxymorphinan and high-affinity KOP receptor agonist.  It has been 
described that induction of conditioned place aversion is observed with an administration of a 
high dose of nalfurafine (80 µg/kg).231  In addition, similarly to the other KOP receptor agonists 
described, nalfurafine was likewise able to lessen the rewarding and locomotor effects of 
morphine in mice.232  The prevention of the effects seen with an increase in the extracellular 
dopamine levels that is achieved as a result of recurrent administration of cocaine is also 
successfully treated with the administration of KOP receptor agonists.229  Funada and colleagues 
demonstrated that pretreatment with KOP receptor agonists U-50,488 and E-2078, a dynorphin 
derivative, led to a decrease in morphine-induced conditioned place preference and it also 
decreased the elevated dopamine metabolites in the limbic forebrain.233    
Evidence points to a possible role for KOP receptors in the development of morphine 
tolerance.  It has been demonstrated that co-administration of the KOP receptor agonist U-
52 
	  
50,488, is capable of preventing morphine tolerance.234-236  Also, of interest is the notion that 
KOP receptors are able to modulate MOP receptors by opposing their actions.237, 238  In rodent 
models of tail-flick and hot plate pharmacological tests, it was observed that administration of 
the endogenous KOP receptor ligand, dynorphin A or the KOP receptor agonist U-50,488 dose-
dependently antagonized morphine antinociception.234, 235, 239-241 
KOP receptor antagonists have been implicated to have a potential utility in the treatment 
of drug abuse due to their modulation of a certain component of stress-induced drug craving, a 
model for relapse.242  It has been demonstrated that states of depression and stress can be 
probable motivating factors and lead to cocaine relapse.243  The development of the first highly 
selective KOP receptor antagonist, JDTic (86, Figure 17), raised interest for the determination of 
its actions in stress-induced models of relapse in rodents.244  It was reported by Beardsley and 
coworkers that JDTic dose-dependently blocked stress-induced reinstatement of extinguished 
cocaine-reinforced responding in the footshock-induced relapse model.245  Additionally, it was 
demonstrated that JDTic also showed antidepressant-like activity in the forced swim test.245   
Despite the positive developments seen with KOP receptor agonists in the quest of drug 
abuse therapies, dysphoria, a characteristic of KOP receptor agonists remains a significant side 
effect.246  Moreover, it has been demonstrated that KOP receptor agonists when under stress 
conditions, will also potentiate the rewarding effects of cocaine in stress-induced reinstatement 
in animals with a history of exposure to KOP receptor agonists.247, 248  In such animals, it is 
likely that the prolonged activation of the KOP receptor system may be the cause for the seen 
success of KOP receptor antagonists have on the reduction in the increased cocaine intake.238, 249  
Thus, in a state where the KOP receptor system is suppressed such as addiction, KOP receptor 
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antagonists may be a prospective target for the treatment of drug addiction.  Another potential 
target for the treatment of drug addiction are partial KOP receptor agonists.  Such agents will 
likely be without the psychotomimetic side effects seen with KOP receptor full agonists and have 
the potential to antagonize the effects of CNS stimulants in a similar manner to that of KOP 
receptor full agonists.178 
 Ventral tagmental area, nucleus accumbens, and the prefrontal cortex are brain regions 
that are involved in the regulation of mood and motivation and it has been shown that the KOP 
receptor system is enriched in these areas.250  KOP receptor activation in these regions of the 
brain has been demonstrated to lead to a decrease in dopamine levels and transmission.  The seen 
reduction in DA transmission has been implicated in certain symptoms of depression.  Thus, 
deactivation of the KOP receptor system with the use of KOP receptor antagonists may be a 
potential target for the treatment for depression.  Additionally, increased levels of the 
transcription factor cAMP-response-element-binding protein (CREB) in the NAc as a result of 
stress have been related to depressive-like effects in rodents, which can be attenuated by KOP 
receptor antagonists.246, 251, 252  Several KOP receptor antagonists have been investigated for 
antidepressant effects.  Pliakas and coworkers demonstrated that nor-BNI (101) was able to 
block the swim stress-induced immobility in rats (Figure 20).253  A structurally different KOP 
antagonist, GNTI (102) was also tested for antidepressant effects.  It was demonstrated that a 
single i.c.v. treatment with GNTI showed antidepressive effects with a more potent activity than 
that seen with nor-BNI.246  ANTI (103), a slightly more lipophilic KOP receptor antagonist was 
also shown to have antidepressant effects in the forced swim test after systemic administration.246  
It has been proposed that a possible mechanism for the seen antidepressive effects of KOP 
54 
	  
receptor antagonists may be due to the blockage of the inhibitory actions that the KOP receptor 
system generally employs in the VTA dopaminergic neurons.254   
 
Despite these promising results, studies of KOP receptor antagonists are somewhat 
hindered by the atypically long duration of action that is seen with the treatment of these agents 
in rodents, non-human primates and humans.255  Thus, the necessity and search for selective 
KOP receptor antagonists with improved pharmacokinetic and pharmacodynamics properties 
continues. 
Salvinorin A in vitro Studies 
 It was identified in 2002 that salvinorin A is a highly selective and potent KOP receptor 
agonist.124  This was done through a screen of a large panel of human GPCRs, transporters and 
ligand-gated ion channels obtained from NIMH-PDSP of a 10 µM concentration of both 
salvinorin A and the classical hallucinogen LSD.  From this screen it was clear that salvinorin A 
inhibited only the [3H]-bremazocine –labeled KOP receptors and did not significantly bind to 
neither of the two opioid receptors nor any of the other 48 molecular targets available in the 
screen.  Results from the screen determined that the Ki value of salvinorin A for cloned KOP 
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receptor is 16 nM, whereas no significant binding was observed for either the MOP or DOP 
receptors (>10,000 nM).  In the functional assay of adenylate cyclase inhibition it was 
determined that salvinorin A is potent agonist of the KOP receptors with an EC50 value of 1.05 
nM, a value comparable to that of the known KOP receptor agonist U-69,593 (EC50 = 1.2 nM).  
Furthermore, in the [35S]GTP-γ-S assay it was found that salvinorin A is also a potent agonist 
with an EC50 value of 235 nM, a value again comparable to that of U-69,593 (EC50 = 377 nM). 
 The results discussed above were independently reproduced and confirmed by Chavkin 
and coworkers using [3H]-bremazocine and inhibition of adenylate cyclase assay.256  In addition, 
they also determined that salvinorin A is a full agonist in a calcium mobilization assay where it 
was tested against other well-known KOP receptor agonists and it had comparable potency 
(salvinorin A, EC50 = 7 nM, U-50,488, EC50 = 24 nM, U-69,593, EC50 = 13 nM).  It is believed 
that down-regulation and internalization of receptors are largely responsible for the development 
of tolerance and it was shown that known KOP receptor agonists down-regulate and internalize 
KOP receptors to a variable degree.  Wang and coworkers utilized fluorescence flow cytometry 
and FLAG-hKOP receptor transfected cells to determine if salvinorin A was able to promote 
internalization of the hKOP receptor which was observed, however with a much lower potency 
than U-50,488.257 
 
Salvinorin A in vivo Studies 
Salvinorin A and KOP receptor Mediated Effects 
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In order to fully understand the observed KOP receptor activity of salvinorin A, drug 
discrimination studies were undertaken.  These behavioral studies involve subjects being trained 
to respond to a drug and are then tested with other drugs to see their ability to generalize to, or 
“substitute” for the training drug.258  Butelman and coworkers reported the first behavioral set of 
studies done with salvinorin A in non-human primates and the first drug discrimination studies of 
salvinorin A, where it was reported that salvinorin A does substituted for U-69,583.259  The 
highest dose of subcutaneously administered salvinorin A (0.032 mg/kg) did not alter the 
responding rate and caused only mildsedation-like effects.  Salvinorin A showed a fast onset of 
action, (5 minutes), and duration of action of 60 minutes.  The discriminatory and 
neuroendocrine effects of salvinorin A were blocked by quadazocine (109), an opioid antagonist 
(Figure 21).  They also determined in a separate drug discrimination experiment that U-69,583 
did not substitute for ketamine, an anesthetic and NMDA receptor antagonist.  An extension of 
these studies was completed in rats by Willmore-Fordham and coworkers.  They determined that 
at the doses administered (1-3 mg/kg, i.p.) salvinorin A fully substituted for U-69,593 without 
modifying response rates.260  Furthermore, it was determined that the KOP selective antagonist 
nor-BNI was able to entirely block the effects of salvinorin A.  Sluggish and uncoordinated 
motor performance was observed with 3-10 mg/kg administration of salvinorin A, an experiment 
done with drug naïve animals that confirmed the results reported in mice by Fantegrossi and 
coworkers and Zhang and coworkers.226, 261  A study reported by Baker and coworkers, extended 
these results with the determination that both U-69,593 and U-50,488 substituted for salvinorin 
A in rats trained to discriminated salvinorin A from saline.262  Additionally, they determined that 
two active analogues of salvinorin A, salvinorin B ethoxymethyl ether (104) and salvinorin B 
methoxymethyl ether (105), substituted completely for U-69,593 (Figure 21). 
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Reports of the hallucinogenic effects exhibited with salvinorin A administration 
prompted additional studies of comparison with known hallucinogens.  The study discussed 
above done with ketamine and salvinorin A was broadly extended by Li and coworkers.263  In 
this study done on rhesus monkeys trained to discriminate DOM, a 5-HT2A receptor agonist that 
exhibits hallucinogenic effects in humans, it was observed that neither salvinorin A nor U-50,488 
substituted for DOM (106).  Butelman and coworkers conducted the first drug discrimination 
study in which rhesus monkeys were trained to discriminate salvinorin A from saline.264  It was 
determined that structurally diverse KOP receptor agonists, bremazocine, U-69,593, and U-
50,488 were all able to substitute for salvinorin A.  However, psilocybin (107), a 5-HT2A 
receptor agonist and a compound with pronounced hallucinogenic/psychotomimetic effects in 
humans did not substitute for salvinorin A.  Furthermore, the 5-HT2A antagonist ketanserin (108) 
did not block the discriminative effects of salvinorin A, an effect that was successfully blocked 
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by the opioid antagonist quadazocine again confirming the notion that the behavioral effects of 
salvinorin A are indeed due to centrally acting KOP receptors (Figure 21).   
Salvinorin A and Behavioral Studies 
 As discussed previously, the opioid receptor system has been implicated in various 
disease states.  Consequently, investigation of salvinorin A and its analogues for their effects in 
various centrally mediated phenomena, such as pain modulation, mood and reward regulation, 
has been carried out by researchers worldwide. 
Salvinorin A and Regulation of Mood, Stress and Reward 
 Disruption of dopamine function within the NAc has been believed to cause ahedonia, 
which is a trademark sign of clinical depression.200  Additionally, elevated stress increases the 
activity of CREB within the NAc and as a result, it increases immobility behavior when tested in 
the forced swim test (FST), a model used to study depression.265  The elevated levels of CREB 
within the NAc are believed to be in part due to the fact that CREB regulates the transcription of 
dynorphin, the endogenous KOP receptor ligand leading to decrease DA function.  CREB-
regulated transcription of dynorphin leads to increased activation of KOP receptors within the 
NAc that causes a decrease in the level of local dopamine function, thus triggering depressive-
like effects.200  As discussed above, KOP receptor antagonists are known to exhibit 
antidepressive effects in rats.  In light of these finding several studies have investigated the 
effects of salvinorin A in the area of mood regulation.  Utilizing two models of depressive-like 
behavior, the FST and intracranial self-stimulation (ICSS) tests, Carlezon and coworkers 
examined the effects of salvinorin A in rats.200  In the FST test they found that salvinorin A 
exerts effects opposite of those seen with currently used antidepressants.  Furthermore, salvinorin 
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A (0.25-2.0 mg/kg) dose-dependently increased the occurrence of immobility and also caused 
significant decrease in the occurrence of swimming, however no effects were seen on climbing 
or diving behaviors.  Conversely, no effects were observed on locomotor activity in an open field 
at any of the doses tested.  In 1953, ICSS was originally described by Olds and Milner as an 
operant model where animals learn to deliver brief electrical pulses into their own brain, 
specifically in regions believed to regulate natural reward pathways.266, 267  Changes in lever 
pressing, which is learned by the animal, can be used to determine the effects that different drugs 
have on ICSS.  Decrease in the ICSS threshold is indicative of an increase of the reward value of 
the stimulation, which occurs because a smaller amount of electrical stimulation is needed to 
recognize the stimulation as rewarding.  On the other hand, the opposite is true when increase in 
the ICSS threshold is observed.  In the ICSS assay completed by Carlezon and coworkers, 
salvinorin A dose-dependently increased the ICSS threshold, thus reducing the rewarding effects 
of the medial forebrain bundle stimulation, an observation opposite from the one seen with 
stimulant drugs such as cocaine.200  This reduced sensitivity to rewarding stimuli has been shown 
to be a sigh of ahedonia, one of the hallmark clinical symptoms of depression.  Furthermore, 
utilizing microdialysis, it was demonstrated that 1.0 mg/kg salvinorin A reduced dopamine 
activation in the mesolimbic dopamine system; however no effects were observed on serotonin 
concentrations in this region.  Taken together, these results provide evidence of depressive-like 
effects of salvinorin A.   
 An extension of the results reported by Carlezon were the experiments completed by 
Ebner and coworkers, where they choose to investigate the temporal effects of a 2.0 mg/kg dose 
of salvinorin A on phasic dopamine release in the NAc core and shell, as well as the effects of 
salvinorin A on motivated behavior in ICSS and sucrose-reinforcing responding.268  Fast scan 
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cyclic voltammetry was used to evaluate the effects of salvinorin A on the phasic dopamine 
release in the NAc core and shell and it was observed that salvinorin A significantly decreased 
dopamine release in both the NAc core and shell as compared to vehicle.  However, no effect on 
dopamine reuptake was observed in either part of the brain.  In the ICSS assay, it was 
demonstrated that a 2.0 mg/kg maximal dose of salvinorin A dose- and time-dependently 
increased ICSS thresholds, which is in accordance with Carlezon and coworkers.  In the sucrose-
reinforced responding assay, animals are trained to press a lever to obtain a sucrose pellet; the 
progressive ration of responding determines the motivation of the subject to respond by 
gradually increasing the number of lever presses necessary to receive the sucrose reward.  It was 
determined that salvinorin A significantly decreased the breakpoint in responding and it also 
blocked the rate of lever-responding, both of which are indicative of a decrease in motivation.  
These results confirm the previously published reports that salvinorin A has depressive-like 
effects and decreases the dopamine concentration in the NAc.   
 Results reported above were further expanded by Braida and coworkers, who evaluated 
the effects of salvinorin A in rodent models of emotional behavior at doses lacking motor 
impairments.269  Such effects were evaluated in the elevated plus maze paradigm, FST, and the 
tail suspension test.  The elevated plus maze is a rodent model for anxiety and the device used 
consists of an open- and closed-arm.  A compound that elicits a greater amount of time spent in 
the open-arm and a greater percentage of open-arm entries may be considered an anxiolytic.  
Rats pre-treated with 0.1-160 µg/kg dose of salvinorin A were shown to make more open-arm 
entries and spent more time in the open-arms than vehicle-injected rats, a result similar to that of 
the clinically used anxiolytic diazepam (1.0 mg/kg, i.p.), indicating that salvinorin A may have 
some anxiolytic effects.  Mixture of the KOP receptor antagonist nor-BNI and the CB1R 
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antagonist AM251 were able to completely block the effects seen with salvinorin A.  In the tail 
suspension test, where animals are suspended by their tails and the time spent between 
immobility and agitation is recorded, it was shown that salvinorin A (0.001-1.0 µg/kg) produced 
a significant decrease in the time spent in immobility.  The seen effects were once again 
completely blocked with pretreatment of both nor-BNI and AM251, administered alone or in 
combination.  The antidepressive effects of salvinorin A were further confirmed in the FST, 
where doses of 0.001 to 10 µg/kg salvinorin A dose-dependently decreased the occurrence of 
immobility and increased swimming, however did not have an effect on climbing behavior.  
Again pretreatment with either nor-BNI or AM251 completely blocked the seen effects.  These 
results, contradict with data previously reported by Carlezon and coworkers and Ebner and 
coworkers.  However, the difference in the dosing regimens between the different groups was 
suggested as a factor for the differences seen between the studies.  The two other studies used 
higher salvinorin A doses, whereas the present authors used relatively small doses of salvinorin 
A.  They stated that a dose of 1 mg/kg of salvinorin A did produce depressant-like effects, 
however these data were not reported.  Based on this finding it is possible that small doses of 
salvinorin A produce antidepressant like effects, whereas larger repeat doses produce depressant-
like effects.   
 These studies were further extended by Harden and coworkers, where they used animals 
previously exposed to a variety of mild stressors over the course of several weeks.270  This 
paradigm termed chronic mild stress (CMS), produces behaviors that model anhedonia, which 
can be detailed in rats by measuring the relative consumption of sweet water as compared to 
regular drinking water.271, 272  Various stressors were used over the testing period including 16 
hour food depravation, 16 hour water depravation, 12 hour of 45° angle cage tilt, 36 hours of 
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continuous illumination from room light, etc.  From this CMS experiment it was determined that 
indeed a state of ahedonia was observed in the tested rats, which was reversed in stressed 
animals by administration of 1 mg/kg of salvinorin A, indicating antidepressant effects of 
salvinorin A.  There are several hypothesis that may explain these contradictive results, however 
additional research has to be conducted for a greater understanding of the mechanism by which 
salvinorin A may produce both antidepressant and pro-depressive effects.  
Salvinorin A and Antinociception Studies 
 The documented use of S. divinorum as a treatment of various ailments, including 
rheumatism and headaches, prompted studies to evaluate of the antinociceptive effects of 
salvinorin A in animal models.  Utilizing the KOP receptor agonists salvinorin A, TRK-820, and 
3FLB, Wang and coworkers developed a study to examine the antipyretic and antinociceptive 
effects of these compounds in mice.257  In a scratching assay induced by the pruritogen 
compound 48/80, only compound TRK-820 showed dose-dependent inhibition in the scratching 
behavior whereas salvinorin A and 3FLB were ineffective.  Similarly, in the acetic acid writhing 
test, salvinorin A (15-50 mg/kg) was inactive.  These results are in conflict with the results 
published by Harding and coworkers, where they demonstrated that salvinorin A was as potent 
as morpheine in the tail-flick assay as well as the p-phenylquinone (PPQ) writhing assay with 
ED50 values of 1.98 mg/kg and 0.59 mg/kg, respectively.273  Additionally, they also tested the 
activity of salvinorin A in the hot plate assay, however no antinociceptive activity was observed.  
Subsequently, McCurdy and coworkers tested the effects of salvinorinA in several 
antinociception assays.274  In the tail-flick assay they demonstrated that salvinorin A displayed 
dose- and time-dependent antinociceptive effects, produced 10-15 minutes after drug 
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administration, an effect that was completely reversed with nor-BNI pretreatment.  They also 
tested the effects of salvinorin A in a hotplate and acetic acid writhing assays, where it was 
demonstrated that salvinorin A at doses of 1.0 mg/kg and 1.0-2.0 mg/kg, respectively, exhibited 
dose dependent antinociceptive effects.  The authors note that in all of the experiments salvinorin 
A exhibited fairly short duration of action for salvinorin A with a peak at 10 minutes, which may 
explain the results reported by Wang and coworkers where no antinociceptive effects were 
observed when salvinorin A was administered 20 minutes prior to the irritant.  John and 
coworkers further extended these results and confirmed the antinociceptive effects of salvinorin 
A.275  An intrathecal (i.t.) administration of salvinorin A displayed antinociceptive effects in a 
tail-flick assay, effects reversed by administration of the KOP receptor antagonist nor-BNI, but 
not by the MOP receptor antagonist β-FNA or the DOP receptor antagonist naltrindole.  Fichna 
and coworkers evaluated the antinociceptive effects of salvinorin A even further, however in a 
different animal models, namely models for colitis.276  These models focus on the inflammation 
caused by bowel disease and it was determined that a 3 mg/kg dose of salvinorin A significantly 
attenuated the effects of 2,4,6,-trinitorbenzene sulfonic acid (TNBS)-induced colitis.  These 
effects of salvinorin A were reversed by nor-BNI but not by the CB1R and CB2R antagonists 
AM251 and AM630.  Lastly, Ansonoff and coworkers tested the antinociceptive and 
hypothermic effects of salvinorin A in KOP receptor knockout mice.277  Intracerebroventricular 
(i.c.v.) injection of salvinorin A (7.5 µg) produced antinociceptive effects, which were not 
present in KOP receptor knockout mice.  These results indicate that the antinociceptive effects of 
salvinorin A are indeed KOP receptor regulated.  Hypothermic effects were only observed at 
much higher doses (50µg) of i.c.v. administered salvinorin A.  
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Effects of Salvinorin A in Non-Human Primates and Human Subjects 
 Prolactin is a hormone synthesized in the anterior pituitary gland and several 
neurotransmitter systems in the CNS regulate its actions.278  The opioid receptor system 
modulates prolactin secretion, which has been used in non-human primates to evaluate the 
potency, receptor selectivity and efficacy of various opioid ligands.278  Butelman and coworkers 
designed a neuroendocrine biomarker study to evaluate the effects of salvinorin A in non-human 
primates.279  In this study, the experiments were set up as follows: rhesus monkeys were injected 
with salvinorin A, vehicle, or U-69,593 at doses of 0.0032-0.056 mg/kg i.v. and samples were 
collected at set intervals for 120 minutes; in antagonism experiment, the antagonist to be tested 
was administered 30 minutes before salvinorin A and the same collection procedure was 
followed.  It was determined that both salvinorin A and U-69,593 dose- and time-dependently 
increased prolactin levels.  The effects of salvinorin A were observed as soon as the 5 minute 
time period, but were shorter acting than those seen with U-69,593.  In addition to the i.v. 
administration route used in this study, the authors tested the neuroendocrine effects of s.c. 
administered salvinorin A.  It was observed that salvinorin A had much smaller effects of 
prolactin secretion than i.v. administered salvinorin A and a slower onset of action was also 
observed.  More robust effects of salvinorin A on prolactin levels were observed in female 
monkeys in both the s.c. and i.v. experiments.  The actions of salvinorin A on the KOP receptors 
were tested with a pretreatment of nalmefene, a universal opioid receptor antagonist and 
ketanserin, a 5-HT2 receptor antagonist.  In these antagonist studies it was shown that only 
nalmefene (0.1 mg/kg) was able to completely antagonize the effects of salvinorin A (0.032 
mg/kg, i.v.), confirming the notion that salvinorin A acts through the KOP receptor system.   
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 In a subsequent study Butelman and coworkers designed a set of experiments to 
determine the unconditioned behavioral effects of salvinorin A in non-human primates and the 
fast onset and entry into the CNS.280  U-69,593 (0.01, 0.32, and 0.056 mg/kg, i.v.) or salvinorin 
A (0.032 and 0.1 mg/kg, i.v.) were administered as a single bolus injection in rhesus monkeys 
and behavior was observed at various time points with an end time of 90 minutes.  The 
behavioral effects were characterized utilizing two rating scales that measured sedation and 
posture, and it was observed that both salvinorin A (peak at 5 minutes, decline at 30 minutes) 
and U-69,593 (peak at 5 minutes, decline at 60 minutes) produced a dose-dependent increase in 
sedation and postural changes, with U-69,593 having a longer duration of action than salvinorin 
A.  The authors also monitored facial relaxation and ptosis.  It was observed that salvinorin A at 
the doses mentioned produced a time- and dose-dependent increase in facial relaxation and ptosis 
with very rapid onset of action (1-2 minutes after i.v. administration).  U-69,593 (0.01 and 0.032 
mg/kg, i.v.) also produced an increase in facial relaxation and ptosis, however with an unclear 
timeline and longer duration of action.  The opioid receptor antagonist nalmefene (0.01 or 0.1 
mg/kg, s.c.) was able to completely inhibit the effects of salvinorin A on sedation and posture as 
well as facial relaxation and ptosis.  In contrast, pretreatment with neither CB1R antagonist 
rimonabant nor the 5-HT2 receptor antagonist ketanserin, were effective in modulating the 
effects of salvinorin A.  Experiments also confirmed the rapid entry of salvinorin A into the brain 
of Hooker and coworkers.281  Salvinorin A was observed in the brain immediately after i.v. 
injection with a peak value at 2 minutes and decreasing gradually up to 30 minutes. 
 In 2011, Johnson and coworkers reported preliminary findings of the basic physiological, 
behavioral and subjective effects of salvinorin A in human subjects.282  In this double blind, 
placebo controlled experiments, 16 doses of salvinorin A were used ranging from 0.375-21 
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µg/kg and administered by vaporization and inhalation.  Blood pressure and heart rate were 
measured throughout the duration of the study and participants were asked to rate the drug 
strength every 2 minutes for 60 minutes after drug administration.  To gain a better 
understanding of the subjective effects of salvinorin A, the subjects were asked to complete two 
questionnaires, The Hallucinogen Rating Scale (HRS, 99 items) and the Mysticism Scale (M 
scale, 32 items).  It was observed that the peak drug strength was at 2 minutes post 
administration and decreased gradually such that at 20 minutes indication of “possible mild” 
effect was noted.  The study found no physiological changes in heart rate or blood pressure and 
no tremors were observed, indicating that salvinorin A was physiologically and psychologically 
well tolerated at the doses tested.  Doses of salvinorin A in the range of 4.5-21 µg/kg were rated 
as significantly stronger than placebo; this outcome was found to correspond to the answers 
given in the HRS and M scale questionnaires all of which resemble results seen with classical 
hallucinogens.  
 A double-blind, placebo study of the behavioral and psychological effects of salvinorin A 
was reported by Addy in 2012, in which a larger group of subjects (30) was used.283  In this 
study the participants smoked either a dose of 1,076 mg of salvinorin A deposited on 25 mg of 
dried S. divinorum leaves.  The control was unaltered plant leaf material that was presumed not 
to be psychoactive (≤100 mg of salvinorin A).  The participant’s vitals were taken one hour after 
drug administration.  As reported by Johnson and colleagues, no dose-related physiological 
changes were observed during the study and the drug was well tolerated by the participants.  
After 60 minutes post administration, each participant was asked to fill out an HRS, and 
behaviors recorded during the first 20 minutes after administration were used for further analysis.  
It was observed that after salvinorin A inhalation, the participants displayed increased laughing, 
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talking, and movement as compared to placebo and also displayed paranoid ideation and physical 
contact with the monitor.  From the completed HRS questionnaire, it was reported that salvinorin 
A produced an effect significantly different than that of placebo with 43% of the participants 
describing it as similar to that of dreaming.  Additionally, 50% of the participants reported that 
the present experience was unlike any other experience of an altered state of consciousness that 
they had encountered before.  The study included an 8 week follow-up session, in which 87% of 
the participants reported that the effects of salvinorin A lasted less than 24 hours and 70% 
reported after effects lasting more than 24 h, in particular up to 3 days.  Despite the undesirable 
after effects, no participant would refuse salvinorin A in the future.  
 An additional double-blind, placebo controlled, randomized, crossover study was 
designed by Ranganathan and coworkers to assess the behavioral and subjective effects of 
salvinorin A (doses 8 and 12 mg/kg).284  Ten subjects participated in this study in which 
subjective feelings were measured with a self-reported visual analog scale (VAS) and 
psychotomimetic symptoms were measured with the Positive and Negative Syndrome Scale 
(PANSS) and the Psychotomimetic States Inventory (PSI).  All subjects were monitored for 
physiological changes and EEGs were obtained after drug administration by inhalation.  No 
changes in heart rate and blood pressure were noted throughout the duration of the study. 
However, salvinorin A did cause a decrease in the resting state of the EEG spectral power.  It 
was observed that salvinorin A significantly elevated both cortisol and prolactin levels, which 
returned to baseline 60 minutes after administration.  As previously reported, salvinorin A had 
short duration of action with a peak at 10 minutes post administration with a return to baseline 
within 30 minutes of administration. 
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 A recent publication by MacLean and colleagues investigated the dose-related effects of 
salvinorin A in a double-blind, placebo controlled study.285  Doses of salvinorin A (0.375-21 
µg/kg) were administered in an ascending order, with a placebo session inserted randomly.  All 
participants completed 20 sessions (16 different salvinorin A doses and 4 placebo doses) where 
salvinorin A was administered by a slow inhalation lasting 40s.  As in their preliminary study, 
data was collected every 2 minutes for 60 minutes after drug administration, which included 
collection of blood pressure and heart rate, drug strength ratings and rating of drug effects.  
Effects of salvinorin A on recall and recognition were also assessed by an auditory memory task 
where salvinorin A produced a decrease in word recall and recognition.  At the end of each 
session, the participants were asked to complete several questionnaires to obtain the subjective 
effects of salvinorin A.  Consistent with previous results, time- and dose-related response was 
observed with rated drug strength peaking at 2 minutes and gradually decreasing toward pre 
administration levels.  No physiological changes and no kinetic tremors were observed in the 
subjects during the experiment.  The end of session measures confirmed the known 
hallucinogenic and dissociative effects of salvinorin A and they also provided evidence of 
possible abuse liability.  Follow-up assessments showed no evidence of lasting negative effects 
and confirmed the notion that salvinoin A produces unique effects.  Additional studies are 
necessary in order to further characterize the unique effects of salvinorin A and other KOP 
receptor agonists.  
 
Salvinorin A and Drug Abuse 
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 In 2008, study designed by Chartoff and coworkers aimed at examining the effects of 
acute activation of KOP receptor system on the behavioral effects of cocaine.286  They 
hypothesized that acute activation of the KOP receptor system would decrease the behavioral 
effects of cocaine and that prior exposure to repeated activation of the KOP receptor system 
would potentiate the behavioral effects of cocaine.  Acute administration of salvinorin A five 
minutes before cocaine challenge in rats was found to block the locomotor stimulant effects of 
cocaine.  It was also demonstrated that acute salvinorin A blocked the locomotor effects of SKF 
82958, a dopamine D1 receptor agonist.  Prior exposure to repeated administration of salvinorin 
A was shown to potentiate the locomotor response to a subsequent cocaine challenge in rats and 
was likewise shown to potentiate the effects of the dopamine agonist SKF 82958.  Furthermore, 
increase of c-Fos expression (indicative of second messenger activation) in the NAc and dorsal 
striatum among others was observed during acute salvinorin A administration.  However, during 
chronic administration of salvinorin A prior to cocaine challenge, no change in c-Fos expression 
was noted in the dorsal striatum.   Collectively, this study demonstrated that salvinorin A has an 
effect on the locomotor stimulant effects of cocaine, effect likely caused by dopamine facilitation 
in the dorsal striatum. 
 As an extension to the above study, in 2009, Morani and colleagues reported the effects 
of several KOP receptor agonists on cocaine-induced drug-seeking in rats.287  As previously 
reported for other KOP receptor agonists, salvinorin A was able to dose-dependently attenuate 
cocaine-induced cocaine seeking, at doses 0.3 and 1.0 mg/kg, i.p.  Doses of 0.3 and 1.0 mg/kg 
salvinorin A failed to significantly decrease sucrose-reinforced responding. 
Metabolism of Salvinorin A 
70 
	  
 In 2005, Schmidt and coworkers reported that the primary metabolite of salvinorin A ex 
vivo in both human and rhesus monkey plasma, as well as rhesus monkey cerebrospinal fluid 
(CSF) was salvinorin B, a C-2 deacetylated derivative of salvinorin A (110, Figure 22).  It was 
observed that in all samples that the concentration of salvinorin B gradually increased as 
salvinorin A concentrations decreased.288   As an extension of their previous work, Schmidt and 
colleagues reported another experiment in which they described the first in vivo 
pharmacokinetics experiment of salvinorin A in non-human primates.289  Four (2 males and 2 
females) rhesus monkeys were injected with an intravenous 0.032 mg/kg dose of salvinorin A, 
and upon administration blood samples were collected at selected intervals (0, 1, 5, 15, 30, and 
60 minutes).  The elimination t1/2 of salvinorin A was determined to be 57 minutes, however 
gender variations were observed.  The authors found that the concentration of salvinorin B did 
not increase over time and that it was below detectable levels, which could be indicative of rapid 
clearance of salvinorin B or its accumulation in other tissues.  Kutrzeba and colleagues, utilizing 
various microorganisms (fungi) and brain homogenates came to the same conclusion that 
salvinorin B is the major metabolite of salvinorin A.290  A human volunteer study reported by 
Pichini and coworkers developed a method for the quantification of salvinorin A (administered 
via inhalation) in blood, urine, sweat and saliva samples.291  They determined that only 0.59 mg 
(1.2%) of the total administered dose was excreted in urine.  
 Teksin and coworkers designed a study where they looked at the in vitro metabolism of 
salvinorin A using recombinant human CYP450 and UGT2B7 enzymes.292  In this study, a series 
of specific human CYP450 isoforms were used and incubation of salvinorin A (5 and 50 µM) 
with CYP2D6, CYP1A1, CYP2C18, and CYP2E1 resulted in a significant decrease in the 
remaining concentration of salvinorin A.  Salvinorin A was also co-incubated with UGT2B7 
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enzyme and similarly to the results seen with CYP450 incubation, reduction of remaining 
salvinorin A concentration was once again observed.  Moreover, the authors noted that there was 
evidence pointing to a saturable metabolism, in which lower concentrations are metabolized 
more efficiently than higher concentrations.  Together, these studies suggest that several CYP450 
as well as UGT2B7 enzymes are involved in the metabolism of salvinorin A. 
 
 Lastly, Tsujikawa and coworkers reported an in vitro study of salvinorin A metabolism 
and stability on rat plasma.293  In this study, they aimed to characterize the esterases responsible 
for salvinorin A metabolism by using selective esterase inhibitors (5).  In control experiments 
where salvinorin A was incubated for 24 hours at 37 °C, production of degradation products was 
not observed.  Additionally, addition of sodium fluoride (NaF), an esterase inhibitor, inhibited 
metabolism of salvinorin A to salvinorn B.  Two of the inhibitors tested showed concentration-
dependent inhibition of metabolism of salvinorin A by hydrolytic inactivation, specifically 
sodium bis-p-nitrophenyl phosphate (BPNP), an inhibitor selective for carboxyesterases (CES) 
and phenylmethylsulfonyl fluoride (PMSF), selective serine esterase inhibitor.  These findings 
support the fact that CES may be involved in salvinorin A metabolism, because CES is a serine 
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esterase.  The authors also report an additional major metabolite of salvinorin A (111, Figure 
22), which was obtained with incubation of NaF with rat plasma.  
 
SAR Studies on Salvinorin A 
Its unique non-nitrogenous structure has prompted many investigations into developing 
SAR studies to identify the pharmacophore required for binding at KOP receptors.  The overall 
summary of the current SAR of salvinorin A is presented in Figure 24.294   
 
Epimerization at C-8 carbon leads to lowered affinity whereas epimerization at C-12 
leads to formation of partial agonists at KOP receptors.  The furan ring is not necessary for 
activity and reduction or replacement are tolerated, however complete removal leads to loss in 
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affinity.  Lowered affinity and efficacy are the result with reduction of C-17 lactone, additionally 
removal of C-1 ketone leads to lowered efficacy and reduction of the C-1 ketone leads to 
lowered affinity.  The ester moiety at C-4 position is necessary for KOP receptor affinity since 
reduction of affinity is seen with reduction or hydrolysis of the methyl ester.  Hydrolysis of the 
acetate at the C-2 position leads to complete loss of activity; however bioisosteric replacements 
such as amides, carbamates, carbononates, sulfonates and thisoesters are well tolerated at this 
position as are ethers and amides, as well as esters other than acetate. 
 
Furan Ring Modifications 
 The furan ring of salvinorin A has been the focus of various modifications in order to 
assess the binding within the KOP receptor pocket and elucidate SAR at this position, which 
would assist in the development of enhanced pharmacokinetic properties at this position of 
salvinorin A.  Furthermore, furan ring modification will assist in the development of compounds 
with potential therapeutic potential for treatment of KOP receptor system related CNS disorders.  
The various furan modifications reported thus far have yielded many analogues with very diverse 
pharmacological profiles. 
 Reduction of the furan ring afforded tetrahydrofuran analogue (112) of salvinorin A 
(Figure 24).295, 296  Different values have been reported for the KOP receptor affinity of the 
racemate of 112 most likely due to different methods of screening.295, 296  The C-13R epimer of 
112 was separated from the mixture using HLPC conditions to yield a full KOP receptor agonists 
with 3.7 nM binding affinity, however the observed efficacy was 17-fold less than salvinorin 
A.296  The retained activity of 112 at the KOP receptors indicates that an aromatic group at the C-
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12 position may not be necessary for activity.  However, complete removal of a substituent at 
this position in the ring (113) resulted in a 1700-fold decrease in KOP receptor affinity (Ki = 
3400 nM vs. Ki = 1.9 nM).296, 297   
 
When salvinorin A is combined with bromine, trans (114) and cis (115) 2,5-
dimethoxydihydrofuran isomers were synthesized.296, 298  These isomers were separated by 
HPLC and upon pharmacological testing it was observed that these isomers have reduced KOP 
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receptor affinity compared to salvinorin A (1.9 nM) of 480 nM and 180 nM, respectively.296  
Moreover, these analogues were found to be weak nonselective opioid receptor antagonists.   
Hydrogenation of isomers 114 and 115 with Rh/C in a mixture of DCM and MeOH, 
resulted in dimethoxytetrahydrofuran derivatives 116 and 117.296  Compound 116 exhibited 
similar affinity to that of salvinorin A of 25 nM, whereas analogues 117 exhibited slightly lower 
affinity for KOP receptors of 125 nM.  Despite the similar affinity, analogue 116 was 52-fold 
less efficacious at KOP receptors than salivnorin A.296  Reaction of the racemic mixture of 119 
and 119 with the appropriate sulfonamide afforded N-sulfonylpurroles 118, 119, and 120.297  
These analogues had significantly reduced affinity compared to salvinorin A, however in the 
[35S]GTP-γ-S functional assay they were found to be partial agonists with Emax values of 70%, 
60%, and 60%, respectively.297  Subjection of salvinorin A to photoxidation in the presence of 
sunlight resulted in the natural products salvidivins A and B, 121, and 122, respectively.296  
Salvidivin A showed to have antagonist activity at MOP and KOP receptors with Ke values of 
760 nM and 440 nM, respectively.296  Selective oxidation of 115 over its diastereomer 114 
resulted in the formation of salvinicin A (123) and salvinicin B (124), natural products present in 
S. divinorum.298, 299  Salvinicin A displayed KOP affinity of 390 nM and it exhibited partial KOP 
receptor activity with an EC50 of 4.1 µM and Emax = 80% relative to U-50,488.  Salvinicin B on 
the other hand, displayed KOP receptor affinity of 7 µM and MOP receptor antagonist activity 
with a Ke of 1.9 µM.294, 299  Reacting salvinorin A with bromine afforded dihydrofuran analogue 
125 as a mixture of C-15 α and β isomers, though the C-15 β isomer was found to be more 
stable.298  Treatment of salvinorin A with NBS affords bromo-salvinorin A 126.296, 298, 300  
Bromo-salvinorin A showed to be a potent KOP receptor agonist with Ki value of 3 nM and an 
EC50 = 50 nM.294  Exposure of bromo-salvinorin A (126) to Stille-coupling conditions afforded 
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analogue 127, which well tolerated at KOP receptors as a full agonist with Ki = 7.1 nM and EC50 
= 4.6 nM.300 
Furan rings are well known to undergo Diels-Alder reaction, where the furan ring acts as 
the 4 π diene.301  Thus, the Diels-Alder reaction was used to synthesize analogues that would 
explore the steric requirements for binding at the KOP receptors.301  Treatment of salvinorin A 
with benzyne afforded analogue 128 (Figure 25).301  This cycloadduct exhibited low KOP 
receptor affinity of 790 nM.  Exposure of salvinorin A to various alkynes resulted in the 
synthesis of analogues 129 – 132.301  Despite the interesting chemistry that led to these 
cycloadducts, it was shown that all of these analogues have lower affinity for KOP receptors than 
salvinorin A, with Ki values of 120 nM (ED50 = 2150 nM) 60 nM (ED50 = 980 nM), 1900 nM, 
and 1900 nM, respectively.301  Submission of analogue 128 to Fe2(CO)9 led to a reductive 
elimination of water and subsequent aromatization to yield compound 133.301  This compound 
was found to be inactive at the opioid receptors.  Reaction of salvinorin A with selected trienones 
resulted to the formation of cycloadducts 134 and 135, whose affinity at the KOP receptors was 
determined to be very poor, with Ki values of >13,000 nM and 290 nM, respectively.301  
Exposure of bicycles 129 – 132 to Fe2(CO)9 once again underwent similar reaction as proposed 
for analogue 133 to yield aromatic analogues 136 – 139, respectively.  These non-heterocyclic 
aromatic analogues exhibited reduced affinity at KOP receptors when compared to salvinorin 
A.301  
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   12-epi-salvinorin A (140), has been synthesized utilizing several methods by both Beguin 
and coworkers and Lovell and colleagues.300, 302   Lovell and coworkers reported KOP receptor 
affinity for 12-epi-salvinorin A very similar to that of salvinorin A (Ki = 17 nM vs. Ki = 7.4 nM), 
however that difference was slightly larger in the hands of Beguin and coworkers (Ki = 41 nM 
vs. Ki = 2.5 nM).300, 302  Although 12-epi-salvinorin A exhibited similar affinity to that of 
salvinorin A, it was 18-fold less potent than salvinorin A at KOP receptors (EC50 = 720 nM vs. 
EC50 = 40 nM).302   
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 Oxidative degradation of salvinorin A with NaIO4 affords salvinorin A acid 141, a 
valuable intermediate (Figure 26).  Besides being an exceptionally valuable intermediate, 
salvinorin A acid retains both affinity and efficacy at KOP receptors with Ki = 55 nM and EC50 = 
167 nM, respectively.294  Exposure of acid 141 to thioesterification results in salvinorin A 
thiophenol intermediate 142.302  Intermediate 142 was subjected to Liebesking-Srogl coupling 
reaction to afford analogues 143 – 160.302  All of the aromatic ketones synthesized exhibited 
affinity for KOP receptors, among those in the low nanomolar range are analogues 143 (Ki = 70 
nm, EC50 = 2280 nM, Emax = 74%), 150 (Ki = 40 nM, EC50 = 730 nM, Emax = 92%), 154 (Ki = 80 
nM, EC50 = 2130 nM, Emax = 92%), 155 (Ki = 36 nM, EC50 = 1630 nM, Emax = 95%), and 157 (Ki 
= 31 nM, EC50 = 620 nM, Emax = 88%).302  In addition to the functional [35S]GTP-γ-S assay, 
compound 150 was also subjected to fluorescent Ca2+ mobilization assay and an EC50 value of 
75 nM was determined.302  Utilizing Stille coupling conditions, Beguin and coworkers also 
synthesized analogues 143, 154, and 155.300  Analogue 143 exhibited similar affinity and 
potency to that reported by Lovell and coworkers.300  Once again utilizing acid 141 to create an 
acid chloride in situ and with exposure to various aryltributyl tin reagents, Beguin and coworkers 
were able to synthesize analogues 161 – 163.300  Analogues 162 and 163 presented to be full 
agonists at KOP receptors with Ki values of 83 nM and 20 nM, respectively; and EC50 values of 
195 nM and 36 nM, respectively, whereas analogue 161 displayed no activity at KOP 
receptors.300 
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 Synthesis of ester and amide analogues 164 – 173 can involve several different routes as 
reported by Beguin and coworkers.300  The synthesized esters exhibited moderate affinity for 
KOP receptors with Ki values in the range of 109 to 196 nM for esters 164 through 166, 
respectively, however increase in size of esters 170 and 172 resulted in complete lack of affinity.  
Salvinorin A amide analogues were completely devoid of activity at the KOP receptors.300 
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 Carboxylic acid 141 can also be employed in the synthesis of analogues 174 and 175 
utilizing either ethanolamine or L-serine methyl ester hydrochloride and amide bong coupling 
conditions, which is followed up by a cyclization with bis(2-methoxyethyl)aminosulfur 
trifluoride (Deoxo-Fluor) (Figure 27).296, 297  Oxazoline 174 exhibited moderate affinity of 300 
nM for KOP receptor however that is 157-fold less than salvinorin A (Ki = 1.9 nM).296  
Conversion of 175 to compound 176 was accomplished using base, however this analogue 
exhibited no activity for the KOP receptors.297  Carboxylic acid 141 was again used as the 
starting material towards the synthesis of various oxadiazoles (177 – 183) together with the 
appropriate amidoximes.296, 297, 300, 303  Simpson and coworkers reported that oxadiazole 177 
exhibited affinity of 59 nM at KOP receptors, and it was also demonstrated that this analogue is a 
functional antagonist at MOP and KOP receptors with Ke values of 430 nM and 360 nM, 
respectively.296  Conversely, no activity was observed for these oxadiazoles (177 – 183) in the 
assays reported by Beguin and coworkers.300 
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 Carboxylic acid 141 has been proven to be one valuable intermediate and it was once 
again used by Beguin and coworkers for the synthesis of analogue 184, which was accomplished 
with reduction of the acid with borane.300  Compound 184 was then used in the synthesis of 
analogues 185 and 186, which were prepared in the presence of silver oxide and either, 
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iodomethane or iodoethane, respectively.300  Acetylation of compound 184 afforded analogue 
170.  Reduction of carboxylic acid 141 to afford alcohol 184 resulted in complete loss of activity, 
whereas analogues 185 – 187 retained some affinity for KOP receptors.300  12-epi-salvinorin A 
was the starting material used in the synthesis of analogue 188, which was accomplished with 
NBS and chloroform.304  This analogue displayed similar affinity and activity for KOP receptors 
as 12-epi-salvinorin A.304   
 Oxidation of analogue 184 with Dess-Martin periodate afforded aldehyde 189, which was 
then subjected to Seyferth-Gillbert homologation conditions which provided alkyne analogues 
190.303  This alkyne intermediate was coupled with various azides under copper (I)-catalyzed 
click reaction conditions to yield analogues 191 – 194.303  Despite the interesting chemistry, the 
analogues synthesized were inactive at the opioid receptors.303  Alkyne 190 was subjected to 
azidomethyl pivalate and copper sulfate condition to afford pivalyl triazole 195, which did not 
exhibit any activity at the opioid receptors.303  Treatment of analogue 195 with base and 
subsequent acetylation at the C-2 position afforded 8-epi-191 (196), which did not show any 
activity at opioid receptors.303 
 Synthesis of salvinoirn A analogues 197 – 222 (Figure 28) was achieved utilizing 
carboxylic acid 141 and appropriate amines or alcohols in the presence of amide coupling 
reagents.305  The prepared amides and esters were shown to display very poor affinity at KOP 
receptors with the best affinity seen with analogues 215 and 221 with Ki values of 140 nM and 
160 nM, respectively.305  In the [35]GTP-γ-S functional assay, analogues 215 and 221 were found 
to be 100-fold less efficacious as ligands at KOP receptors, with compound 221 showing partial 
agonist characteristics (Emax = 57%).305 
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 Thioester analogue 223 was a valuable intermediate in the synthesis of salvinorin A 
aldehyde 189.305  Aldehyde 189 was asymmetrically allylated using B-allyl-(10S)-
(trimethylsilyl)-9-borabicyclo[3.3.2.]decane, to afford analogue 224.305  Compound 224 showed 
to be a versatile analogue that can undergo several different conditions such as esterification to 
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yield Mosher ester 226 (used to determine the stereochemistry of the allylic alcohol 224) and 
acylation followed by ring closing metathesis with 2nd generation Grubb’s catalyst to afford 
analogue 225.305  Analogue 225 was determined to be inactive at KOP receptors.305  Liebesking-
Srogl coupling reaction was employed to afford analogue 227 from salvinorin A thiophenol ester 
142 (Figure 26), which was then subjected to oxidative conditions with SeO2 to yield the 
cyclized 2-furan analogue of salvinorin A (228).302  It was determined that these analogues 
exhibited affinity for KOP receptors, Ki = 320 nM and Ki = 30 nM, respectively.302  Although the 
similar affinity to salvinorin A, 2-furan 228 was showed to be 3.5-fold less potent at KOP 
receptors determined with the [35]GTP-γ-S functional assay.302  Conversely, utilizing the 
fluorescent Ca2+ mobilization assay, analogue 228 displayed efficacy only 2-fold lower than that 
of salvinorin A.302 
 Salvinorin A’s unique structure has been of interests to many researchers, and many 
derivatives have been synthesized, especially focusing at the C-13 and C-2 positions in the 
scaffold.168, 294, 306  The various derivatives synthesized exhibited interesting pharmacological 
profiles that will help us better understand the SAR that lead to activity at the KOP receptors.295-
305  Additional furan ring modifications that introduce steric bulk and examine the favored 
oxygen atom position will help us better understand the furan binding pocket at the KOP 
receptor. 
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Rationale and Specific Aims 
 Despite the great therapeutic potential of salvinorin A, there are several disadvantages 
that need to be addressed before savinorin A can become a valuable therapeutic agent.  The 
presence of hallucinations and dysphoria with salvinorin A administration are two of the 
drawbacks that need optimization if salvinorin A were to ever become a useful therapeutic agent.  
Poor pharmacokinetic properties that salvinorin A exhibits represent another difficulty in the 
development of salvinorin A as a useful agent.  Typically, pharmacokinetics are referred to and 
known as ADMET, which stands for Absorption, Distribution, Metabolism, Excretion and 
Toxicity.  ADMET properties are important for every clinical candidate and are assessed early in 
drug discovery, normally through total synthesis efforts or semi-synthetic modifications of the 
molecule of interest.   
Teucrin A (Teucrium chamaedrys L.), a neoclerodane diterpene structurally similar to 
salvinorin A was reported to cause hepatic necrosis.307  This hepatotoxicity was attributed to the 
formation of reactive metabolites produced by CYP450 bioactivation.  Interestingly, a 
tetrahydrofuran analogue of teucrin A (229, Figure 29) was showed not to produce any 
hepatotoxicity in mice.  In 2006, Druckova and Marnett proposed that the toxic side effects of 
teucrin, the major constituent of germander are due to the formation of an enedial metabolite that 
arises from formation of an epoxide intermediate.308, 309  Furthermore, aflatoxin B1 (230), a 
difuranyl containing natural product has also been associated with hepatotoxicity due to the 
formation of a similar enedial species through CYP450 bioactivation.310  Salvinorin A is a 
neoclerodane diterpene that possesses similar structural characteristics with teucrin A and 
aflatoxin B1, a structural feature that may not be viable for medicinal use.  Modification of the 
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furan ring through semi-synthetic efforts may lead to salvinorin A analogues without the risk for 
hepatotoxicity.  However, before such studies are undertaken, additional information into the 
furan binding pocket of the KOP receptor must be obtained. 
	  
	   Our hypothesis is that further investigation into the SAR will assist in identifying novel 
salvinorin A analogues with improved pharmacological profiles that could have potential as 
clinical therapies.  Our knowledge of the chemistry and pharmacology of salvinorin A would be 
facilitated with the proposed specific aims.  
Specific Aim 1:  Prepare selected salvinorin A analogues that will assist in the 
determination of the favored oxygen atom position of the furan ring at the KOP receptors, 
as well as explore the steric requirements at the C-13 position. 
Evidence suggests that furan containing natural products may have the potential to be 
hepatotoxic, examples of this include aflatoxin B1 and teucrin A, diterpenes structurally similar 
to salvinorin A.307, 310  While further modifications of the furan ring will identify compounds 
with reduced risk for hepatotoxicity, additional information into the furan ring binding pocket 
must be initially obtained.  Analogues that explore the addition of steric bulk, the required 
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conformation of the furan oxygen atom for activity at the KOP receptors, and the optimal 
distance between the furan ring and the salvinorin A core will be synthesized.  This additional 
SAR will assist in demonstrating that modification at the C-13 position of salvinorin A are well 
tolerated at the KOP receptors and that opioid receptor selectivity can be obtained. 
Specific Aim 2:  Evaluate C-13 salvinorin A analogues for opioid receptor affinity and 
efficacy. 
 Compounds generated from Specific Aim 1 will be evaluated for their pharmacological 
profile at the opioid receptors.  Where applicable radioligand binding assay that measures the 
displacement of the opioid ligands [3H]DAMGO (MOP), [3H]U-69,593 (KOP), and [3H]DADLE 
(DOP) will be used to determine affinity for the opioid receptors.  Selected ligands will then be 
evaluated in one of two functional screens; [35S]GTP-γ-S functional assay or inhibition of 
adenylate cyclase activity assay.  Characterization of the pharmacological behavior for selected 
analogues synthesized in Specific Aim 1 will be accomplished with the proposed assays. 
 
Completion of the proposed specific aims will help us probe and increase our 
understanding of the furan binding pocket at the KOP receptor.  Rational design of said 
analogues will allow us to explore the steric potential, the ideal position for binding of the furan 
oxygen atom, as well as the optimal distance between the furan ring and the core of the 
molecule.  Completion of these studies will also afford us with novel opioid receptor analogues 
that can be further utilized as biological probes with a potential as clinical therapies.  The results 
of these studies will be presented and discussed.  
 
88 
	  
Results and Discussion 
Introduction 
 In order to further investigate the furan binding pocket in the KOP receptor and the SAR 
of salvinorin A at the opioid receptors, additional salvinorin A analogues were designed and 
synthesized.  The analogues prepared were designed to explore the changes at the C-13 position 
of the molecule and their effect on the activity at the KOP receptors.  These modifications were 
designed to attain the optimal distance between the furan ring and the salvinorin A core, the 
steric requirements necessary for binding and activity at this position, the necessity of an 
aromatic substituent at the C-13 position, as well as the preferred orientation of the furan ring 
oxygen atom (Figure 30).  Utilizing olefination and hydrogenation chemistry, several analogues 
were synthesized to test the proposed goals.  The two carbon homologated analogues of 
salvinorin A were designed to test the steric requirements for activity at the KOP receptors, as 
well as to determine the preferred orientation of the furan oxygen atom, since the analogues were 
locked in a given conformation that came from the olefination process.  Reduction of the set 
double bond would allow free rotation around the C-13 and examine the preferred orientation of 
the C-13 substituent.  Furthermore, overall reduction of the implemented double bond and furan 
ring will examine both the preferred orientation of the substituent, as well as the necessity of an 
aromatic substituent at this position.  Lastly, reduction of the furan ring of salvinorin A will 
further assess the necessity of aromatic substituents at the C-13 position for activity at KOP 
receptors.   
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Synthesis 
 To further understand the SAR of salvinorin A at KOP receptors, several analogues were 
synthesized.  As reported previously, salvinorin A (83) was extracted from commercially 
available dried S. divinorum leaves.311  Synthesis of the homologated C-13 salvniroin A 
analogues began with the synthesis of the Julia-Kocienski precursor as represented in Scheme 1.  
To obtain the needed Julia-Kocienski precursor, synthesis was initiated with 3-furaldehyde 231 
that was reduced with NaBH4 to yield the corresponding alcohol 232 in 88% yield.  Alcohol 232 
was then displaced with bromine in 45% yield (233) and treated with ammonium 
heptamolybdatetetrahydrate-peroxide complex to afford the Julia-Kocienski precursor 234 in 
86% yield.312  Julia-Kocineski olefination was chosen as the preferable method of homologation 
after several other procedures were attempted. Wittig olefination and Horner-Wadsworth-
Emmons olefination conditions were ineffective due to low yields, difficulties in purification, 
and ultimately aldehyde degradation.  Selective olefination of 83 was envisioned by introduction 
of an aldehyde at C-13, exploiting the reactivity of the aldehyde relative to the other four 
carbonyls present in 83.   
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 Aldehyde 189 was achieved following our previously published methods (Scheme 2).298, 
313  Briefly, oxidative degradation with NaIO4 and catalytic RuCl3·H2O of salvinorin A (83) 
afforded carboxylic acid 141 in 74% yield.  This valuable intermediate was then subjected to 
thioesterification with 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT), N-methylmorpholine 
(NMM) and ethanethiol at ambient temperature to produce salvinorin A thioester 225 in 88% 
yield.  Thioester 224 was then subjected to a reduction with triethylsilane and Pd/C to afford 
salvinorin A aldehyde 188 in 82% yield.  Julia-Kocienski olefination conditions are applicable 
for use with base-sensitive aldehydes and are milder than previously attempted olefination 
conditions.  The reaction of 189 and 234 in the presence of KHMDS afforded alkenes 235 and 
236 in overall reaction yield of 25%.  The individual isomers were isolated by flash column 
chromatography followed by additional HPLC purification in a 2:1 ratio of 235 to 236. 
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 Analogues 235 and 236 were combined and subjected to hydrogenation conditions, where 
palladium on carbon, and EtOAc were utilized to afford analogue 237 in 40% yield (Scheme 3).  
Furthermore, analogues 235 and 236 were combined and again subjected to hydrogenation 
conditions, however with a higher quantity of palladium catalysts to afford all reduced alkane 
238 in 39% yield.  Salvinorin A (83) was additionally subjected to hydrogenation conditions 
utilizing a different metal catalyst, rhodium on carbon in a mixture of MeOH and DCM to 
produce all reduced furan 239 in 25% yield.  Stereochemistry at the C-13 of analogue 239 was in 
accordance with previously published reports by Simpson and coworkers.296   
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Pharmacological Evaluation 
In vitro Binding and Functional Assays 
 Analogues synthesized were then subjected for pharmacological testing.  Analogues 235 
and 236 were subjected to radioligand binding studies using methodology described previously 
(Table 12).314  As represented in Table 12, it was found that the cis analogue 236 had almost 40-
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fold higher affinity for the KOP receptor compared to the trans analogue 235 (Ki = 30 ± 4 nM vs. 
Ki = 1,120 ± 30 nM).   
Table 12.  Opioid receptor binding affinity for C-13 cis and trans salvinorin A analogues 
 Ki ± SD, nM  
Cmpd 
[3H]DAMGO 
(MOP) 
[3H]DADLE 
(DOP) 
[3H]U69,593 
(KOP) 
MOP/KOP DOP/KOP 
83a – – 7.4 ± 0.7 N.D.c N.D.c 
235b > 1,700 > 5,000 1,120 ± 30 > 1.5 > 4 
236b 2,600 ± 140 > 5,000 30 ± 4 87 > 165 
aData from Lozama A. et al. J. Nat. Prod. 2011, 74, 718-726. 
bReceptor binding was performed in CHO cells which express the human MOP, DOP or KOP 
receptors. All results are n = 3 
cND = not determined 
 
Cis salvinorin A analogue (236) was also subjected to a functional assay to determine its activity 
at the KOP receptors using the [35]GTP-γ-S assay (Table 13).315  Despite the high affinity of cis 
analogue 236, it was shown to be 34-fold less potent than 83 in the [35]GTP-γ-S assay with an 
ED50 of 1,370 ± 180 nM while maintaining activity as a full agonist (Emax = 105 ± 4%).   
Table 13.  [35S]GTP-γ-S KOP receptor potency for analogue 236 
Cmpd 
KOP 
ED50 ± SDa 
KOP 
Emax ± SDb 
83c 40 ± 10 120 ± 2 
236 1,370 ± 180 105 ± 4 
aED50 = Effective dose for 50% maximal response 
bEmax is % which compound stimulates binding compared to (-)-U-
50,488 (500 nM) at KOP receptors. n  = 3 
cData from Lozama A. et al. J. Nat. Prod. 2011, 74, 718-726. 
 
 Analogues 237, 238, and 239 were subjected to pharmacological testing, utilizing the 
calcium mobilization assay (Table 14).316  It was determined that the analogues did retain 
potency at KOP receptors.  However, not all compounds exhibited high potency at the KOP 
receptors.  Analogue 239 displayed potency at KOP receptors with an EC50 of 17 nM, compound 
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238 exhibited potency with an EC50 value of 229 nM and compound 237 displayed KOP receptor 
potency with an EC50 of 43 nM.  Simpson and coworkers reported in 2007 the activity of 
analogue 239 in the [35S]GTP-γ-S functional assay to be much lower than that seen for salvinorin 
A (EC50 = 750 nM vs. EC50 = 45 nM).296  The differences seen in the potencies of this analogue 
could be due to the different conditions the two functional assays were performed.  These results 
indicate that the interactions of the all reduced analogue 238 with the KOP receptor pocket are 
not as favorable as the ones seen with the homologated furan analogue 237.  Additionally, 
comparison of salvinorin A 83 and tetrahydrofuran 239 suggests that an aromatic substituent at 
the C-13 position is not necessary for activity at the KOP receptors.  Although some of the 
analogues were not as potent as salvinorin A, modifications at the C-13 carbon are well tolerated 
and were all demonstrated to be full agonists at the KOP receptors.  
Table 14.  Analysis of potency of analogues 237 – 239 in the Ca2+ 
mobilization functional assay 
Cmpd 
KOP 
EC50 ± SEM (nM)a 
KOP 
Emax ± SEMb 
83 1.7 ±	  0.6 103 ± 2 
237 43.0 ± 7.1 124 ± 2 
238 229 ± 12 98 ± 3 
239 17.8 ± 1.6 111 ± 2 
aEC50 = Effective concentration for 50% maximal response.  
bEmax is % which compound stimulates binding compared to (-)-
U-69,593 at KOP receptors. n  = 3 
 
 
Conclusions 
 C-13 Modified analogues of salvinorin A were designed and synthesized in order to 
further explore the SAR of the furan ring binding pocket.  The analogues synthesized were 
95 
	  
designed to address several key features including: (a) the optimal distance between the furan 
ring and the salvinorin A core and the steric requirements at this position; (b) the preferred 
orientation of the furan ring oxygen atom; and (c) the necessity of an aromatic substituent at the 
C-13 position of the molecule.  
 Upon completion of the synthesis, the designed analogues were subjected to 
pharmacological evaluation.  Pharmacological evaluation of the cis and trans constricted alkene 
analogues of salvinorin A revealed a preferential conformation for activity at the KOP receptors 
as seen with the activity profile exhibited by the cis alkene conformer.  Further, the C-13 two 
carbon homolog of salvinorin A was well tolerated at the KOP receptors.  Moreover, a preferred 
furan ring O-atom orientation for activity at the KOP receptors was indeed observed in that the 
orientation of the O-atom in the cis conformer was more favored for binding at the KOP 
receptors than the orientation exhibited by the O-atom in the trans conformer.  From the present 
study it can be concluded that a two carbon homolog at the C-13 position of salvinorin A is well 
tolerated at the KOP receptors, however additional studies need to be completed in order to 
determine the optimal distance between the furan ring and the diterpene core.  Additionally, two 
carbon furan and tetrahydrofran homologs of salvinorin A were also well tolerated at the KOP 
receptor; nonetheless additional analogues need to be designed to determine the definite steric 
requirements at this position.  Lastly, it was determined that an aromatic substituent at the C-13 
position of the salvinorin A scaffold is not necessary for activity at the KOP receptors.   
 
Future Directions 
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 It is essential that the SAR exploration of the salvinorin A scaffold continue, especially at 
the furan ring position and the interactions of a C-13 substituent with the KOP receptor.  The 
homologated furan ring analogues revealed that there may be features within the KOP receptor 
furan ring binding pocket that have yet to be explored.  In this regard, a series of analogues with 
varying alkyl chain length could be used to determine the optimal length between the terpene 
core and the furan ring that would retain affinity and activity at the KOP receptors.  The use of 
the Arndt-Eistert homologation reaction could be utilized as one of the strategies for the 
synthesis of such a series of analogues.  A different series of analogues should also be designed 
to further test the steric requirements at this position, some of which could include the 
incorporation of various substituents off of the furan ring of a homologated analogue.  This could 
be achieved utilizing Suzuki coupling reaction conditions employing bromo furan salvinorin A 
analogue 126 as the starting material.  Based on the results reported above, a π – π interaction is 
not necessary for activity at the KOP receptors and could be used as the basis for a series of 
different analogues that could be used to further probe the furan ring binding pocket.  Such a 
series of analogues should explore the addition of various cycloalkyl substituents at the C-13 
position in the molecule.  Such prospective studies would help to further elucidate the SAR of 
the C-13 position in the salvinorin A scaffold.   
 The introduction of the X-ray crystal structures of the opioid receptors opened many 
opportunities for molecular modeling studies where the resolved structures can be implemented 
in the design of novel salvinorin A analogues.  Despite the use of a KOP receptor antagonist to 
resolve the structure of the KOP receptor, one could implement such molecular modeling study 
as guidance towards the synthesis of novel salvinorin A analogues.  
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CHAPTER 2:  SALVINORIN A 
PART II:  QUINONE CONTAINING SALVINORIN A ANLOGUES 
 
Introduction to Marine Natural Products 
 The foremost traditional sources of drug molecules that have been the key players in the 
development of the pharmaceutical industry are natural products, specifically those derived from 
terrestrial sources, such as plants and microbes.317  Agrochemicals, modern pharmaceuticals, 
traditional medicines, as well as herbal medicines were discovered through terrestrial 
bioprospecting, a search for biologically active substances from nature that has generated many 
structurally diverse bioactive molecules.318  Despite the fact of the very successful and valuable 
terrestrial biodiversity that has and will certainly continue to provide us with valuable new 
bioactive molecules, the significance of exploration of novel ecosystems of molecular diversity 
continues to be indispensable.318  This will allow for the discovery of exceptional structures with 
continuous scaffold diversity, however without previously being exposed to any known drug 
resistance mechanisms, a problem that has threatened the use of current therapies for various 
conditions.318 
 Oceans cover more than 70% of our planet’s surface.319  It has been estimated that certain 
marine ecosystems, such as coral reefs or the deep sea floor, contain a greater biological 
diversity than that seen in tropical rain forests.  The ability of marine organisms to synthesize 
toxic compounds or attain them from other marine microorganisms, which are then used as a 
defense mechanism, lies in their sedentary life style and soft physical appearance.319  
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Consequently, the oceans represent an area of huge biological diversity that may lead to various 
novel structurally diverse bioactive compounds with potential for use in the clinic. 
 The first report of marine biologically active natural products was described by 
Bergmann and Feeney in 1950, where they reported the isolation of a mixture of nucleosides, 
spongothymidine and spongouridine from the Caribbean sponge Tethya crypta.320  Their 
discovery led to the development of the antileukemic agent Ara-C (240) and its derivative Ara-A 
(241), an antiviral agent (Figure 31).321  The introduction of scuba diving techniques allowed for 
a more comprehensive collection method of marine source organisms.317   
 
Several interdisciplinary research areas such as ecology, biology, biochemistry, organic 
chemistry and pharmacology have been integral in the development of drug discovery from 
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marine organisms and to date there are many marine natural products and derivatives in the 
clinic or undergoing clinical trials.  For instance, ziconotide (242) is a 25 amino acid derivative 
of the conotoxin peptide MVIIA isolated from a cone snail that is currently used as treatment for 
chronic pain; ecteinascidin 743 (243) is the first marine natural product that has reached the 
market as an anticancer drug and was isolated from a carribean tunicate; bengamide B, isolated 
from Jaspidae sponges has been investigated for its antihelminthic activity (Figure 31).317, 321  
These are just few examples of the pronounced structural diversity and diverse biological 
profiles of marine natural products that indicate the great potential of marine bioprospecting in 
drug discovery.  
 
Introduction to Nakijiquinines 
 In the center of many ancient civilizations and their ethnomedicinal traditions and 
spiritual practices were natural products.  Stress from competition, changes in environmental 
factors such as temperature, growth, infection and competition are the sort of stimuli that lead to 
the formation and production of natural products as secondary metabolites.322  As previously 
mentioned, natural products have played an enormous role in the development of many 
pharmaceuticals and in the growth of the pharmaceutical industry.145  Natural products and 
natural product derivatives represent one third of the top selling drugs worldwide, thus 
confirming their role in the development of clinical agents.322  Natural products have found their 
niche in various diseases and to date natural products have contributed to the development of 
anti-cancer agents, anti-infectives, antichlolesterolemics, and various other, some of which are 
still currently used in the clinic.143  Therefore, further investigation into natural products, both 
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terrestrial and marine, will provide us with novel scaffold with intriguing strictures that have 
potential to be therapeutic agents and biological probes. 
Nakijiquinones are marine sesquiterpene quinones from the Spongiidae family that were 
isolated from an Okinawan sponge in the early 1990s.323  To date, there are eighteen 
nakijiquinones all isolated from an Okinawan marine sponge (Figure 32).  The original isolation 
of nakijiquionones A and B was completed by Shigemori and coworkers in 1994, where they 
reported the isolation and structure of the two new sesquiterpenoids.323  They also described the 
rarity of such aminoquinone species from natural sources, though reports of such compounds 
isolated from marine sponges have been reported.324-326  In 1995, Kobayashi and coworkers 
further extended their work on the Okinawan sponge and isolated nakijiquinones C and D as red 
amorphous solids.327  Interestingly, the natural products isolated in the early 1990s were all 
monomer quinones, and it was not until 2009 when Kobayashi and coworkers isolated 
nakijiquinones E and F, isolated as dimer quinones.328   
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Nakijiquinones A – F possess natural amino acid side chains off of the quinone ring and 
it was not until the discovery of nakijiquinones G, H, and I that other substituents were 
discovered at that position.329  Nakijiquinone G and F contain side chains that are derived from 
amino acids, like histidine and arginine, respectively, whereas nakijiquinone I contains an 
interesting substituent, namely a methyl sulfoxide group.329  Several other nakijiquinones were 
also isolated from two different collections of Okinawan marine sponges by Takanashi and 
coworkers in 2010 (Figure 33).330  The newly isolated nakijiquinones J – R contained various 
quinone side chains, however these side chains were mainly aliphatic and only one resembled an 
amino acid side chain (nakijiquinones P and Q).330  In addition to the isolated quinones, several 
other previously reported sesquiterpenoid quinones were also isolated from the collections of the 
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Okinawan marine sponge, such as the isospongiaequinone and mamanuthaquinone (Figure 
33).330   
	  
This family of natural products possesses three structural elements: a diterpene core, an 
amino acid side chain, and a central p-quinoid moiety.331  Upon their isolation, this family of 
quinones showed to be the first naturally occurring inhibitors of the Her-2/Neu receptor tyrosine 
kinase.327  Nakijiquinones C and D exhibited activity against Her-2/Neu tyrosine kinase D of 26 
µg/mL and 29 µg/mL, respectively.327  The nakijiquinones were tested for their cytotoxic activity 
against several different cancer cell lines, specifically the L1210 murine leukemia cells, KB 
human epidermoid carcinoma cell line, and the P388 murine leukemia cell line.  Most of the 
nakijiquinones tested exhibited cytotoxic activity with IC50 values in the range of 1.2 µg/mL – 
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8.5 µg/mL (Table 15).323, 327, 329  Of the marine quinones tested, the most potent against KB 
human epidermoid carcinoma line was nakijiquinone D, with an IC50 of 1.2 µg/mL; against 
L1210 murine leukemia cell line, nakijiquinone I exhibited the highest activity with an IC50 
value of 2.4 µg/mL; lastly the highest cytotoxic activity exhibited by any nakijiquinone against 
the P388 murine leukemia cell line was that of nakijiquinone H, with an IC50 value of 2.4 
µg/mL.323, 327, 329 
Table 15.  Cytotoxic activities of najikiquinones A – I   
IC50 (µg/mL)a 
Cmpd 
L1210 murine 
leukemia cells 
 
KB human 
epidermoid 
carcinoma cells 
 
P388 murine 
leukemia 
 
Her2/Neu 
 
Nakijiquinone A 3.5 4.0 – – 
Nakijiquinone B 4.0 3.2  – – 
Nakijiquinone C 5.8 6.2 – 26.0 
Nakijiquinone D 8.1 1.2 – 29.0 
Nakijiquinone E >10 >10 >10 – 
Nakijiquinone F >10 >10 >10 – 
Nakijiquinone G 2.9 4.8 3.2 – 
Nakijiquinone H 8.5 >10 2.4 – 
Nakijiquinone I 2.4 5.6 2.9 – 
aIC50 = Inhibitory concentration for 50% maximal response 
 
 In addition to the seen cytotoxic activity of these marine natural products, several of the 
nakijiquinones exhibited antimicrobial and antifungal activity against various gram positive, 
gram negative microorganisms and yeast strains.  Nakijiquinones A and B exhibited 
antimicrobial activity against the yeast strain C. albicans with MIC values of 2.5 and 33 µg/mL, 
respectively, as well as against A. niger with MIC values of 5.0 and 133 µg/mL, respectively 
(Table 16).323  Nakijiquinones G, H, and I were also subjected to testing for their antimicrobial 
and antifungal activity and it was determined that nakijiquinone H was the most active of the 
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three and it excited activity against C. neoformans (MIC = 8.35 µg/mL), M. luteus (MIC = 16.7 
µg/mL), C. albicans (MIC = 8.35 µg/mL), and A. niger (MIC = 16.7 µg/mL) (Table 17).329 
Table 16.  Antamicrobial activities of nakijiquinones A and B  
MIC ((µg/mL) a 
Cmpd 
C.albicans A. niger 
 
Nakijiquinone A 2.5 5.0 
Nakijiquinone B 33.0 133.0 
aMIC = Minimal inhibitory concentration for 50% maximal response 
 
Table 17.  Antimicrobial activities of nakijiquinones G – I  
MIC (µg/mL)a  
Cmpd 
S. 
aureus  
C. 
neoformans 
B. 
subtilus 
E. 
coli 
 
M. 
luteus  
C. 
albicans 
A. 
niger 
Nakijiquinone G 33.3 >33.3 33.3 >33.3 33.3 >33.3 >33.3 
Nakijiquinone H 33.3 8.35 33.3 >33.3 16.7 8.35 16.7 
Nakijiquinone I >33.3 >33.3 >33.3 >33.3 33.3 >33.3 >33.3 
aMIC = Minimal inhibitory concentration for 50% maximal response  
 
Due to their interesting activity, the nakijiquinone family of natural products has been of 
interest to many researchers.  Structure-activity relationship studies as well as total synthesis 
efforts have been undertaken for the nakijiquinones and similar scaffolds, namely avarol and 
avarone.331-335 
 
Rationale and Specific Aims 
 Nakijiquinones are a family of diterpene natural products isolated from a marine sponge 
that exhibit significant cytotoxic activity in various cancer cell lines.  One can envision that the 
quinone moiety present in the molecule may be responsible for the cytotoxic activity exhibited 
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by these natural products.  Salvinorin A possesses a diterpene core similar to the nakijiquinone 
family of marine natural products.  Interestingly, salvinorin A has been shown to cross the BBB 
and have a fast onset of action.280  It was determined in a non-human primate study conducted by 
Butelman and coworkers that a 0.032 mg/kg dose of salvinorin A elicited a response after only 1 
minute of intravenous administration, thus confirming the fast BBB penetration of salvinorin 
A.280  It was hypothesized that a combination of the nakijiquinone and salvinorin A scaffolds 
would yield a molecule with potential as a biological probe and a diagnostics tool for brain 
tumors.  Thus, quinone containing salvinorin A analogues were designed and synthesized.  To 
this end, the following specific aims were proposed: 
Specific Aim 1:  Prepare quinone containing salvinorin A analogues for biological 
evaluation through semi-synthesis.  
 A series of quinone containing analogues were prepared through modification of 
salvinorin A.  Analogues that explore free rotation around the C-13 carbon of the salvinorin A 
core will be synthesized in addition to analogues that explore different positions of substitution 
on the quinone moiety now present in the salvinorin A scaffold.  Such analogues will provide 
additional SAR for salvinorin A at KOP receptors and demonstrate that this scaffold can be 
manipulated in a way that will lead to novel biological activity. 
Specific Aim 2:  Evaluate quinone containing salvinorin A analogues KOP receptor activity 
and antiproliferative potential. 
 Analogues proposed and synthesized in Specific Aim 1 will be evaluated for activity at 
the KOP receptors utilizing a known calcium mobilization assay protocol.316  This assay will be 
utilized because of its simpler format and definitive data and the lack of radiolabeled ligand use.  
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Analogues prepared from Specific Aim 1 will also be subjected to an antiproliferative assay to 
determine their activity in two cancer breast cell lines, MCF7 and SKBr3.  The purpose of these 
assays is to determine the activity of the chimeric compounds at the KOP receptors as well as to 
attain their antiproliferative activity in vitro. 
 The studies presented in the above specific aims are intended to investigate the 
hypothesis that a combination of two natural products scaffold will be a useful biological probe 
and represent an extension in the development of novel CNS diagnostic tools.  Completion of 
these studies will further extend the SAR of the salvinorin A scaffold at the KOP receptors and 
will represent the first report of salvinorin A analogues with antiproliferative activity.  The 
results of these studies will be presented and discussed.   
 
Results and Discussion 
Introduction 
 In an effort to elucidate the ability of salvinorin A as a biologic probe, several quinone 
containing analogues of salvinorin A were synthesized.  These compounds were meant to 
investigate the possibility of changing the biological activity of the salvinorin A core.  The 
similarity between the two natural products, both diterpene natural products, represented an 
opportunity for exploration of a combination of the two in one single molecule (Figure 34).  As 
previously determined reports have stated, nakijiquinones exhibit cytotoxic activity, likely do to 
the quinone moiety present in the scaffold.  Similarly, salvinorin A whose interesting biological 
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activity has also been determined was shown to pass through blood-brain-barrier, making it a 
prime target for the development of a biological probe.   
The combined scaffold analogues were synthesized to examine the hypothesis that 
quinone barring salvinorin A analogues may have a potential as a diagnostic tools and biological 
probes.  Several analogues were synthesized with the purpose of examining the ability for free 
rotation within the active site and the quinone substituents necessary for antiproliferative 
activity.   
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Synthesis 
 Salvinorin A (83, Scheme 5) was isolated from S. divinorum leaves as previously 
described and the synthesis of quinone containing salvinorin A analogues begun with the 
synthesis of several boronic acids (Scheme 4).311  The main carbon-carbon bond cross-coupling 
reaction was the Leiebeskind-Srogl reaction which was chosen based on the recent discovery by 
our laboratory that the mild coupling conditions of this reaction, which utilize 
bis(dibenzylideneacetone)palladium(0), copper (I) thiophene carboxylate and triethylphosphite at 
ambient temperature are well tolerated by the salvinorin A scaffold.302  However, prior to the use 
of the Lebeskind-Srogl coupling reaction, several boronic acids were prepared, which was 
accomplished following previously published reports.  2,3,4,5-Tetramethoxyphenyl boronic acid 
was synthesized following slightly modified conditions proposed by Tremblay and coworkers.336  
The synthesis began with commercially available 2,3,4-trimethoxybenzaldehyde 259, which was 
subjected to oxidation conditions with hydrogen peroxide to yield intermediate 260 in 84% yield 
(Scheme 5).  This intermediate was then subjected to methylation conditions using iodomethane 
and potassium carbonate to afford compound 261 in 67% yield.  2,3,4,5-Trimethoxyphenyl 
boronic acid 262, was synthesized from intermediate 261 in 52% yield.  2,4,5-Trimethoxyphenyl 
boronic acid was prepared following conditions proposed by Sutherland and coworkers.337  
Briefly, commercially available 1,2,4-trimethoxybenzene 263 was used as the starting material 
for the synthesis of intermediate 264 utilizing bromine in 96% yield.  Intermediate 264 was then 
subjected to lithium-halogen exchange and in the presence of trimethyl borate compound 265 
was synthesized in 38%.   
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Intermediate 141 was synthesized according to our previous reports in 74% yield 
(Scheme 5).298  This intermediate was then subjected to esterification with thiophenol to yield 
salvinorin A thioester 142 in 60% yield.  Compound 142 was used as the starting material in the 
cross-coupling reaction with several different boronic acids to yield aromatic ketones 266, 267, 
and 268 in 48%, 79%, and 90% yield, respectively (Scheme 5).  The next step towards the 
synthesis of the desired analogues was a deoxygenation reaction that would ultimately yield a 
CH2 homolog from a ketone starting material.  Several different methods were attempted for a 
transformation that would produce the CH2 homolog directly from its ketone precursor, however 
they demonstrated to unsuccessful because they all produced a hydroxyl product instead the 
desired CH2 product (Table 18).  In the end the Corey-Bakshi-Shibata reduction was chosen 
because of the higher yields and the mild conditions.  Intermediates 266, 267, and 268 were then 
subjected to Corey-Bakshi-Shibata reduction condition to yield compounds 269, 270, and 271 in 
90%, 89%, and 64% yield, respectively.  Utilizing trimethylsilane and boron trifluoride diethyl 
etherate, compounds 269, 270, and 271 were subjected to a deoxygenation reaction to afford 
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intermediates 272, 273, and 274 in 36%, 55%, and 56%, respectively.  Intermediates 272, 273 
and 274 were further oxidized utilizing CAN to yield final compounds 275, 276, and 277 in 
39%, 28%, and 72% yield, respectively.   
Table 18.  Conditions attempted towards the synthesis of the deoxygenated intermediate 
 
Test System Conditions Used Desired Product Product Formed 
	  
 
InCl3, Ph2SiH, DCM None 	  
	  
 
[1,5-HDRhCl]2, β-
cyclodextrin, THF 
None 
ZnCl2, Et3SiH, DCE None 
PdCl2, Et3SiH, EtOH None 
TFA, Et3SiH None 
B(C6F5)3, Et3SiH, DCM None 
B(C6F5)3, Ph2SiH, DCM None 
GaCl3, Me2ClSiH, DCM None 
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Pharmacological Evaluation 
In vitro Functional Assay 
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 Quinone containing analogues of salvinorin A were subjected to pharmacological testing 
to determine their activity at the KOP receptors as well as their antiproliferative properties.  
Analogues 275 – 277 were subjected to a calcium mobilization assay, which is a functional assay 
that will determine their activity at the KOP receptors.  As expected, the majority of the 
analogues tested showed to be inactive at the KOP receptors, with the exception of analogue 275, 
which displayed an EC50 value of 2.5 µM and was observed to be a partial agonist with an Emax 
value of 27% (Table 19).   
Table 19.  Analysis of potency of analogues 275 – 267 in the Ca2+ 
mobilization functional assay 
Cmpd 
KOP 
EC50 ± SEM (nM)a 
KOP 
Emax ± SEMb 
83 1.7 ±	  0.6 103 ± 2 
275 2500 ± 900 27 ± 4 
276 >10,000 N.D.c 
277 >10,000 N.D.c 
aEC50 = Effective concentration for 50% maximal response.  
bEmax is % which compound stimulates binding compared to (-)-
U-69,593 at KOP receptors. n  = 2 
cN.D. = not determined 
 
In vitro Antiproliferation Assay 
The analogues synthesized were also tested in an antiproliferative assay to determine 
their effects in several cancer cell lines, particularly breast cancer cell lines MCF7 and SKBr3, 
(Table 20).  As expected, the quinone containing salvinorin A analogues did indeed show 
antiproliferative effects in the cancer cell lines tested.  It was determined that analogues 275 – 
277 exhibited low to moderate antiproliferative activity, with analogue 276 showing the most 
promise in the MCF7 and SkBr3 breast cancer cell line with an EC50 value of 4.5 µM and 8.3 
µM, respectively.  Analogues 275 and 277 also exhibited antiproliferative activity with EC50 
113 
	  
values of 8.3 µM in the MCF7 cancer cell line and 14 µM and 23 µM, respectively in the SKBr3 
cancer cell line.  Though the analogues synthesized displayed low to moderate antiproliferative 
activity, they were not as active as geldanamycin (GDA) in this assay.  The present results 
indicate that a double substitution of the quinone ring in these analogues is better tolerated than a 
single substitution or no substitution of the quinone ring.  However, additional information is 
needed before a conclusion of an optimal substitution pattern for the quinone ring can be 
reached.   
Table 20.  Antiproliferative activity of compounds 275– 277 
Cmpd 
MCF7 
EC50 ± SEM (µM)a,b 
SKBr3 
EC50 ± SEM (µM)a,b 
GDAc 0.05 ± 0.03 0.01 ± 0.02 
275 8.28 ± 0.72 13.9 ± 0.21 
276 4.53 ± 1.78 8.34 ± 0.41 
277 8.25 ± 0.89 23.0 ± 1.66 
aEC50 = Effective concentration for 50% maximal response.  
bValues represent mean ± standard deviation for at least two 
separate experiments performed in triplicate 
cData from Khandelwal, A. et al. J. Org. Chem. 2013, 78, 7859-
7884. 
 
 
Conclusions 
 The similarity between two natural products, a plant derived terpene salvinorin A and the 
marine sponge derived nakijiquinone family of terpene natural products, prompted an idea that a 
combination of the two scaffolds may yield a biological probe that could have potential as a 
diagnostic tool.  Several compounds were synthesized with similarities to both scaffolds, mainly 
as salvinorin A analogues that possess a quinone moiety instead of the furan ring of salvinorin A.   
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 Upon synthesis, the designed analogues were subjected to pharmacological testing for 
their activity at the KOP receptors.  As expected, the quinone containing analogues of salvinorin 
A exhibited negligible activity at the KOP receptors.  Furthermore, the analogues reported were 
also subjected to an antiproliferative assay to determine their activity against several breast 
cancer cell lines.  It was determined that the analogues exhibited low to moderate 
antiproliferative activity, indicating their possible use as a biological probes in the diagnosis of 
certain brain cancer ailments.  To the best of our knowledge, this represents the first report of 
salvinorin A analogues that exhibit antiproliferative activity.  
 
Future Directions 
 Aside from possessing a quinone moiety, the nakijiquionone family of natural products 
also contains various amino acid-like side chains which are appended to the quionone ring.  In 
order for a more complete SAR representation for this chimeric scaffold, additional quinone 
containing salvinorin A analogues need to be synthesized with side chains resembling those or 
derivatives of the original natural products.  Furthermore, the in vitro activity of these analogues 
for the KOP receptors needs to be correlated with their ability to pass through the BBB.  There 
are several methods that could assess the ability of a compound to pass through the BBB, 
including in vitro, in silico and in vivo models.338  One of the most versatile and high throughput 
in vitro assays used in drug discovery is the parallel artificial membrane permeability assay for 
the blood-brain barrier (PAMPA-BBB), where the rate of transcellular passive diffusion of a 
drug across the BBB is accomplished by measuring the effective permeability of an artificial 
lipid membrane.339  Moreover, analogues that contain fluorescent ligands in place of the quione 
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moiety could be beneficial in determining the mechanism of action of these salvinorin A derived 
ligands in brain tissue.  In addition to the mentioned assays, the analogues synthesized as well as 
any additional analogues should also be examined for their activity at the other opioid receptors.  
116 
	  
CHAPTER 3: EXPERIMENTAL PROCEDURES FOR SALVINORIN A ANALOGUES 
PART I:  DESIGN AND SYNTHESIS OF STERICALLY CHALLENGED 
SALVINORIN A ANALOGUES 
Chemistry 
General Procedures. Unless otherwise indicated, all reagents were purchased from 
commercial suppliers and were used without further purification.  Melting points were 
determined on a Thomas-Hoover capillary melting apparatus.  NMR spectra were recorded on a 
Bruker DRX-400 with qnp probe or a Bruker AV-500 with cryoprobe using δ values in ppm 
(TMS as internal standard) and J (Hz) assignments of 1H resonance coupling.  High resolution 
mass spectrometry data were collected on either a LCT Premier (Waters Corp., Milford, MA) 
time of flight mass spectrometer or an Agilent 6890 N gas chromatograph in conjunction with a 
quarto Micro GC mass spectrometer (Micromass Ltd, Manchester UK).  Thin-layer 
chromatography (TLC) was performed on 0.25 mm plates Analtech GHLF silica gel plates using 
ethyl acetate/n-hexanes, in 1:1 ratio as the solvent system unless otherwise noted. Spots on TLC 
were visualized by UV (254 or 365 nm), if applicable, and phosphomolybdic acid in ethanol.  
Column chromatography was performed with Silica Gel (32 – 63 µ particle size) from MP 
Biomedical (Solon, OH).  Analytical HPLC was carried out on an Agilent 1100 Series Capillary 
HPLC system with diode array detection at 209.4 nm on an Agilent Eclipse XDB-C18 column 
(250 × 10 mm, 5 µm) with isocratic elution in 60% CH3CN/40% H2O at a flow rate of 5.0 
mL/min unless otherwise noted, or on a Phenomenex Luna column (250 × 4.5 mm, 5 µm) with 
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isocratic elution in 60% CH3CN/40% H2O unless otherwise noted.  The systematic name for 
salvinorin A (1) is (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(furan-3-yl)-6a,10b-
dimethyl-4,10-dioxo-dodecahydro-1H-benzo[f]iso-chromene-7-carboxylate.  Salvinorin A was 
isolated from S. divinorum as previously described.340 
(4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-((E)-2-(furan-3-yl)vinyl)-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (235) and 
(4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-((Z)-2-(furan-3-yl)vinyl)-6a,10b-dimethyl-
4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (236).  KHMDS (1.64 mL of 
a 0.5 M solution in toluene, 0.83 mmol) was added in a dropwise manner to a cooled (-78 °C) 
solution of 8312(263 mg, 0.91 mmol) in THF (9 mL). After 30 min, a cooled solution of aldehyde 
5 (300 mg, 0.761 mmol) in THF (20 mL) was added in a dropwise manner over 3 minutes. The 
reaction mixture was stirred at -78 °C for 2 hours or until completion reaction and then it was 
diluted with EtOAc (9 mL) and quenched by the addition of H2O (10 mL). After warming to 
room temperature over 30 min, the phases were separated and the aqueous phase was extracted 
with EtOAc (2 × 10 mL). The combined organic extracts were washed with brine (2 × 10 mL) 
and dried over Na2SO4. Filtration and concentration under reduced pressure afforded 235 and 
236 as a 2:1 mixture, which was separated by flash column chromatography to afford, in order of 
elution, major isomer 236 as a white solid and the minor isomer 236 also as a white solid. The 
minor isomer was further purified by HPLC (40% ACN/60% H2O) on an Agilent Eclipse XDB-
C18 column (250 × 10 mm, 5 µm) at a flow rate of 5 mL/min. 
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235: Isolated as an off-white solid (25 mg, 7.2% yield) of trans isomer after purification; 
mp = 192 – 194°C.  1H NMR (500 MHz, CDCl3) δ 7.45 (s, 1H), 7.39 (s, 1H), 6.51 (d, J = 13.0 
Hz, 2H), 5.88 (dd, J = 6.3, 15.8Hz, 1H), 5.15 (d, J = 9.7Hz, 2H), 3.76 (s, 3H), 2.77 (d, J = 8.1Hz, 
1H), 2.43 (d, J = 8.3Hz, 1H), 2.34 (d, J = 9.9Hz, 2H), 2.20 (s, 3H), 2.18 (s, 1H), 2.05 (s, 1H), 
1.84 (s, 1H), 1.63 (s, 3H), 1.45 (s, 3H), 1.14 (s, 3H).  13C NMR (126 MHz, CDCl3) δ 201.85, 
171.38, 171.06, 169.84, 143.57, 141.07, 126.66, 122.82, 121.74, 107.15, 77.40, 74.92, 63.96, 
53.46, 51.82, 51.17, 42.89, 41.96, 38.05, 35.17, 30.56, 20.40, 17.95, 16.19, 15.04.  HRMS (m/z): 
[M+Na] calcd for C25H30O8Na, 481.1838; found, 481.1832.  HPLC tR= 8.832 min; purity = 
98.2%.  
 
236: Isolated as a white solid (11.7 mg, 3.4 % yield) of cis isomer after purification; mp = 
182 – 184 °C.  1H NMR (500 MHz, CDCl3) δ 7.52 (s, 1H), 7.45 (s, 1H), 6.45 (s, 1H), 6.40 (d, J = 
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11.2Hz, 1H), 5.54 (d, J = 11.2Hz, 1H), 5.47 – 5.41 (m, 1H), 5.20 – 5.15 (m, 1H), 3.76 (s, 3H), 
2.81 – 2.75 (m, 1H), 2.34 (d, J = 9.9Hz, 4H), 2.20 (s, 3H), 2.18 (s, 1H), 2.09 – 2.04 (m, 1H), 1.84 
– 1.79 (m, 1H), 1.63 (s, 3H), 1.45 (s, 3H), 1.14 (s, 3H).  13C NMR (126 MHz, CDCl3) δ 202.14, 
171.81, 171.47, 170.21, 143.76, 142.04, 128.49, 124.02, 121.01, 110.94, 75.23, 74.12, 64.36, 
53.84, 52.23, 51.65, 43.04, 42.30, 38.44, 35.70, 30.99, 20.83, 18.36, 16.65, 15.52.  HRMS (m/z): 
[M+Na] calcd for C25H30O8Na, 481.1838; found, 481.1830.  HPLC tR= 8.691 min; purity = 
100.0%.  
 
(2S,6aR,7R,9S,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-dioxo-2-
(tetrahydrofuran-3-yl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (239).  
Salvinorin A was dissolved in a 1:1 mixture of DCM:MeOH and Rh/C (5%, 0.5 g, 4..95 mmol, 5 
equiv) was then added.  The flask was then charged with H2 and the resulting mixture was 
allowed to stir at ambient temperature for 24 hrs.  Upon completion (TLC monitoring), the 
rection mixture was filtered through a pad of Celite and thoroughly washed with DCM (150 mL) 
and concentrated under reduced pressure.  The resulting residue was purified by silica gel 
column chromatography using DCM/MeOH to afford 0.12g (28% yield) as a white solid.  mp = 
173-175 °C.  TLC system: 10% MeOH/90% DCM. 1H NMR (500 MHz, CDCl3) δ 5.15 (dd, J = 
11.6, 8.4 Hz, 1H), 4.51 – 4.33 (m, 1H), 3.96 (dd, J = 9.1, 7.5 Hz, 1H), 3.85 (dd, J = 4.9, 3.5 Hz, 
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1H), 3.81 – 3.74 (m, 1H), 3.73 (s, 3H), 3.55 (dd, J = 9.0, 6.7 Hz, 1H), 2.78 – 2.69 (m, 1H), 2.48 – 
2.40 (m, 1H), 2.39 – 2.23 (m, 3H), 2.18 (s, 3H), 2.12 (d, J = 4.6 Hz, 1H), 2.10 – 2.02 (m, 1H), 
1.94 (tdd, J = 12.9, 6.1, 3.6 Hz, 2H), 1.87 – 1.73 (m, 2H), 1.59 – 1.52 (m, 2H), 1.36 (s, 3H), 1.30 
– 1.19 (m, 1H), 1.10 (s, 3H).  13C NMR (126 MHz, CDCl3) δ 202.03, 202.01, 171.54, 171.52, 
171.30, 171.09, 169.96, 169.93, 79.34, 78.22, 74.98, 70.42, 68.86, 68.07, 67.97, 64.12, 64.08, 
53.58, 53.56, 51.99, 51.43, 51.41, 45.65, 45.10, 42.08, 42.06, 41.98, 41.20, 38.15, 38.13, 35.14, 
35.10, 30.79, 28.26, 28.20, 20.61, 18.16, 16.36, 15.13.  HRMS (m/z): [M+K] calcd for 
C23H32O8K, 475.1734; found, 475.1714.  HPLC tR= 4.855 min; purity = 95.0%.  
 
(2R,6aR,7R,9S,10bR)-methyl 9-acetoxy-2-(2-(furan-3-yl)ethyl)-6a,10b-dimethyl-
4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (237).  
(2S,6aR,7R,9S,10bR)-methyl 9-acetoxy-2-(2-(furan-3-yl)vinyl)-6a,10b-dimethyl-4,10-
dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate synthesized as described above for 
compounds 235 and 236) and Pd/C (10%, 0.004 g, 0.0033 mmol, 0.03 equiv) were placed in 
around bottom flask and charged with H2 and EtOAc (5 mL).  The resulting mixture was allowed 
to stir at ambient temperature until completion (TLC monitoring).  Upon completion, the 
resulting mixture was filtered through pad of Celite and thoroughly washed with EtOAc and 
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concentrated under reduced pressure.  The resulting residue was purified by silica gel column 
chromatography using 35% EtOAc/65 % pentane to afford 0.02g (40% yield) as a white solid, 
mp = 149-151 °C..  TLC system: 60% EtOAc/40% n-hexanes.  1H NMR (500 MHz, CDCl3) δ 
7.35 (t, J = 1.7 Hz, 1H), 7.23 (t, J = 1.3 Hz, 1H), 6.26 – 6.23 (m, 1H), 5.17 – 5.09 (m, 1H), 4.51 
(td, J = 7.6, 4.2 Hz, 1H), 3.72 (s, 3H), 2.78 – 2.69 (m, 1H), 2.62 (ddd, J = 14.7, 9.4, 5.2 Hz, 1H), 
2.57 – 2.49 (m, 1H), 2.34 – 2.22 (m, 3H), 2.18 (s, 3H), 2.17 – 2.11 (m, 2H), 1.95 (dd, J = 11.7, 
3.1 Hz, 1H), 1.91 – 1.83 (m, 1H), 1.82 – 1.74 (m, 2H), 1.66 – 1.56 (m, 2H), 1.34 (s, 3H), 1.28 – 
1.21 (m, 2H), 1.09 (s, 3H).  13C NMR (126 MHz, CDCl3) δ 202.05, 171.56, 171.47, 170.01, 
142.98, 139.04, 123.63, 110.79, 76.44, 75.08, 64.18, 53.62, 51.98, 51.39, 42.75, 42.11, 38.24, 
37.14, 35.13, 30.75, 20.60, 20.23, 18.17, 16.36, 15.15.  HRMS (m/z): [M+K] calcd for 
C23H32O8K, 499.1734; found, 499.1728.  HPLC tR= 10.264 min; purity = 95.0%. 
 
(2R,6aR,7R,9S,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-dioxo-2-(2-
(tetrahydrofuran-3-yl)ethyl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (238).  
(2S,6aR,7R,9S,10bR)-methyl 9-acetoxy-2-(2-(furan-3-yl)vinyl)-6a,10b-dimethyl-4,10-
dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate synthesized as described above for 
compounds 235 and 236) and Pd/C (10%, 0.007 g, 0.0065 mmol, 0.06 equiv) were placed in 
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around bottom flask and charged with H2 and EtOAc (5 mL).  The resulting mixture was allowed 
to stir at ambient temperature until completion (TLC monitoring).  Upon completion, the 
resulting mixture was filtered through pad of Celite and thoroughly washed with EtOAc and 
concentrated under reduced pressure.  The resulting residue was purified by silica gel column 
chromatography using 60% EtOAc/40 % pentane to afford 0.02g (39% yield) as a white solid, 
mp = 82-85 °C.  TLC system: 60% EtOAc/40% n-hexanes.  1H NMR (500 MHz, CDCl3) δ 5.17 
– 5.10 (m, 1H), 4.53 – 4.45 (m, 1H), 3.89 (ddd, J = 8.7, 7.2, 1.9 Hz, 1H), 3.84 (td, J = 8.4, 4.7 
Hz, 1H), 3.77 – 3.71 (m, 4H), 3.31 (ddd, J = 8.4, 7.3, 1.3 Hz, 1H), 2.79 – 2.68 (m, 1H), 2.34 – 
2.21 (m, 4H), 2.21 – 2.09 (m, 7H), 2.03 (ddq, J = 11.8, 7.7, 3.9 Hz, 1H), 1.93 (dd, J = 11.7, 3.1 
Hz, 1H), 1.78 (dt, J = 13.1, 2.5 Hz, 1H), 1.64 – 1.57 (m, 2H), 1.48 (dq, J = 11.9, 7.8 Hz, 1H), 
1.36 (s, 3H), 1.22 (t, J = 12.5 Hz, 1H), 1.09 (s, 3H), 0.92 – 0.82 (m, 1H), 13C NMR (126 MHz, 
CDCl3) δ 202.08, 171.55, 171.49, 170.02, 75.08, 73.23, 67.93, 64.18, 53.62, 51.99, 51.38, 42.72, 
42.11, 39.08, 39.05, 38.23, 35.62, 35.12, 32.33, 30.76, 28.38, 20.61, 18.15, 16.37, 15.15.  HRMS 
(m/z): [M+K] calcd for C25H36O8K, 503.2047; found, 503.2019.  HPLC (50% CH3CN/50% H2O) 
tR= 10.982 min; purity = 95.1%. 
Binding and Efficacy Studies 
Radioligand Binding Studies.314  MOP receptor binding sites were labeled using [3H]D-
Ala2-MePhe4,Gly-ol5]-enkephalin ([3H]DAMGO, SA = 44 – 48 Ci/mmol) while DOP receptor 
binding sites were labeled using [3H][D-Ala2, D-Leu5]-enkephalin ([3H]DADLE, SA = 40 – 50 
Ci/mmol) in rat brain homogenates.  KOP receptor binding sites were labeled using [3H]N-
methyl-2-phenyl-N-[(5R,7S,8S)-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]dec-8-yl]acetamide 
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([3H]U69,593, SA = 50 Ci/mmol).  On the day of the assay, cell pellets were thawed on ice for 
15 minutes followed by homogenization with a polytron in 10 mL/pellet of ice-cold 10mM Tris-
HCl, pH 7.4.  The membranes were centrifuged at 30,000 × g for 10 minutes, then resuspended 
in 10 mL/pellet ice-cold 10mM Tris-HCl, pH 7.4 followed again by centrifugation at 30,000 × g 
for 10 minutes.  Membranes were then resuspended in 25°C 50 mM Tris-HCl, pH 7.4 (~100 
mL/pellet hMOP-CHO, 50 mL/pellet hDOP-CHO, and 120 mL/pellet hKOP-CHO).  All assays 
were performed in 50 mM Tris-HCl, pH 7.4 in a final assay volume of 1.0 mL, with a protease 
inhibitor cocktail: bacitracin (100 µg/mL), bestatin (10 µg/mL), leupeptin (4 µg/mL) and 
chymostatin (2 µg/mL).  Drug dilution curves were determined with buffer containing 1 mg/mL 
BSA.  20 µM levallorphan ([3H]DAMGO and [3H]DADLE) or 10 µM (-)-U69,593 (for 
[3H]U69,593 binding) was used to account for nonspecific binding.  [3H]Radioligands were used 
at concentrations of approximately 2 nM.  After 2 hours of incubation at 25°C, triplicate samples 
were filtered with Brandell Cell Harvesters (Biomedical Research & Development Inc., 
Gaithersburg, MD), over Whatman GF/B filters.  The filters were the punched into 24-well 
plates in which 0.6 mL of LSC-cocktail (Cytoscint) was added.  After an overnight extraction, 
the samples were counted in a Trilux liquid scintillation counter at 44% efficiency.  
Approximately 30 µg protein was used in each assay tube for the opioid binding assays.  The 
inhibition curves were determined by displacing a single concentration of radioligand by 10 
concentrations of drug. 
[35S]GTP-γ-S Functional Assay.315  The [35S]GTP-γ-S assays were conducted as 
previously described.  Buffer A is 50 mM Tris-HCl, pH 7.4, containing 100 mM NaCl, 10 mM 
MgCl2, 1 mM EDTA and buffer B is buffer A with the addition of 1.67 mM dithiothreitol (DTT) 
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and 0.15% bovine serum albumin (BSA).  On the day of the assay, cells were thawed on ice for 
15 min and homogenized using a polytron in 50 mM Tris-HCl, pH 7.4, containing a protease 
inhibitor cocktail: bacitracin (100 µg/mL), bestatin (10 µg/mL), leupeptin (4 µg/mL) and 
chymostatin (2 µg/mL). The homogenate was centrifuged at 30,000 × g for 10 minutes at 4°C, 
and the supernatant discarded. The membrane pellets were then resuspended in buffer B and 
used for [35S]GTP-γ-S binding assays.  50 µL of buffer A plus 0.1% BSA, 50 µL of GDP in 
buffer A/0.1% BSA (final concentration = 40 µM), 50 µL of drug in buffer A/0.1% bovine 
serum albumin, 50 µL of [35S]GTP-γ-S in buffer A/0.1% BSA (final concentration = 50 pM), and 
300 µL of cell membranes (50 µg of protein) in buffer B were added in test tubes.  Final 
concentrations of reagents in the assay were: 50 mM Tris-HCl, pH 7.4, containing 100 mM 
NaCl, 10 mM MgCl2, 1 mM EDTA, 1 mM DTT, 40 µM GDP, and 0.1% BSA.  Media was 
incubated at 55°C for 3 hours.  Non-specific binding was accounted for and determined using 
GTP-γ-S (40 µM).  Vacuum filtration through Whatman GF/B filters separated bound and free 
[35S]GTP-γ-S.  The filters were punched into 24-well plates followed by the addition of 0.6 mL 
of liquid scintillation media (Cytoscint).  An overnight extraction was performed and samples 
were counted in a Trilux liquid scintillation counter at an efficiency of 27%. 
Calcium Mobilization Assay.316  All cells were maintained in F-12 nutrient medium 
(Ham), supplemented with 10% fetal bovine serum (FBS), 1% penicillin and streptomycin (p/s), 
and 0.2% normocin.  Cell culture supplies were from Invitrogen (Carlsbad, CA) unless otherwise 
specified.  Chinese hamster ovary (CHO) cells stably expressing MOP-, KOP-, DOP-receptors, 
or CB1-Gαq16 were removed from their flasks using Versene and quenched with the Ham 
media, centrifuged and re-suspended in media.  Cells were counted with a Cellometer Auto T4 
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(Nexcelom Bioscience, Lawrence, MA) and 30,000 cells were transferred to each well of a black 
Costar 96-well optical bottom plate (Corning Corporation, Corning, NY).  Each plate was 
incubated at 37°C/5% CO2 overnight to confluence.  The culture media was removed from the 
plates and cells were subsequently loaded with a fluorescent calcium probe (Calcium 5 dye, 
Molecular Devices, Sunnyvale, CA) in an HBSS-based buffer containing 20 mM HEPES, 0.25% 
BSA, 1% DMSO (or 0.5% DMSO + 0.5% EtOH for CB1-expressing cells), and 10 µM 
probenecid (Sigma) in a total volume of 225 µL.  Cells were incubated at 37°C/5% CO2 for 1 h 
and then stimulated with DMSO solutions of DAMGO, U-69,593, DPDPE, ethanol solutions of 
CP-55,940 or DMSO solutions of test compounds at various concentrations using a Flexstation 3 
plate-reader, which automatically added 25 µL of the compounds at 10X concentration to each 
well after reading baseline values for ∼17 sec.   Agonist-mediated change in fluorescence (485 
nm excitation, 525 nm emission) was monitored in each well at 1.52 sec intervals for 60 sec and 
reported for each well.  Data were collected using Softmax version 4.8 (MDS Analytical 
Technologies) and analyzed using Prism software (GraphPad, La Jolla, CA).  Nonlinear 
regression analysis was performed to fit data and obtain maximum response (Emax), EC50, 
correlation coefficient (r2) and other parameters.  All experiments were performed at least 2 
times to ensure reproducibility and data reported as mean ± standard error, unless noted 
otherwise. 
 Salvinorin A extraction from S. divinorum leaves.311  Briefly, dried Salvia divinorum 
leaves (1.5 kg), obtained commercially from Ethnogens.com, were ground to a fine powder and 
percolated with acetone (5 x 4 L).  The acetone extract was concentrated under reduces pressure 
to afford a crude green gum (93 g), which was subjected to column chromatography on silica 
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gel; with elution in n-hexanes containing increasing amounts of EtOAc.  Fractions eluting in 
20% n-hexanes/EtOAc contained salvinorin A (TLC) and other minor diterpenes and some 
pigmented material.  These fractions were pooled and concentrated under reduced pressure to 
give a green gum (24 g).  A mixture of the crude green gum, acetic anhydride (50 mL, 530 
mmol) and DMAP (0.2 g) in DCM (250 mL) was stirred at ambient temperature overnight.  The 
DCM solution was dried over Na2SO4 and the solvent was removed under reduced pressure to 
afford a yellow-green gum (23 g).  The resulting gum was subjected to column chromatography 
on silica gel and elution was performed with mixtures of n-hexanes/EtOAc in 1 L fraction 
aliquots in increments of 10% EtOAc with the final elution in 100% EtOAc.  Fractions eluting in 
30% n-hexanes/EtOAc and subsequent fractions were pooled and the solvent removed under 
reduced pressure to afford salvinorin A (7.5 g, 0.5%) as a green powder. 
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CHAPTER 3: EXPERIMENTAL PROCEDURES FOR SALVINORIN A ANALOGUES 
PART II:  QUINONE CONTAINING SALVINORIN A ANALOGUES 
Chemistry 
 General Methods.  Unless otherwise indicated, all reagents were purchased from 
commercial sources and were used without further purification.  Melting points were determined 
on a Thomas-Hoover capillary melting apparatus.  NMR spectra were recorded on a Bruker 
DRX-400 with qnp probe or a Bruker AV-500 with cryoprobe using δ values in ppm (TMS as 
internal standard) and J (Hz) assignments of 1H resonance coupling.  High resolution mass 
spectrometry data were collected on either a LCT Premier (Waters Corp., Milford, MA) time of 
flight mass spectrometer or an Agilent 6890 N gas chromatograph in conjunction with a quarto 
Micro GC mass spectrometer (Micromass Ltd, Manchester UK). Thin-layer chromatography 
(TLC) was performed on 0.25 mm plates Analtech GHLF silica gel plates using ethyl acetate/n-
hexanes, in 50%:50% ratio as the solvent unless otherwise noted.  Spots on TLC were visualized 
by UV (254 or 365 nm), if applicable, and phosphomolybdic acid in ethanol.  Column 
chromatography was performed with Silica Gel (40-63 µ particle size) from Sorbent 
Technologies (Atlanta, GA).  Analytical HPLC was carried out on an Agilent 1100 Series 
Capillary HPLC system with diode array detection at 254 nm on an Agilent Eclipse XDB-C18 
column (250 x 10 mm, 5 µm) with isocratic elution in 60% CH3CN/40% H2O  unless otherwise 
specified.   
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2,3,4-trimethoxyphenol (260).  To a solution of 2,3,4-benzaldehyde 259 (6 g, 30.58 
mmol) in H2SO4/MeOH (1:100 v/v), at 0 °C under an argon atmosphere was added 30% H2O2 (8 
mL, 78.29 mmol).  After completion (24 hrs), the reaction mixture was diluted with Et2O and 
washed successively with H2O, brine, dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  The crude mixture was purified by flash column chromatography (20% 
EtOAc/80% n-hexanes) to afford 4.72 g (84% yield) as a clear oil.  Spectral data matched 
previously reported data.336 
 
1,2,3,4-tetramethoxybenzene (261).  To a stirred solution of phenol 260 and K2CO3 in 
acetone was added MeI. The reaction mixture was stirred at reflux overnight and upon 
completion, the mixture is allowed to cool to ambient temperature and filtered.  Filtrate was 
washed with H2O, brine, dried over Na2SO4, filtered and concentrated under reduced pressure.  
The crude mixture was purified by flash column chromatography (20% EtOAc/80% n-hexanes) 
to afford 3.38 g (67% yield) as a white solid.  Spectral data matched previously reported data.336  
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(2,3,4,5-tetramethoxyphenyl)boronic acid (262).  To s stirred solution of benzene 261 
(0.78 g, 3.94 mmol) in THF at ambient temperature under an argon atmosphere, n-BuLi (1.6 M, 
2.7 mL, 4.33 mmol) was added dropwise.  The mixture was stirred for 15 minutes and then 
cooled to -78 °C, upon which trimethyl borate (2.64 mL, 23.64 mmol) was added dropwise.  
Reaction mixture allowed to slowly warm up up to ambient temperature.  Upon completion 
(TLC monitoring), reaction mixture was cooled in an ice bath and quenched with 1 N HCl and 
allowed to warm up to ambient temperature.  After 2 hours the solution was diluted with Et2O 
(50 mL) and washed successively with 1N HCl, brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure.  The crude mixture was purified by flash column 
chromatography (20% EtOAc/80% n-hexanes) to afford 0.46 g (52% yield) as a clear oil.  
Spectral data matched previously reported data.336 
 
1-bromo-2,4,5-trimethoxybenzene (264).  Bromine (0.64 mL, 12.49 mmol) in DCM (10 
mL) was added dropwise to a solution of benzene 263 (2g, 1.77 mL, 11.89 mmol) in DCM (35 
mL) at 0 °C and allowed to stir at that temperature until completion (TLC monitoring).  Upon 
completion, the reaction mixture was washed successively with sodium sulfite, NaHCO3, H2O, 
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and brine, dried over Na2SO4, filtered and concentrated under reduced pressure to afford 2.81 g 
(96% yield) as a white solid that was used without further purification.337 
 
(2,4,5-trimethoxyphenyl)boronic acid (265).  To a solution of bromobenzene 264 (2.81 
g, 11.37 mmol) in THF (20 mL) at -78 °C was added n-BuLi (1.6 M, 7.1 mL, 12.51 mmol) 
dropwise over a period of 10 minutes.  The solution was allowed to stir for 30 minutes and 
trimethyl borate (1.42 mL, 12.51 mmol) was added dropwise keeping the temperature at -78 C.  
The mixture was stirred at -78 °C until completion (TLC monitoring) and upon completion 
quenched with aq. NH4Cl. Water was then added to the mixture and extracted with DCM.  
Organic extracts were then washed with brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure.  The crude mixture was purified by flash column chromatography (45% 
EtOAc/55% n-hexanes) to afford 0.91 g (38% yield) as a clear oil.  Spectral data matched 
previously reported data.337 
General Procedure A: Liebskind-Srogl coupling reaction.  Salvinorin A thiophenol ester 
(1 equiv), appropriate boronic acid (3 equiv), bis(dibenzylideneacetone)palladium (0) (5 mol%), 
copper (I) thiophene carboxylate (1.5 equiv) were placed in a 100 mL round bottom flask and 
flushed with argon (2x).  Anhydrous THF was then added and immediately after 
triphenylphosphite was also added (20 mol%, color change from red to green with a brown tint). 
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Reaction allowed to stir at ambient temperature and upon completion (TLC monitoring) the 
reaction was diluted with 30 mL of Et2O and washed successively with sat. NaHCO3, brine, dried 
over Na2SO4, filtered and concentrated under reduced pressure.  The resulting residue was 
purified by flash chromatography on silica gel using mixtures of EtOAc/n-hexanes.  
General Procedure B: CBS reduction.  Aromatic ketone (1 equiv) was placed in a 
round bottom flask and flushed with argon (3x).  (R)-(+)-2-Methyl-CBS-oxazaborolidine 
solution (1 M in toluene, 1 equiv) was added at -78 °C and allowed to stir for 5 minutes.  Boron-
dimethyl sufide (2 M in diethyl ether, 1 equiv) was then added dropwise at -78 °C and the 
reaction mixture was warmed up to -30 °C and allowed to stir at that temperature until 
completion (TLC monitoring).  Upon completion, 1 mL of MeOH, 0.5 mL of H2O and 5 mL 
Et2O were added to quench the reaction, which was allowed to warm up to room temperature 
over a period of 1 hour.  To the reaction mixture were then added 20 mL of H2O and 20 mL of 
Et2O.  The aqueous layer was wased with Et2O (2x) and the combined organic layers were 
washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure.  The 
resulting residue was purified by flash chromatography on silica gel using mixtures of EtOAc/n-
hexanes.  
General Procedure C. Deoxygenation procedure.  Alcohol (1 equiv, 0.21 mmol) was 
placed in a round bottom flask and flushed with argon before being dissolved in DCM (10 mL) 
and cooled to 0 °C.  Triethylsilane (2 equiv) was then added and after a 2 minute period boron 
trifluoride diethyl etherate (2 equiv) was the added in a dropwise manner.  The reaction mixture 
was allowed to stir at 0 °C overnight until completion (TLC monitoring).  Upon completion, 
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reaction was quenched with H2O and allowed to warm up to ambient temperature.  The mixture 
was then extracted with EtOAc (3x), dried over Na2SO4, filtered and concentrated under reduced 
pressure.  The resulting residue was purified by flash chromatography on silica gel using 
mixtures of EtOAc/n-hexanes.  
General Procedure D. Quinone formation.  To a solution of salvinorin A derivative (1 
equiv, 0.21 mmol) in acetonitrile (7 mL) was added an aqueous solution of cerium (IV) 
ammonium nitrate, 2-3 equiv, 0.42 mmol, 1.4 mL).  Reaction was allowed to stir at ambient 
temperature until completion (TLC monitoring) and upon completion 20 mL of DCM were 
added and successively washed with H2O and brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure.  The resulting residue was purified by flash chromatography on silica 
gel using mixtures of EtOAc/n-hexanes.  
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(2,5-dimethoxybenzoyl)-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (266).  Compound 
266 was synthesized from compound 144 using general procedure A and 2,5-dimethoxyphenyl 
boronic acid to afford 0.250 g (48% yield) isolated as a white solid, mp = 97-100 °C.  TLC 
system 45% EtOAc/55% n-hexanes.  1H NMR (500 MHz, CDCl3) δ 7.36 (d, J = 3.2 Hz, 1H), 
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7.10 (dd, J = 9.0, 3.2 Hz, 1H), 6.93 (d, J = 9.0 Hz, 1H), 5.95 (t, J = 8.1 Hz, 1H), 5.13 – 5.03 (m, 
1H), 3.90 (s, 3H), 3.80 (s, 3H), 3.71 (s, 4H), 2.78 – 2.66 (m, 2H), 2.31 – 2.22 (m, 2H), 2.19 – 
2.07 (m, 7H), 1.80 – 1.60 (m, 3H), 1.54 (td, J = 13.4, 3.8 Hz, 1H), 1.42 (s, 3H), 1.40 – 1.32 (m, 
1H), 1.07 (s, 3H).  13C NMR (126 MHz, CDCl3) δ 201.84, 196.68, 171.61, 169.78, 153.78, 
153.42, 124.04, 122.28, 114.45, 113.45, 79.12, 74.86, 65.02, 56.20, 55.84, 53.31, 51.96, 49.45, 
42.04, 38.04, 37.88, 35.58, 30.75, 20.64, 18.31, 16.68, 16.05.  HRMS (m/z): [M+Na] calcd for 
C28H34NaO10, 553.2050; found 553.2063. 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-((2,5-
dimethoxyphenyl)(hydroxy)methyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate (269).  Compound 269 was synthesized from compound 
266 using general procedure B to afford 0.31 g (90% yield) isolated as a white solid, mp = 125-
128 °C.  1H NMR (500 MHz, CDCl3) δ 6.96 (dd, J = 11.1, 2.5 Hz, 1H), 6.85 – 6.70 (m, 2H), 5.27 
(dd, J = 5.2, 3.1 Hz, 1H), 5.12 (dd, J = 12.4, 7.5 Hz, 1H), 3.78 – 3.76 (m, 5H), 3.72 (d, J = 4.7 
Hz, 3H), 2.80 – 2.70 (m, 2H), 2.35 – 2.19 (m, 2H), 2.19 – 2.09 (m, 5H), 2.02 (dd, J = 11.5, 3.3 
Hz, 1H), 1.87 (dd, J = 13.2, 6.1 Hz, 1H), 1.75 (dt, J = 10.1, 2.9 Hz, 1H), 1.60 – 1.52 (m, 3H), 
1.30 (s, 3H), 1.06 (d, J = 6.0 Hz, 3H).  13C NMR (126 MHz, CDCl3) δ 202.16, 172.13, 171.67, 
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169.60, 153.82, 150.10, 127.29, 113.79, 113.21, 111.26, 78.80, 74.92, 70.54, 64.28, 55.92, 55.72, 
53.44, 51.94, 50.56, 42.13, 38.10, 34.85, 34.81, 30.91, 20.60, 18.18, 16.15, 15.21.  HRMS (m/z): 
[M+Na] calcd for C28H36NaO10, 555.2206; found 555.2217. 
 
(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(2,5-dimethoxybenzyl)-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (272).  Compound 
272 was synthesized from compound 269 using general procedure C to afford 0.11 g (36% yield) 
isolated as a white solid, mp = 96-98 °C.  TLC system: 40% EtOAc/60% n-hexanes.  1H NMR 
(500 MHz, Chloroform-d) δ 6.79 – 6.73 (m, 3H), 5.12 (dd, J = 11.6, 8.4 Hz, 1H), 4.76 (dq, J = 
11.3, 5.6 Hz, 1H), 3.76 (s, 3H), 3.75 (s, 3H), 3.72 (s, 3H), 2.91 (dd, J = 5.8, 2.7 Hz, 2H), 2.73 
(dd, J = 11.7, 5.2 Hz, 1H), 2.33 – 2.23 (m, 3H), 2.17 (s, 3H), 2.14 – 2.06 (m, 2H), 1.92 – 1.83 
(m, 1H), 1.79 – 1.71 (m, 1H), 1.59 – 1.49 (m, 2H), 1.33 (s, 3H), 1.08 (s, 3H).  13C NMR (126 
MHz, CDCl3) δ 202.11, 171.61, 171.58, 169.88, 153.31, 151.83, 125.67, 117.47, 112.57, 111.30, 
75.05, 64.20, 55.79, 55.73, 53.58, 51.96, 51.23, 42.25, 42.15, 38.22, 37.22, 35.08, 30.81, 20.60, 
18.16, 16.31, 15.18.  HRMS (m/z): [M+Na] calcd for C28H36NaO9, 539.2257; found 539.2269. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-((3,6-dioxocyclohexa-1,4-dien-1-
yl)methyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate 
(275).  Compound 275 was synthesized from compound 272 using general procedure D to afford 
0.04 g (39% yield) isolated as a yellow solid, mp = decomp at 212-214 °C.  1H NMR (500 MHz, 
CDCl3) δ 6.80 – 6.72 (m, 2H), 6.70 (dd, J = 2.3, 1.2 Hz, 1H), 5.14 (dd, J = 11.5, 8.5 Hz, 1H), 
4.69 (dddd, J = 11.9, 9.6, 4.9, 3.2 Hz, 1H), 3.73 (s, 3H), 2.81 – 2.70 (m, 2H), 2.60 – 2.50 (m, 
1H), 2.39 (dd, J = 13.3, 4.8 Hz, 1H), 2.34 – 2.25 (m, 2H), 2.18 (s, 3H), 2.12 (d, J = 3.7 Hz, 1H), 
1.97 (dd, J = 11.5, 3.1 Hz, 1H), 1.81 – 1.74 (m, 1H), 1.65 – 1.57 (m, 1H), 1.53 (s, 1H), 1.35 (s, 
3H), 1.32 – 1.22 (m, 1H), 1.09 (s, 3H).  13C NMR (126 MHz, CDCl3) δ 201.91, 187.17, 187.10, 
171.50, 170.74, 170.00, 143.61, 136.61, 136.59, 135.20, 75.11, 75.03, 64.04, 53.60, 52.00, 51.41, 
43.04, 42.09, 38.14, 36.78, 35.26, 30.75, 20.59, 18.12, 16.37, 15.17.  HRMS (m/z): [M+K] calcd 
for C26H30KO9, 525.1527; found 525.1528.  HPLC tR = 6.424; purity = 99.2%. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-dioxo-2-
(2,3,4,5-tetramethoxybenzoyl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (267). 
Compound 267 was synthesized from compound 144 using general procedure A and 2,3,4,5-
tetramethoxyphenyl boronic acid to afford 0.57 g (79% yield) isolated as an amorphous solid.  
TLC system: 45% EtOAc/55% n-hexanes.  1H NMR (500 MHz, CDCl3) δ 7.06 (s, 1H), 5.88 (t, J 
= 8.2 Hz, 1H), 5.13 – 5.04 (m, 1H), 3.98 (s, 3H), 3.94 (s, 3H), 3.90 (s, 3H), 3.86 (s, 3H), 3.72 (s, 
3H), 2.71 (ddd, J = 12.1, 8.3, 2.5 Hz, 2H), 2.28 (td, J = 9.5, 2.2 Hz, 2H), 2.18 – 2.17 (m, 3H), 
2.14 – 2.13 (m, 3H), 2.12 (s, 1H), 1.76 (dt, J = 13.4, 3.2 Hz, 1H), 1.72 – 1.58 (m, 2H), 1.43 (s, 
3H). 1.07 (s, 3H).  13C NMR (126 MHz, CDCl3) δ 201.81, 196.30, 171.58, 171.37, 169.80, 
149.46, 148.77, 148.54, 146.62, 122.46, 107.23, 78.79, 74.89, 64.92, 62.02, 61.25, 56.16, 53.38, 
51.97, 49.51, 42.07, 38.38, 37.91, 35.55, 30.95, 30.71, 20.60, 18.29, 16.51, 16.05. HRMS (m/z): 
[M+Na] calcd for C30H38NaO12, 613.2261; found 613.2289. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(hydroxy(2,3,4,5-
tetramethoxyphenyl)methyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate (270).  Compound 270 was synthesized from compound 
267 using general procedure B to afford 0.78 g (89% yield) isolated as a white solid, mp = 104-
107 °C.  TLC system: 55% EtOAc/44% n-hexanes. 1H NMR (500 MHz, CDCl3) δ 6.65 (s, 1H), 
5.26 (dd, J = 4.7, 2.9 Hz, 1H), 5.11 (dd, J = 12.2, 7.7 Hz, 1H), 4.73 (ddd, J = 11.5, 5.8, 3.0 Hz, 
1H), 3.93 (s, 3H), 3.90 (s, 3H), 3.83 (d, J = 5.1 Hz, 6H), 3.72 (s, 3H), 2.96 (s, 1H), 2.88 (s, 1H), 
2.74 (dd, J = 12.7, 4.1 Hz, 1H), 2.65 (d, J = 4.9 Hz, 1H), 2.31 – 2.22 (m, 2H), 2.17 (s, 2H), 2.12 
(s, 3H), 1.97 (td, J = 13.2, 12.6, 7.0 Hz, 2H), 1.81 – 1.74 (m, 1H), 1.31 (s, 3H), 1.06 (s, 3H).  13C 
NMR (126 MHz, CDCl3) δ 202.18, 171.89, 171.55, 169.53, 149.68, 146.51, 144.04, 142.65, 
125.54, 104.67, 79.77, 74.90, 70.07, 64.23, 61.07, 61.05, 60.99, 56.33, 53.51, 51.91, 50.64, 
42.19, 38.14, 34.81, 34.62, 30.82, 20.50, 18.12, 16.15, 15.14.  HRMS (m/z): [M+Na] calcd for 
C30H40NaO12, 615.2418; found 615.2435. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-dioxo-2-
(2,3,4,5-tetramethoxybenzyl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (273).  
Compound 273 was synthesized from compound 270 using general procedure C to afford 0.42 g 
(55% yield) isolated as a white solid, mp = 91-94 °C.  TLC system: 45% EtOAc/55% n-hexanes.  
1H NMR (500 MHz, CDCl3) δ 6.45 (s, 1H), 5.12 (dd, J = 11.5, 8.4 Hz, 1H), 4.71 (dq, J = 11.3, 
5.5 Hz, 1H), 3.92 (s, 3H), 3.88 (s, 3H), 3.80 (d, J = 9.0 Hz, 6H), 3.72 (s, 3H), 2.88 (qd, J = 13.8, 
5.9 Hz, 2H), 2.77 – 2.70 (m, 1H), 2.33 – 2.22 (m, 3H), 2.16 (s, 3H), 2.10 (d, J = 3.9 Hz, 2H), 
1.87 (dd, J = 11.6, 3.1 Hz, 1H), 1.80 – 1.72 (m, 1H), 1.59 – 1.49 (m, 2H), 1.34 (s, 3H), 1.30 – 
1.24 (m, 1H), 1.08 (s, 3H).  13C NMR (126 MHz, CDCl3) δ 202.14, 171.58, 171.49, 169.85, 
149.22, 146.94, 145.69, 141.92, 123.97, 108.53, 77.69, 75.05, 64.12, 61.15, 61.06, 61.04, 56.23, 
53.57, 51.97, 51.28, 42.28, 42.14, 38.20, 36.72, 35.07, 30.78, 20.58, 18.17, 16.33, 15.18.  HRMS 
(m/z): [M+Na] calcd for C30H40NaO11, 599.2468; found 599.2459. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-((4,5-dimethoxy-3,6-
dioxocyclohexa-1,4-dien-1-yl)methyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate (276).  Compound 276 was synthesized from compound 
273 using general procedure D to afford 0.11 g (28% yield) isolated as an orange solid, mp = 
102-104 °C.  TLC system: 55% EtOAc/45% n-hexanes.  1H NMR (500 MHz, CDCl3) δ 6.55 – 
6.48 (m, 1H), 5.14 (dd, J = 11.7, 8.3 Hz, 1H), 4.68 (dddd, J = 11.7, 9.5, 4.7, 3.2 Hz, 1H), 4.02 (s, 
3H), 4.00 (s, 3H), 3.73 (s, 3H), 2.80 – 2.70 (m, 2H), 2.54 (ddd, J = 14.6, 9.3, 1.1 Hz, 1H), 2.38 
(dd, J = 13.3, 4.9 Hz, 1H), 2.34 – 2.26 (m, 2H), 2.18 (s, 3H), 2.14 – 2.09 (m, 2H), 2.00 – 1.93 
(m, 1H), 1.81 – 1.75 (m, 1H), 1.60 – 1.51 (m, 2H), 1.34 (s, 3H), 1.30 – 1.21 (m, 1H), 1.09 (s, 
3H).  13C NMR (126 MHz, CDCl3) δ 201.92, 183.85, 183.80, 171.51, 170.80, 169.98, 145.04, 
144.87, 141.74, 133.24, 75.19, 75.02, 64.01, 61.31, 61.24, 53.58, 52.00, 51.38, 42.97, 42.08, 
38.12, 36.43, 35.25, 30.74, 20.59, 18.11, 16.36, 15.17.  HRMS (m/z): [M+Na] calcd for 
C28H34NaO11, 569.1999; found 569.1960.  HPLC tR = 6.959; purity = 98.1%. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-dioxo-2-
(2,4,5-trimethoxybenzoyl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (268).  
Compound 268 was synthesized from compound 144 using general procedure A  and 2,4,5-
trimethoxyphenyl boronic acid to afford 1.01 g (90% yield) isolated as a white solid, mp = 103-
106°C.  TLC system: 60% EtOAc/40% n-hexanes.  1H NMR (500 MHz, CDCl3) δ 7.47 (s, 1H), 
6.47 (s, 1H), 5.94 (dd, J = 8.8, 7.3 Hz, 1H), 5.07 (ddd, J = 10.8, 9.3, 1.0 Hz, 1H), 3.96 (s, 3H), 
3.94 (s, 3H), 3.87 (s, 3H), 3.70 (s, 3H), 2.78 (dd, J = 13.7, 8.8 Hz, 1H), 2.72 – 2.65 (m, 1H), 2.30 
– 2.22 (m, 2H), 2.21 – 2.07 (m, 6H), 1.74 (dt, J = 12.9, 3.1 Hz, 1H), 1.65 (ddd, J = 14.8, 11.6, 
3.3 Hz, 1H), 1.57 – 1.49 (m, 1H), 1.42 (s, 3H), 1.35 – 1.27 (m, 1H), 1.06 (s, 3H).  13C NMR (126 
MHz, CDCl3) δ 201.89, 171.94, 171.63, 169.81, 155.64, 155.37, 143.68, 118.18, 114.77, 112.83, 
96.12, 78.93, 74.89, 65.22, 56.30, 56.26, 56.20, 53.30, 51.95, 49.16, 42.07, 38.37, 37.88, 35.62, 
30.76, 20.66, 18.35, 16.95, 16.00.  HRMS (m/z): [M+K] calcd for C29H36KO11, 599.1895; found 
599.1903. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(hydroxy(2,4,5-
trimethoxyphenyl)methyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate (271).  Compound 271 was synthesized from compound 
268 using general procedure B to afford 0.78 g (64% yield) isolated as a white solid, mp = 133-
136 °C.  TLC system: 60% EtOAc/40% n-hexanes.  1H NMR (500 MHz, CDCl3) δ 6.92 (s, 1H), 
6.49 (s, 1H), 5.28 (dd, J = 5.0, 2.8 Hz, 1H), 5.15 – 5.05 (m, 1H), 4.75 (ddd, J = 11.6, 5.8, 3.0 Hz, 
1H), 3.90 (s, 3H), 3.83 (s, 3H), 3.80 (s, 3H), 3.71 (s, 3H), 2.74 (dd, J = 12.7, 4.2 Hz, 1H), 2.63 
(d, J = 5.2 Hz, 1H), 2.32 – 2.19 (m, 2H), 2.14 (d, J = 19.1 Hz, 5H), 2.02 – 1.94 (m, 1H), 1.91 
(dd, J = 13.2, 5.8 Hz, 1H), 1.80 – 1.72 (m, 1H), 1.58 – 1.50 (m, 2H), 1.30 (s, 3H), 1.05 (s, 3H).  
13C NMR (126 MHz, CDCl3) δ 202.19, 172.04, 171.63, 169.55, 150.16, 149.20, 143.24, 117.56, 
111.01, 96.89, 79.36, 74.93, 69.90, 64.31, 56.73, 56.12, 56.02, 53.56, 51.94, 50.67, 42.23, 38.20, 
34.85, 34.74, 30.89, 20.55, 18.18, 16.18, 15.19.  HRMS (m/z): [M+K] calcd for C29H38KO11, 
601.2051; found 601.2029. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-dioxo-2-
(2,4,5-trimethoxybenzyl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (274).  
Compound 274 was synthesized from compound 271 using general procedure C to afford 0.42 g 
(56% yield) isolated as a white solid, mp = 108-111 °C.  TLC system: 55% EtOAc/45% n-
hexanes.  1H NMR (500 MHz, CDCl3) δ 6.70 (s, 1H), 6.51 (s, 1H), 5.15 – 5.01 (m, 1H), 4.71 (dd, 
J = 11.4, 5.5 Hz, 1H), 3.89 (s, 3H), 3.81 (s, 3H), 3.78 (s, 3H), 3.71 (s, 3H), 2.96 – 2.80 (m, 2H), 
2.76 – 2.67 (m, 1H), 2.32 – 2.21 (m, 3H), 2.17 (s, 3H), 2.07 (d, J = 11.7 Hz, 2H), 1.85 – 1.71 (m, 
2H), 1.57 – 1.46 (m, 2H), 1.32 (s, 3H), 1.20 (dd, J = 13.5, 11.6 Hz, 1H), 1.07 (s, 3H).  13C NMR 
(126 MHz, CDCl3) δ 202.13, 171.65, 171.60, 169.89, 151.77, 148.48, 142.77, 115.84, 115.16, 
97.43, 77.47, 75.07, 64.24, 56.62, 56.18, 56.15, 53.60, 51.95, 51.20, 42.18, 41.92, 38.23, 36.07, 
35.02, 30.80, 20.60, 18.15, 16.32, 15.20.  HRMS (m/z): [M+K] calcd for C29H38KO10, 585.2102; 
found 585.2084.  
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(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-((4-methoxy-3,6-dioxocyclohexa-
1,4-dien-1-yl)methyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-
carboxylate (277).  Compound 277 was synthesized from compound 274 using general 
procedure D to afford 0.50 g (72% yield) isolated as a yellow solid, mp = 127-130 °C.  TLC 
system: 60% EtOAc/40% n-hexanes.  1H NMR (500 MHz, CDCl3) δ 6.63 (t, J = 1.1 Hz, 1H), 
5.93 (s, 1H), 5.14 (dd, J = 11.6, 8.4 Hz, 1H), 4.70 (dddd, J = 14.6, 8.6, 4.8, 3.3 Hz, 1H), 3.83 (s, 
3H), 3.73 (s, 3H), 2.83 – 2.71 (m, 2H), 2.56 (ddd, J = 14.4, 9.2, 1.0 Hz, 1H), 2.38 (dd, J = 13.3, 
4.9 Hz, 1H), 2.34 – 2.28 (m, 2H), 2.18 (s, 4H), 2.11 (d, J = 4.1 Hz, 2H), 2.00 – 1.94 (m, 1H), 
1.82 – 1.75 (m, 1H), 1.54 (d, J = 12.9 Hz, 1H), 1.35 (s, 3H), 1.27 (t, J = 12.5 Hz, 1H), 1.09 (s, 
3H).  13C NMR (126 MHz, CDCl3) δ 201.90, 187.00, 181.77, 171.52, 170.77, 169.98, 158.75, 
144.44, 133.15, 107.66, 75.35, 75.02, 64.04, 56.31, 53.59, 52.00, 51.40, 43.01, 42.08, 38.14, 
36.65, 35.26, 30.76, 20.60, 18.11, 16.37, 15.17.  HRMS (m/z): [M+K] calcd for C27H32KO10, 
555.1633; found 555.1678.  HPLC tR = 6.049; purity = 95.4%. 
Cell Culture341 
The media for each cell line was supplemented with streptomycin (500 µg/mL), penicillin 
(100 units/mL), and 10% FBS.  MCF7 and SKBr3 cells were maintained in Advanced 
DMEM/F12 (1:1; Gibco) supplemented with L-glutamine (2 mM).  Cells were grown in a 
humidified atmosphere (37 °C, 5% CO2) and passaged when confluent.  
Anti-proliferation Assay341 
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Cells were grown to confluence, seeded (2000 cells/well, 100 μL total media) in clear, 
flat-bottom 96-well plates and allowed to attach overnight.  Compound or geldanamycin at 
varying concentrations in DMSO (1% DMSO final concentration) was added.  Cells were 
returned to the incubator for an additional 72 h.  After 72 h, cell growth was determined using an 
MTS/PMS cell proliferation kit (Promega) per the manufacturer’s instructions.  Cells incubated 
in 1% DMSO were used as 100% proliferation (i.e. DMSO = 100% growth) and the relative 
growth for each compound concentration was compared to 1% DMSO.  IC50 values were 
calculated from two separate experiments performed in triplicate using GraphPad Prism 6.0.  
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CHAPTER 4: SYNTHETIC CANNABINOIDS AND THEIR POTENTIAL AS 
ALCOHOL ABUSE TREATMENTS 
 
Cannabis sativa L. 
 One of the oldest psychotropic drugs, whose use dates back to the Neolithic period is 
cannabis.342  Originating in Central Asia, cannabis has been cultivated and consumed even 
before the appearance of writing.342  Its medicinal, recreational, and spiritual use by many 
ancient cultures dates back to 4000 B.C.343  Chinese, Indian, and Tibetan ancient cultures have 
utilized the seeds and fruit of cannabis to treat a variety of ailments such as pain of childbirth, 
gastrointestinal disorders, seizures, malaria, snake bites and various others.343  Besides its 
medicinal use, cannabis has been also used in the spiritual practices and religious ceremonies of 
many cultures where such practices were conducted by Tantric Buddhists, Hindus and ancient 
shamans.344 
It is believed that the properties and therapeutic uses of cannabis were originally 
described by the Emperor of China, Shen Nung, who also discovered tea and ephedrine, and 
inscribed it in his compendium of Chinese medicinal herbs.345  The extent of the numerous 
therapeutic effects of cannabis resulted in its fast migration to many cultures and from 2000 to 
1400 B.C., its use spread to India, Egypt, Persia, and Syria.346  Furthermore, evidence suggests 
that cannabis was used as incense as well as medicinally by the Assyrians as early as 9th century 
B.C.347  Additionally, aside from its therapeutic applications, the ancient Greek and Roman 
cultures valued the plant for its ropelike qualities.346   Introduction of cannabis to the Western 
civilizations however, didn’t occur until 1830s when Irish physician W. B. O’Shaughnessy 
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presented the traditional Eastern medicine in his paper about the “Indian hemp”, where he 
recommended cannabis for various conditions including spasticity, pain, vomiting, and 
convulsions.346, 348  Cannabis is found in several species and among the most relevant are 
Cannabis sativa, Cannabis indica, and Cannabis ruderalis.  Of the three, Cannabis sativa is the 
most represented and is found in both tropical and temperate climates.342  Aside from its uses as 
a medicinal agent and psychoactive component of spiritual practices and tradition, cannabis has 
been exploited as a recreational drug worldwide.347  
With the beginning of the 20th century, use of cannabis as a medicinal agent significantly 
decreased even though reports from the late 19th century supported its medicinal values.343  In the 
Unites States in particular, the passing of the Harrison Act of 1914, which grouped cannabis with 
other illicit drugs and the earlier introduction of the Pure Food and Drug Act of 1906, which 
advocated for improved safety of food and medicine, initiated the significant decrease in the use 
and marketing of cannabis derived products.343, 349  Increase in the recreational use of cannabis 
was observed as a result of the decrease in marketing and production of cannabis derived 
products.343  The introduction of the Marijuana Tax Act of 1937 was implemented with the intent 
to reduce the increased recreational use of cannabis.349  However, although illegal the use of 
cannabis has been steadily increasing and today it has been estimated that approximately 50% of 
the population in the United States reported to have tried cannabis at least once in their life.350   
Despite its immense popularity worldwide, it was not until 1964 when Gaoni and 
Mechoulan elucidated the structure of the principal psychoactive compound in Cannabis sativa, 
∆9-tetrahydrocannabinol (∆9-THC) (Figure 35).  Sixty different cannabinoids have been isolated 
147 
	  
from Cannabis and selected examples are ∆8-tetrahydrocannabinol (∆8-THC), cannabinol 
(CBN), cannabidiol (CBD), and cannabichromene (CBC).153, 342   
	  
 
The Endocannabinoid System 
 ∆9-THC and related cannabinoids exert their effects on cannabinoid receptors.  There are 
two main types of cannabinoid receptors: CB1Rs and CB2Rs.343  The principal demonstration of 
the presence of a cannabinoid binding site in the rat brain was demonstrated by Devane and 
coworkers in early 1988.351  However, conclusive evidence of the existence of a cannabinoid 
receptor was provided in 1990 by Matsuda and coworkers when they reported the isolation of a 
cDNA of a cannabinoid receptor from a rat cerebral cortex, which was named CB1 receptor 
(CB1R).352  A few years after the isolation and characterization of the CB1R, Munro and 
colleagues reported the cloning of a second cannabinoid receptor, found in the periphery and 
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termed CB2R.353  Both of the cannabinoid receptors are members of the G-protein coupled 
receptor superfamily (GPCRs) and share 44% sequence identity.354  A greater sequence 
similarity is seen between the clones of human, rat and mice CB1Rs, whereas the CB2Rs are 
much more divergent among the three species.355  Activation of both receptors leads to the 
inhibition of adenylate cyclase leading to reduction of cAMP levels, as well as activation of the 
mitogen-activated protein kinase (MAPK), events accomplished with the coupling to the α-
subunit of the Gi/o protein family.354, 356  Particularly for the CB1Rs, lowering the level of cAMP 
causes an enhancement of voltage-sensitive outwardly rectifying K+ channels, which is caused as 
a result from the decreased phosphorylation of the K+ channel protein by A-kinase.357  Moreover, 
CB1Rs have been shown to interact and couple to Go.356  CB1Rs but not CB2Rs have been 
shown to also couple to Gs proteins under certain conditions.358  Several other systems that act as 
intracellular mediators and are also utilized by CB1Rs and occur from activation of Gi/o: 
inhibition of N-type Ca2+ channels and expression of immediate early genes such as Krox-24.357  
Together, both CB1Rs and CB2Rs recruit the signaling mechanism of activation of MAPK and 
expression of Knox-24 presumably through the activation of the G-protein βγ subunit.354  
Activation of CB1Rs has also been shown to modulate the production of nitric oxide, inhibit 5-
HT3 ion channels, activate the Na+/H+ transporter and alter the conductance of the sodium 
channel.354  Besides the two main cannabinoid receptors CB1R and CB2R, there is evidence that 
points to the presence of additional cannabinoid receptors.  In 2007, Ryberg and coworkers 
identified that an orphan receptor GRP55 expressed in the CNS and various peripheral tissues 
binds a range of endogenous, plant-derived, and synthetic cannabinoids and it was shown to 
activate the G13 proteins.359  Furthermore, Brown reported GRP119 as an additional cannabinoid 
receptor that is expressed predominately in the pancreas and gastrointestinal tract and activates 
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the Gs proteins.360  However, additional evidence is necessary to determine the connection of 
these novel receptor subtypes to the endocannabinoid system.354 
CB1 Receptors 
 CB1Rs are located mainly in the CNS in both neural and non-neural tissues and to a 
lesser extent are expressed in peripheral tissues.  The CB1Rs are the most abundant receptors in 
the brain with high density seen in the basal ganglia, substantia nigra pars reticulate, cerebellum, 
and the external segment of the globus palladis, hippocampus, and putamen.354, 357  In the 
periphery, the CB1Rs are localized in the adrenal gland, adipose tissue, heart, liver, lung, 
prostate, ovary, testes, bone marrow, thymus, tonsils, and presynaptic nerve terminals.354  The 
activation of the CB1Rs present in presynaptic nerve termini leads to the inhibition of 
neurotransmitter release, which is a result of the decreasing calcium conductance and by the 
increase in the potassium conductance.354, 361   
CB2 Receptors 
 CB2Rs on the other hand are mainly localized in tissues of the immune system, such as 
the spleen, tonsils, and thymus.  B cells, T4 and T8 cells, mast cell, macrophages, natural killer 
cells, and microglial cells are the types of immune cells where localization of CB2Rs is high and 
out of those natural killer cells have the highest expression levels of CB2Rs.  Recently, studies 
disputed previous reports of CB2Rs absence in the CNS and it has now been demonstrated that 
CB2Rs are also present in the CNS and are found on the dorsal root ganglia, the lumbar spinal 
cord, and sensory neurons.362, 363  When CB2Rs expressed immune cells are activated they can 
modulate the migration of immune cells and cytokine release both outside and within the 
brain.356 
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Cannabinoid Ligands 
 The term cannabinoid was originally coined for any compound isolated from 
Cannabis.364 However, today it refers to any compound that demonstrates similar pharmacology 
to that of ∆9-THC.343  There have been several classes of ligands found to have affinity at the 
CBRs.  These include the endocannabinoid ligands, classical, non-classical cannabinoids, and 
synthetic cannabinoids.  
Endocannabinoid Ligands 
 The discovery of the cannabinoid receptors prompted the notion which suggested that 
there are endogenous ligands that exert their physiological activity upon binding to these 
receptors.357  One of the first endocannabinoids isolated form porcine brain extracts was 
anandamide (N-arachidonoylethanolamine, AEA, 283, Figure 36), whose discovery was based 
on the hypothesis that the endogenous ligands of the cannabinoid receptors should be lipophilic 
like the classical exogenous cannabinoids.365  It was determined (using transfected hCB1R and 
hCB2R CHO cells) that anandamide has affinity for both CB1R and CB2R with Ki values of 89 
nM and 371 nM, respectively.366  In 1995, shortly after the isolation of anandamide, Mechoulam 
and coworkers reported the canine gut isolation of 2-arachidonoylglycerol (2-AG, 284), a non-
amidic derivative of arachidonic acid.367  Similarly to AEA, 2-AG also interacts with both 
cannabinoid receptors and has a binding affinity of 58 nM for CB1R and 145 nM for CB2R.366  
This endocannabinoid was also found to be present in the spleen and brain.368, 369  Interestingly, 
2-AG release was demonstrated to be Ca2+ dependent and its concentration can reach up to 170-
fold higher than that of anandamide in the brain.357, 368  Several other endocannabinoids have 
been isolated since the original discovery of AEA and 2-AG and they include: noladin ester, 
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vriodhamine (285), N-arachidonoyldopamine (NADA, 286), oleamide, N-oleoyl dopamine, N-
dihomo-γ-linolenoylethanolamine, and N-docosatetraenoylethanolamine (287); however not 
much is known about the endocannabinoid-like properties of these ligands (Figure 36).354, 370   
 
 Activity-dependent or receptor-stimulated cleavage of membrane phospholipid 
precursors are the most common mechanisms by which the endocannabinoids are normally 
produced, generally on demand.354  Because of their high lipophilic character, endocannabinoids 
are released immediately after their biosynthesis and endocannabonoid signaling is regulated by 
their synthesis, release, uptake and degradation.354  Activation of the enzymatic processes that 
lead to the cleavage of membrane phospholipid precursors and consequent biosynthesis of 
endocannabinoids can be initiated through several processes, namely membrane depolarization, 
increase in the intracellular calcium levels or receptor stimulation.354  Several different enzymes 
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are involved in the biosynthesis of AEA and 2-AG, specifically calcium-independent N-acyl-
transferase, phospholipase C, and diacylglycerol lipase.354, 371  Upon biosynthesis, 
endocannabinoid signaling is limited by degradation of the endocannabinoids.  Enzymes 
involved in the efficient degradation of the endocannabinods have been well characterized and 
include fatty-acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL).372  FAAH a 
membrane bound enzyme is involved in the hydrolysis of AEA whereas MGL, a serine 
hydrolase, is involved in the hydrolysis of 2-AG.373-375 
Classical Cannabinoids 
 Compounds resembling the structure of ∆9-THC that contain a tricyclic terpenoid 
scaffold bearing a benzopypan moiety are considered classical cannabinoids (Figure 37).357  
Numerous compounds isolated from Cannabis are members of this class of cannabinoids.  Many 
SAR studies were undertaken on this class of cannabinoids at both CB1R and CB2Rs, however 
to much greater extent at the CB1Rs.  The SAR developed for classical cannabinoids at CB1Rs 
goes as follows: (a) the absolute stereochemistry present in ∆9-THC is necessary for activity at 
CB1Rs; (b) the alkyl side chain appended at the C-3 carbon is necessary for activity, the optimal 
length being between five to eight carbon atoms; (c) presence of a dimethylheptyl side chain 
maximizes CB1R activity and the presence of a gemdimethyl group either at the C-1’ carbon or 
C-1’, C-2’-dimethyl substituent enhances CB1R affinity; (d) a hydroxyl group at the C-1 carbon 
is necessary for binding at CB1Rs but a hydroxyl substituent ate the C-11 position can also be a 
replacement for hydrogen bonding interaction with the receptor; (e) phenolic group at the C-1 
carbon can also be substituted with an amine group but not a thiol moiety in order to attain CB1R 
affinity; (f) the pyran oxygen atom can be substituted for a nitrogen atom leading to preserved 
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CB1R affinity; and (g) substituents other than methyl at the C-9 position are generally accepted 
and a hydroxyl group at either the C-11 or the C-9 improves CB1R affinity.357, 376 
 
 The SAR of the classical cannabinoids at the CB2R is less developed but it encompasses 
the following: (a) for optimal activity and selectivity at the CB2Rs, the phenolic group at the C-1 
carbon must be replaced with a hydrogen atom; (b) additionally, a methoxy group at C-1 alters 
affinity at CB2Rs; (c) as mentioned C-11 and C-9 hydroxyl groups enhance CB1R and CB2R 
affinity; and (d) with no hydroxyl on the C-1 carbon, the length of the C-3 carbon alkyl 
substituent does not affect CB2R affinity.376  Thus far, not much has been revealed regarding the 
SAR and the effects of different substituents at the C-1 and C-9 carbons and the alkyl side chain 
in the scaffold.376   
Non-Classical Cannabinoids 
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 A molecular dissection approach was undertaken by Pfizer researchers in order to gain a 
better understanding of the pharmacophore of ∆9-THC for binding at the cannabinoid receptors 
and discovered that a compound (CP-55,940) lacking the pyran ring retained activity at the 
cannabinoid receptors (Figure 38).357, 377  This class of compounds includes various bicyclic as 
well as tricyclic analogues.  Both the classical and non-classical cannabinoid have very similar 
SAR in that the aliphatic chain off of the C-3 carbon is necessary for activity.377  Furthermore, 
similar to the SAR of classical cannabinoids, the phenolic hydroxyl moiety on C-1 carbon is 
necessary for activity of non-classical cannabinoids.377  Elimination of the C-9 hydroxyl moiety 
resulted in decreased affinity, whereas complete removal of the cyclohexyl ring leads to 
complete loss of activity at the cannabinoid receptors.377  Decreasing the size of the cyclohexyl 
group to a five membered ring resulted in a decrease in affinity, whereas increasing the size of 
this substituent to a cyclohephtyl, or adamantyl ring causes a slight increase in affinity.377  
Heteroatom substitution of the cycloalkyl group results in significantly diminished activity at 
both cannabinoid receptors.377  Addition of different alkyl substituents off of the cyclohexyl ring 
in the molecule generally lead to a small to moderate decrease of affinity.377  Substitution of the 
C-1 hydroxyl moiety with a ketone moiety resulted in a switch of activity from CB1Rs to 
CB2Rs.378  It has been also demonstrated that unsaturation in the scaffold leads to a decrease in 
affinity.377  Selective CB2R activity for the non-classical cannabinoids was attained with a 
methoxy substitution at the C-1 carbon, as well as the addition of a tertiary alcohol moiety at the 
C-10a carbon.377 
 In addition to the classical and non-classical cannabinoids, researchers have attempted to 
synthesize compounds that represent a hybrid of both scaffolds.  Several groups succeeded in the 
development of such analogues (296, Figure 38) and established valuable SAR.  Thakur and 
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colleagues synthesized a hybrid cannabinoid that possesses an alkyl hydroxyl group at the C-6a, 
seen in CP-55,940, which is conformationally constrained with a pyran ring and a double 
bond.379  It was determined that both isomers are potent cannabinoid receptor ligands, exhibiting 
subnanomolar affinity for both recepotrs.379  Additionally, the optimal length for the 
hydroxyalkyl moiety at the C-6 position was determined to be between 1 and 3 carbon atoms.380  
Iodoalkyl or alkyl chain appended at the C-6 position are both well tolerated and exhibit similar 
cannabinoid receptor affinity to that of the original classical and non-classical cannabinoids.381  
A C-11 or a C-9 hydroxyl groups are both well tolerated and do not cause any significant change 
in the affinity at the cannabinoid receptors.380  Bourne and coworkers synthesized several Δ9-
THC/anandamide hybrid cannabinoids, which demonstrated equal or higher affinity at both 
cannabinoids receptors to that of the parent compounds.382 
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Synthetic Cannabinoids - Aminoalkylidoles 
 In 1992, during a developmental study for a non-steroidal anti-inflammatory drug 
(NSAID), a group of scientists at Sterling-Winthrop synthesized pravadoline (297, Figure 39), 
an aminoalkylindole (AAI).383  In addition to exhibiting prostaglandin inhibition, it was also 
shown to inhibit contractions of the electrically stimulated mouse vas deferens.384, 385  During 
their investigation and pharmacological testing, it was observed that pravadoline was shown to 
interact with cannabinoid CB1Rs and exhibit classical cannabinoid pharmacology in vivo.383, 386  
Its interesting pharmacology prompted many researchers into the development of preliminary 
SAR for the interaction of pravadoline derivatives with the cannabinoid receptors.  From this 
primary search, D’Ambra and coworkers developed and synthesized a novel aminoalkylindole 
derivative, WIN-55,212-2 (298), a ligand with high potency for both cannabinoid receptors, 
whose tritiated form has extensively been used in many pharmacological investigations of this 
group of cannabinoid ligands since its discovery.383   
 
Investigations into the SAR of the aminolakylindoles continued and in 1994, Huffman 
and Dai reported the synthesis and pharmacological testing of several acyl indoles derived from 
the WIN-55,212-2 structures (Figure 40).387  It was determined that a naphthalene ring or a 
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bulkier substituent at this position may be necessary for affinity at the cannabinoid receptors. 
Additionally, analogues containing an alkyl chain consisting of 4-6 carbon atoms appended from 
the N-atom of the indole ring exhibited similar in vitro and in vivo pharmacology to that of Δ9-
THC and WIN-55,212-2, a finding similar to that observed for the classical cannabinoid Δ9-
THC.   
	  
 An extension to the Huffman study, Eissenstat and coworkers, researchers from the 
Sterling Winthrop laboratory, reported additional analogues of the novel aminoalkylindole class 
of cannabinoid ligands that were products of several modeling studies (Figure 41).388  They 
determined that a bulky substituent is needed at the C-3 position of the indole core confirming 
previous studies of Huffman and Dai.  Furthermore, they determined that for activity at the 
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cannabinoid receptors, a small substituent of preferably a hydrogen atom at the C-2 position of 
the indole core is necessary.  Additionally, an ethylmorpholine or other aminoethyl substituents 
at the N-1 position of the indole yielded compounds with high activity at the cannabinoid 
receptors.   
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 The above report described AAI analogues in which the heterocyclic amine nitrogen 
atom is attached to the indole ring nitrogen via a carbon chain.  As an extension to that work the 
authors also synthesized AAI analogues, however with a different connectivity from the one 
described above.389  In particular, this series of AAI analogues contained a series of compounds 
where the heterocyclic amine is attached to the indole ring via a carbon atom of the heterocycle 
rather than the nitrogen atom of the heterocycle (Figure 42).389   
 
 From this study it was determined that ideal carbon linker between the indole N-atom and 
the heterocyclic N-atom is two carbons (Figure 43).389  On the other hand, attachment of the 
heterocycle directly to the indole moiety was not favorable, despite the two carbon distance 
between the heterocycle N-atom and the indole N-atom.  Various heterocycles are well tolerated 
as substituents, which was not the case of the N-attached analogues synthesized previously, 
where only morpholine and thiomorpholine heterocycles proved active at the cannabinoid 
receptors.  Similarly to results seen with the N-attached analogues, it was observed that a small 
substituent preferably a hydrogen atom at the C-2 position of the indole ring was also necessary 
for activity in the C-attached analogue series.  N-alkyl substituents of the heterocycle side chain 
resulted in a significant decrease in activity.  
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 In 1998, Wiley and coworkers reported further SAR of the aminoalkylindoles with a 
study done on indole- and pyrrole-derived compounds (Figure 44).390  In the course of their 
study, in the three series that were synthesized, it was determined that a methyl group off of the 
indole ring substituted for the original ethylmorpholine group led to complete inactivity at the 
CB1Rs.  However, affinity was regained with the extension of carbon atoms with the ultimate 
alkyl substituent being a N-pentyl group in the C-2 carbon substituted derivatives and in the C-2 
non-substituted analogues the ultimate length was between four and six carbon atoms.  On the 
other hand, in the C-2 substituted pyrrole analogues, N-pentyl was also the optimal chain length 
however not as active as the the indole series.  In general, pyrrole-derived analogues exhibited 
lower activity at the CB1Rs then their indole-derived counterparts.  Substitution of the alkyl 
chain with double bond barring substituents yielded compounds slightly less active at the 
CB1Rs, which was also the case with cycloalkyl N-side chains off of the indole core.  
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 In order to test the possibility that the activity of the aminoalkylindole derived 
cannabinoids and classical cannabinoids for the cannabinoid receptors could come from one 
pharmacophore, Huffman and coworkers designed a hybrid molecule to test this hypothesis.391  
This hybrid cannabinoid (358) combined the hydroxybenzopyran ring system of the classical 
cannabinoid Δ9-THC with the 1-pentylindole moiety present in most potent aminoalkylindole 
derivatives lacking an aminoalkyl group (Figure 45).  It was determined that this hybrid 
cannabinoid exhibits similar affinity for the CB1R to that of Δ9-THC, Δ8-THC, WIN-55,212-2, 
and JWH-007.  It whoever is slightly less potent in vivo than WIN-55,212-2 and JWH-007, but it 
does represent a unique probe for further investigations of cannabinoid ligands at the CB1Rs.   
With the intention of developing aminoalkylindoles that are potent analogues at the 
CB1R and are also easily iodine radioisotope labeled, Deng and coworkers designed and 
synthesized a group of compounds that could be suitable for biochemical and imaging studies 
(Figure 45).392  From their analysis of the compounds synthesized, it was determined that a 
potent non-selective iodinated aminoalkylindole ligand (359) was synthesized with high affinity 
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for both cannabinoid receptors with Ki values of 1.80 nM and 2.2 nM, respectively.  Despite the 
lack of selectivity, this class of ligand will provide excellent probes for further radiolabeled 
imaging investigations. 
 
 Utility of positron emission tomography (PET) in the design and pharmacological testing 
of potential cannabinoid ligands and their interactions with the cannabinoid receptors is on the 
rise, and a suitable PET ligand is necessary.393  In order for a ligand to be suitable for PET and 
single photon emission computed tomography (SPECT) imaging one has to have lower 
lipophilicity than the original aminoalkyindoles and relatively high binding affinity for its 
target.393  With these criteria in mind, Willis and colleagues synthesized a group of 
aminolakylindole derivatives with lower lipophilicity (logD in the range of 2.7-4.5) and 
increased affinity (Figure 46).393  Most of the analogues exhibited high affinity in the low 
nanomolar range for the CB1Rs.  Out of the analogues synthesized, one compound exhibiting a 
Ki of 0.7 nM was chosen to be labeled with positron emitting isotope and subjected to in vivo 
mice model studies, where it was determined that this analogue specifically labels CB1Rs in the 
mouse brain and could be a useful tool further PET radioligand studies.  
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 The SAR for the aminoalkylindoles continued and in 2010, the Russo group reported 
several new indole-based analogues (Figure 47).394  They performed molecular modeling and 
dynamic studies on the compounds synthesized and they also subjected the synthesized 
analogues for antinociceptive assays in mouse models.  Most of the analogues showed to have 
affinity for the CB1Rs, however only one analogue exhibited similar affinity for CB1Rs as WIN-
55,212-2.  In the antinociceptive assay, the formalin test, several of the compounds exhibited 
moderate antinociceptive activity.  These indole 2,3-dione derivatives of the aminoalkylindole 
class of cannabinoids could be used as the starting point for further analogue design.   
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 A further extension of the SAR studies of aminolakylindole cannabinoid was reported by 
Frost and coworkers in 2010, where they synthesized several series of analogues focusing of 
various indole N-atom substitutions and C-3 carbon ketone derivatives (Figure 48).395  From 
their study they established that several CB2R selective compounds were synthesized with high 
affinity for the CB2R.395  From their SAR they determined that an amino cycloalkyl group is not 
well tolerated as an indole N-atom substituent.395  Additionally, aromatic side chain at the N-1 
position are well tolerated as well as non-amine alkyl and cycloalkyl substituents.395  In 
agreement with previously reported data, they also found that aminoethyl side chain at the N-1 
position was optimal for activity.395  They also observed a stereochemical effect where one 
isomer produced higher selectivity for the CB2R than the other.395  Furthermore, changes in 
polarity of the N-1 side chain were tolerated, however carboxylic acid side chain proved to be 
inactive at both cannabinoid receptors.395  The preliminary results of the in vitro affinity of the 
synthesized analogues were further confirmed in a functional calcium mobilization assay 
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(FLIPR).395  The prepared compounds allow for better understating of the SAR of the 
aminoalkyindole class for the cannabinoid receptors.   
 
In addition to the CB2R selective analogues designed and synthesized in this series, 
Makriyannis and coworkers reported an aminoalkylindole (AM1241, 405) that is highly selective 
for the CB2Rs with potential for modulation of neuropathic pain (Figure 49).396  To accompany 
this report, Hynes and coworkers from Bristol-Myers Squibb laboratories, designed and 
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synthesized several additional CB2R selective analogues (Figure 49) with C-3 amido-indole 
structural characteristics.397  From this study they established that there is only limited 
substitution tolerability at the C-3 position of the indole core apart from ester substituents.  A C-
3 amido indole analogue with acceptable Ki value for the CB2R was selected for further SAR 
development that yielded several analogues with anti-inflammatory characteristics in a murine 
model of acute inflammation.  Together these studies demonstrate that the aminoalkylindole 
scaffold can be modulated to produce receptor selective ligands.   
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Therapeutic Potential of Cannabinoids 
 The therapeutic potential of Cannabis has been known and well utilized throughout many 
centuries.  With the widespread distribution of the cannabinoid receptors within the CNS as well 
as in the periphery, one can envision that the endocannabinoid receptor system may be involved 
in various physiological processes.398  The SAR of all the classes of cannabinoid ligands has 
generated compounds with very interesting pharmacological profiles that highlight the potential 
of the cannabinoids in a wide variety of clinical disorders.399  These include multiple sclerosis, 
pain, drug abuse, obesity, and alcohol abuse. 
 
Cannabinoids and Multiple Sclerosis 
 In 1868, Charcot described what is today known as multiple sclerosis (MS), the most 
common demyelinating disease worldwide.400  The hallmark of this CNS disease is the formation 
of sclerotic plaques in the white matter of the spinal cord, as well as in other CNS structures.401  
The formation of plaques may be caused by several mechanisms such as inflammation, edema, 
demyelination and remyeination, oligodendrocyte depletion, astroliosis, and neuronal death.400  
The disease is characterized by muscle rigidity (spasticity), painful muscle cramps, chronic pain, 
tingling and prickling of the fingers, and blindness.342  The Multiple Sclerosis Society estimates 
that approximately 2.1 million people worldwide are affected with MS.402  MS affects more 
females than males and in an age range of 20 to 50 years.402  There is no cure for MS, however 
there are several effective disease-modifying agents currently used as MS treatments.403   
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 It has been demonstrated that endocannabinoids are elevated in tissues that are 
undergoing inflammation, suggesting that such endocannabinoid accumulation represents an 
adaptive attempt of the body to alleviate inflammation.404  Furthermore, the difference in the 
concentration of anandamide from a post mortem healthy brain and a brain affected with MS has 
been reported to be 3.7 fold higher in the MS affected brain.405  Originally, it was believed that 
only the CB2Rs were responsible for modulation of immune function, however it has been 
validated that the CB1Rs can also modify inflammation and therefore play an important role in 
modulating neuroinflammation.406   
 Initial evidence of the involvement of the cannabinoid system in MS has come from 
several experiments with animal models of this disease, including experimental autoimmune 
encephalomyelitis (EAE), Theiler’s murine encephalomyelitis virus (TMEV), and chronic 
relapsing experimental allergic encephalomyelitis (CREAE).  These models arise from the 
induction of MS-like demyelination produced by injection with Theiler’s murine 
encephalomyelitis virus or inoculation with mixtures containing material such as CNS tissue or 
myelin basic protein.407  Non-selective, as well as selective cannabinoid receptor agonists have 
been shown to ameliorate the signs of motor dysfunction exhibited by EAE, TMEC, and CREAE 
animals.407  These results were observed with single or repeated administration of the said 
agonists in pre or post infected animals.407  Accompanying evidence reported by Maresz and 
coworkers and Xu and coworkers supports the hypothesis that activation of CB1Rs on centrally 
located neurons will ameliorate signs of spasticity associated with MS, and that CB2Rs 
expressed on T-cell within the CNS will decrease inflammation associated with MS and possibly 
slow the progression of the disease.407, 408   
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 Given the preclinical data, several clinical trials have been undertaken to evaluate the 
effects of cannabinoid in MS.  The clinical trials have focused on several aspects of the disease, 
mainly alleviation of symptoms, such as pain, incontinence, motor control, and spasticity.398  
Despite several reports of positive findings, general results are of mixed nature; nevertheless they 
are promising for future research of the role of the endocannabinoid system in MS.398, 403  
 
Cannabinoids and Neuroprotection 
 One of the most serious public health problems in the United States is traumatic brain 
injury (TBI), a condition that accounts for an estimated 2 million cases per year.409  TBI 
represents one of the leading causes of mortality and disability in young individuals throughout 
the world and currently no treatments are available.409, 410  It is characterized by numerous 
neurological and cognitive changes and by the release of various chemical mediators, whose 
release can reveal weakening of brain ionic homeostasis and release of immense glutamate 
concentrations from presynaptic terminals.409  Additionally, release of reactive oxygen species 
has also been reported together with the release of endothelium-derived active mediators whose 
release can lead to ischemia and late hyperemia.411, 412  It has been demonstrated that activation 
of presynaptic CB1Rs by 2-AG may modify neurotransmission and inhibit glutamate release, 
which would in turn limit its excitotoxicity.409   
 Utilizing animal models of brain injury, Muthian and coworkers determined that 
anandamide concentration is increased during transient, focal cerebral ischemia.413  Additionally, 
utilizing similar animal models of brain trauma, Panikashvili and colleagues determined that in 
mice after a closed head injury (CHI), the concentration of 2-AG was found to be 10-fold higher 
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in the injured hemisphere and persisting for 24 hours.414  Furthermore, treatment of mice with 
exogenous 2-AG given 1 hour after CHI was proven to be very effective as seen by the reduction 
in edema formation, decrease in clinical recovery, and decline of infarct volume.414  Differences 
in species were noted with the report by Hansen and colleagues that in young rats, anandamide 
and not 2-AG concentrations were increased as a response to brain injury.415  In support of 
previously published results, van der Stelt and coworkers reported that the volume of formed 
edema in neonatal rats using the ouabain-induced excitotoxicity model was significantly lowered 
than that of untreated rats.416  Marsicano and coworkers focused their research efforts on the 
hypothesis that one of the important roles of the endocannabinoid system is to protect against 
neuronal excitotoxicity.417  In order to test this hypothesis they used two mouse models: CB1R (-
/-) deficient animals and animals lacking CB1Rs in the principal glutamatergic (excitatory) 
neurons of the forebrain.  During the study it was observed that both types of animals exhibited 
more severe seizures after kainic acid treatment than control animals.  This effect was blocked by 
the CB1R antagonist rimonabant, which was not successful however in decreasing seizures in 
mice lacking CB1RS in principal neurons.  Reports of CB1R antagonists as neuroprotective 
agents were also reported by Hansen and coworkers, Amantea and colleagues and Muthian and 
coworkers.413, 418, 419   
 These contradictory reports may be better understood when one considers that 
endocannabinoids can act as anticonvulsants and proconvulsants in different situations.420  This 
comes from the notion that endocannabinoids may be inhibitory by blocking glutamate release or 
excitatory by blocking GABA release in different neuronal circuits.421  Despite the conflicting 
results, there is no doubt that the endocannabinoid receptor system plays a role as a defense 
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system against excitotoxic damage in the brain; however further research is needed to identify 
the exact mechanism of this action.420 
 
Cannabinoids and Pain 
 The use of cannabinoids as treatments for pain is known for many centuries. Specifically, 
in ancient China Cannabis and cannabinoids were used as surgical anesthesia; in ancient Israel 
they were used to decrease the pain during childbirth; throughout the middle ages in Asia they 
were used as valuable analgesics and the many Western civilizations used cannabis as treatment 
for many painful ailments during the 1800s.422   
 One of the earliest reported animal studies in which it was demonstrated that 
cannabinoids block pain response was done by Walter Dixon in 1899 in which he demonstrated 
that either inhaled cannabis or subcutaneously injected cannabis were able to suppress canine 
reactions to pin pricks.422  Since then various other animal models for both acute and chronic 
pain have been used to demonstrate the effectiveness of cannabinoids in the production of 
antinociception.  Several models of acute pain or postoperative pain are utilized in the analysis of 
cannabinoid modulation of acute pain such as mechanical stimuli or incision to the hindpaw of 
rats.423  Δ9-THC, WIN-55,212-2, CP-55,940 as well as anandamide have been shown to have 
antinociceptive effects in various animal models.423  The actions of these ligands was blocked by 
the pretreatment with CB1R antagonists rimonabant and AM251 and no antinociceptive effects 
were observed in CB1R knockout mice, indicative of a CB1R mechanism.423  There are also 
examples of CB2R agonists exciting antinociceptive effects such as AM1241, HU308, JWH-133, 
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and GW405833, however these results are less consistent when compared to CB1R mediated 
antinociceptive effects.   
 In addition to the antinociceptive effects of cannabinoids in animal models of acute pain, 
the effects of cannabinoids in animal models of chronic pain have also been well studied.  
Utilizing the carrageenan-induced inflammatory animal model it was determined that WIN-
55,212-2 reduced and mechanical hyperalgesia, actions blocked by both the CB1R antagonist 
rimonabant and the CB2R antagonist SR144528.423  Additionally, cannabidiol was shown to 
exhibit time- and dose-dependent antinociceptive effects in inflammation induced by intraplantar 
injection of carrageenan in rats.424  The synthetic cannabinoid nabilone exhibited similar results 
as those observed with cannabidiol.425  The ability of CB2R antagonists AM630 and SR144528 
to block the effects of the agonist AM1241, which caused reduction in mechanical and thermal 
hypersensitivity produced by a carrageenan intraplantar injection, indicating a CB2R related 
mechanism of antinocicpetion.423  Peripheral administration of anandamide reduced hyperalgesia 
and it also inhibited the formation of oedema in the capsaicin-induced inflammatory model, an 
effect blocked by the CB1R antagonist rimonabant.423  Similar results were seen with AM1241, 
however mediated via CB2Rs.423  In the complete Freund’s adjuvant (CFA) rat animal model of 
inflammation, an intrathecal administration of HU-210 caused a reduction of mechanical 
allodynia and thermal hyperalgesia, effects blocked by the CB1R antagonist AM251.426  Similar 
results in the CFA rodent model were observed with the CB2R agonist GW405833.427  Along 
with chronic pain models, Δ9-THC and WIN-55,212-2 have been screened in various 
neuropathic pain models, the most common of which include chronic constriction injury, partial 
sciatic nerve ligation and the spinal nerve ligation, where they were shown to be very 
effective.423   
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 With the numerous positive preclinical results for the effects of cannabinoids on pain 
modulation, several human clinical trials were undertaken to determine their efficacy in human 
volunteers.428, 429  Briefly, in healthy volunteers low doses of smoked Δ9-THC were seen to 
reduce the pain induced by intradermal capsaicin.430  Additionally, inhaled Δ9-THC was shown 
to effectively relieve chronic neuropathic pain from HIV-induced sensory neuropathy.431  In 
patients suffering from advanced cancer, Δ9-THC and cannabindiol significantly reduced pain.432  
Many other clinical trials with Δ9-THC and related cannabinoids regarding various forms of pain 
have been carried out, indicating the great potential of cannabinoids in the treatment of pain.  
 
Cannabinoids and Drug Abuse – Psychostimulants 
 The ventral tegmental area (VTA), the medial forebrain bundle (MFB), nucleus 
accumbens (NAc), ventral pallidum (VP) and the prefrontal cortex (PFC) are brain neuron 
strictures that encompass the brain reward system, which controls and regulates behaviors by 
inducing pleasurable effects.433  These structures are part of the mesolimbic pathway, the major 
rewarding pathway, whose primary neurotransmitter is dopamine.433  Because of the 
involvement with formation of reward-associated memories and the location of the perikarya of 
the mesolimbic neurons, the NAc and the VTA, respectively, play a critical role in addiction.433   
As mentioned previously, drug addiction represents a complex and chronic brain 
disorder, which is characterized by multifaceted processes that lead to drug seeking and loss of 
control over drug consumption.434  Activation of the cannabinoid receptors with cannabinoids 
leads to the production of several physiological effects, mainly through the CB1Rs, that activate 
the same mesolimbic reward pathway as drugs of abuse.433  These effects can be blocked with 
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CB1R antagonist and with the use of CB1R knock out animals further confirming the 
involvement of the endocannabinoid system in the reward pathway.433   
Utilizing the self-administration model one can assess the rewarding actions of drugs of 
abuse, mainly cocaine.435  Pre-treatment with rimonabant failed to modulate cocaine self-
administration in rats and squirrel monkeys.435  Additionally, CB1R knockout mice can be 
trained to self-administer cocaine, indicating that the endocannabinoid system does not mediate 
cocaine reward.436  Conversely, treatment with exogenous cannabinoids was shown to modulate 
cocaine self-administration.435  Pre-treatment with WIN-55,212-2 was demonstrated to decrease 
intravenous cocaine self-administration in rats, an event mediated by CB1Rs, and blocked by 
rimonabant.437  However, rimonabant was unable to affect the behavior maintained by cocaine 
when administered alone, indicating that endocannabinoid system modulation of cocaine self-
administration may be indirect.437, 438 
Reinstatement of self-administration is a known model of drug relapse that can be 
correlated to individuals that are cocaine dependent.435  De Vries and coworkers demonstrated 
that pre-treatment with rimonabant was able to reduce reinstatement of cocaine seeking 
promoted by cocaine-associated clues or injections, but was unable to however reverse stress-
induced reinstatement.439  Additionally, rimonabant was also able to block the reinstatement of 
methamphetamine-seeking behavior in rats.440  The authors also demonstrated that HU-210, a 
potent cannabinoid, dose-dependently promoted the reinstatement of cocaine-seeking 
behavior.439  Moreover, the systematic administration of the CB1R antagonist AM251 was 
shown to selectively inhibit cocaine-induced reinstatement of reward-seeking behavior, by a 
glutamate-defendant mechanism.441  Conditioned place preference (CPP) is an animal model that 
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is utilized to evaluate the perception of the rewarding value of the reinforcer.442  It was 
demonstrated that co-administration of rimonabant with cocaine during the conditioning phase 
eliminated the CPP of cocaine in rats.   
The recent reports indicating the presence of CB2Rs in certain parts of the brain such as 
the cerebral cortex, the cerebellum, the hippocampus, the striatum, the brainstem and the anterior 
olfactory nucleus have prompted researchers to re-examine the role of CB2Rs in drug reward and 
drug addiction.443  Recently, Xi and colleagues determined that systematic administration of the 
CB2R selective agonist JWH-133 dose-dependently inhibited intravenous cocaine self-
administration and it also inhibited cocaine-induced locomotion.443  These effects were further 
mimicked by another selective ligand, GW405833 and blocked by AM630, a selective CB2R 
antagonist, an effect not exhibited with the selective CB1R antagonist AM251, all of which is 
suggestive of a CB2R mechanism.443  Conformation of brain acting CB2Rs came from an 
experiment where they showed that an intranasal microinjection of JWH-133 once again dose-
dependently inhibited intravenous cocaine self-administration, which was not seen with an 
intravenous microinjection of the agonist.  Furthermore, Aracil-Fernandez and colleagues 
recently reported the adaptive effects of cocaine of mice overexpressing CB2Rs.444  They 
established that CB2R overexpressing mice showed reduced motor response to acute cocaine 
compared to WT mice; displayed reduced motor sensitization induced by chronic cocaine 
administration; and exhibited cocaine-induced conditioning place aversion; exhibited reduced 
cocaine self-administration, a few of the results seen in CB2R overexpressing mice.444  
Collectively, these findings indicate that inhibition of CB1Rs and/or activation of CB2Rs can 
affect psychostimulant-induced behaviors, thus establishing the cannabinoid receptor system as 
target for ligands with possible use as treatments for drug abuse. 
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Cannabinoids and Obesity  
 Obesity represents a global epidemic that significantly threatens the health of those 
affected.445  In 2008, according to the World Health Organization (WHO), nearly 1.5 billion 
adults, 20 years or older were overweight.446  Furthermore, more than 40 million children under 
the age of 5 were overweight in 2011.446  In the United States alone approximately 65% of adults 
are overweight, 30% of those are obese and 5 % are morbidly obese.446  Overall, these facts 
suggest that obesity is a multifactorial disease with increasing occurrence worldwide.447 
 The hypothalamus is one of the areas involved in the regulation of energy balance, in 
which the endocannabinoids and the CB1R are produced and expressed.448  Despite the low 
CB1R expression in the hypothalamus, activation of these receptors leads to profound effects.448  
One of the first reports that suggested a role between the endocannabinoid system in the 
hypothalamus and its role in control and food intake came from Trojniar and Wise in 1991, 
where they demonstrated that the systematic administration of Δ9-THC facilitated eating which 
was elicited by electrical stimulation of the lateral hypothalamus.449  Moreover, it was 
demonstrated that fasting raises the endocannabinoid levels in the limbic forebrain structures, 
including the NAc, a structure of the reward system, which is also linked to the ‘liking’ and 
‘wanting’ behaviors associated with availability and variety of food.450  Additionally, increase in 
food intake through a CB1R dependent manner was observed after a direct administration of 2-
AG into the NAc shell, an area directly linked to eating motivation.450  Aside from centrally 
regulating food intake, the endocannabinoid system was shown to also peripherally regulate food 
intake, by the activation of peripheral sensory terminals in the gastrointestinal tract.451  Despite 
being exposed to a similar caloric intake as WT mice, CB1R knockout mice were demonstrated 
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to be resistant to high fat diet-induced obesity.452  Additionally, CB1R knockout mice were 
shown to be leaner than their WT littermates and blockage of the CB1Rs was shown to also 
reduced food intake in mice.452, 453  Consequently, the endocannabinoid system plays a 
significant role in food intake, energy balance and metabolism through both the central and 
peripheral nervous systems.451  
 With the seen actions of endocannabinoid system and cannabinoid agonists on food 
intake and energy balance, several human clinical trials have been conducted on CB1R 
antagonists to determine their therapeutic potential in obesity.  After successful animal model 
studies, the putative CB1R antagonist/inverse agonist, rimonabant was advanced to human 
clinical trial where treatment with rimonabant for 7 days and later 16 weeks led to significant 
reduction of food and calorie intake and weight.454  Despite the great success of rimonabant and 
its analogue taranabant in successfully reducing weight gain and diminishing related metabolic 
processes, peripheral and CNS-related side effects related to their inverse agonist activity led to 
their withdrawal from clinical applications and the market.455  Research efforts are being made in 
the design and synthesis of true neutral antagonists or peripherally constrained CB1R 
antagonists, which will limit the seen side effect profile and preserve the antiobesity effects.456 
 
Cannabinoids and Alcohol Abuse 
 One of the oldest substances abused by man is alcohol.457  Alcohol dependence is a costly 
and socially devastating disorder and problems related to alcohol dependence cost the United 
States economy alone up to $185 billion per year.458  Alcohol consumption causes 
multidimensional and complex effects on the health of those affected and the effects seen on the 
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mortality, morbidity and disability are overwhelming.459  According to the WHO, approximately 
2.5 million people die of alcohol abuse each year among which 320,000 young adults between 
the ages of 15 and 29 die from alcohol-related causes.460   
 The original link between the neurophysiological effects of cannabinoids and alcohol was 
demonstrated in the early 1970s, when evidence of cross-tolerance to ethanol amongst cannabis 
users was reported.458  In 1994, Hungund and coworkers were the first to report that 
demonstrated the modulating effects of alcohol on the biosynthesis of endocannabinoids when it 
was revealed that chronic exposure of ethanol in mice up-regulated the activity of phospholipase 
A2 (PLA2), one of the enzymes in the biosynthetic pathway of AEA.461  Shortly thereafter, 
reports followed of the decreased expression and function of CB1Rs in mice chronically exposed 
to ethanol vapor and the increase in the levels of AEA and 2-AG in cultured cells chronically 
exposed to ethanol.462, 463  In 2003, Wang and coworkers eloquently demonstrated that the high 
preference for ethanol of C57BL/6J mice was completely reversed by rimonabant.464  
Additionally, in agreement with previous findings, rimonabant was also able to reduce ethanol 
drinking in WT mice but not in CB1R knockout, indicative of CB1R involvement.464  As an 
extension to this study, Hungund and colleagues reported that mice lacking the CB1R consumed 
considerably less ethanol than their wild type littermates.465   
The role of cannabinoid CB1R system in animal models of alcoholism is further evident 
by the effective reduction of alcohol drinking in rats with a history of ethanol dependence as well 
as alcohol-preferring Marchigian Sardinian (msP) rats by rimonabant.466, 467  CB1R antagonism 
of rimonabant and surinabant was also related to the decrease in alcohol deprivation effect and 
cue-induced reinstatement on alcohol preferring msP rats.467, 468  Acute administration of the 
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CB1R agonist CP-55,940 or WIN-55-212,2 on the other hand, significantly increased the 
motivation to consume alcohol of Wistar rats or alcohol-preferring msP rats, an effect reversed 
with the pretreatment of rimonabant.469, 470  Additional behavioral effects were seen with WIN-
55,212-2 administration, where it was shown to have an increase in alcohol relapse during a 
period of alcohol deprivation in rats.471  Recent reports have indicated the role of the CB2R in 
alcohol-related behaviors.  In 2007, Ishiguro and coworkers reported that downregulation of Cb2 
gene expression in the midbrain was related to ethanol reinforcement in that mice experiencing 
higher ethanol preference exhibited reduced Cb2 gene expression.457  Collectively, these studies 
suggest that targeting the central cannabinoid signaling system has potential in treating alcohol 
dependence. 
 
Rationale and Specific Aims 
 The great interest in the SAR of the synthetic cannabinoids, in particular the 
aminoalkylindoles, and their activity at the cannabinoid receptors has yielded various analogues 
with very interesting pharmacological activity.  Specifically, the work of Huffman and 
colleagues from 1998, describes a series of aminolalkylindole analogues with very potent 
activity at the cannabinoid receptors, with potencies greater than that of the classical cannabinoid 
Δ9-THC while exhibiting psychotropic effects similar to those seen with Δ9-THC.390  Their non-
regulated nature and pronounced pharmacological similarity to Δ9-THC made several of these 
analogues popular as ingredients to the widely abused incense blends known as Spice/K2.343  
Among the most common components of K2/Spice are JWH-018, JWH-073, JWH-200, and CP-
47,497 (Figure 50).472   
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Despite the recreational popularity of these commercial preparations, very little is known 
regarding K2/Spice metabolism, pharmacology, and toxicity.  It was recently reported that a 
mono-hydroxylated metabolite of aminoalkylidole JWH-073, compound JWH-073-M4 (432, 
Figure 50), retains relatively high affinity for CB1Rs, but lacks intrinsic activity when examined 
in the [35S]GTP-γ-S functional assay.473  Additionally, it was determined that JWH-073-M4 
antagonizes JWH-018-induced hypothermia in vivo, indicative of antagonistic mechanism of 
activity for this metabolite.473   
 With the new found neutral antagonistic activity seen with the metabolite of JWH-073 
and the widely demonstrated therapeutic potential of CB1R antagonists, principally as 
prospective therapy for alcohol abuse, it was hypothesized that utilizing the JWH-073-M4 
scaffold as the lead for further SAR modifications would identify novel indole-based analogues 
with improved pharmacological profiles. 
181 
	  
Specific Aim 1:  Prepare analogues based on the JWH-073-M4 scaffold with dual CB1R 
antagonist/CB2R agonist activity that have potential as alcohol abuse therapies. 
 Modifications of the JWH-073-M4 scaffold and further exploration into the SAR of this 
compound will allow us to gain a better understating for its interactions with the cannabinoid 
receptors and lead us to the structural elements responsible for its activity.  A series of analogues 
will be synthesized that will explore different structural features of the JWH-073-M4 scaffold 
such as the introduction of rotational bond, exploration of electronic potential at various 
positions in the molecule, and assessment of the optimal distance between the indole core and the 
substituent.  These represent a few of the modifications to the lead scaffold that will be 
undertaken in order for a greater understanding of the SAR of this scaffold for the cannabinoid 
receptors.  These modifications are intended to show that alterations of this scaffold is well 
tolerated at the cannabinoid receptors and that such analogues will retain and improve upon the 
antagonistic activity of the lead molecule.   
Specific Aim 2:  Evaluate JWH-073-M4 analogues for their cannabinoid receptor affinity 
and efficacy. 
 Compounds generated from Specific Aim 1 will be evaluated for their pharmacological 
profile at the cannabinoid receptors in vitro.  Initially, analogues will be subjected to a 
radioligand binding screen to determine their affinity at the CB1R and CB2Rs.  Compounds 
were selected for further testing if a 1 µM concentration produced over 50% displacement of a 
0.2 nM concentration of [3H]CP-55,940, indicating a relatively high sub-micromolar affinity.  
Such compounds were then subjected to a functional screen for inhibition of adenylate cyclase 
(AC) activity utilizing a 10 µM concentration of each test compound and comparing it to the 
182 
	  
inhibition of AC-activity seen with the non-selective CB1R/CB2R agonist CP-55,940.  
Analogues exhibiting weak partial agonist to antagonist activity would then be subjected to 
further examination and determination of their affinity for the cannabinoid receptors by 
determining their Ki values.  The final assay in the pharmacological testing of analogues 
synthesized in Specific Aim 1 will be to determine their potency at the cannabinoid receptors by 
calculating their IC50 values using inhibition of AC-activity assay.   
Specific Aim 3:  Evaluate selected JWH-073-M4 analogues for their behavioral effects in 
vivo. 
 Selected analogues generated in Specific Aim 1 with promising in vitro activity generated 
in Specific Aim 2 will be subjected to in vivo pharmacological testing to determine their activity 
against alcohol abuse-related behaviors in mice.  Compounds will be subjected to initial 
thermoregulation assay to determine their in vivo cannabinoid receptor activity.  With the 
successful completion of the thermoregulation assay, analogues will be subjected to two animal 
models of alcohol-abuse; the ethanol self-administration assay (SA) and ethanol-conditioned 
place preference assay (CPP).  The proposed studies will further characterize and evaluate the 
pharmacology of indole-based JWH-073-M4 derived analogues. 
The purpose of the proposed studies in the presented specific aims is to provide a greater 
insight into the SAR of the JWH-073-M4 scaffold required for activity at the cannabinoid 
receptors.  The ability to develop novel cannabinoid ligands based on the JWH-073-M4 structure 
suggests that the aminoalkyindole class of synthetic cannabinoids represent a useful scaffold for 
the construction of molecules with activity for the cannabinoid receptors.  Completion of these 
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studies will also afford us with novel indole-derived analogues that could have the potential as 
alcohol abuse therapies.  The results of these studies will be presented and discussed.  
 
Results and Discussion 
Introduction 
 In order to elucidate the structural requirements needed for activity at the cannabinoid 
receptors, a series of analogues based on the JWH-073-M4 scaffold were designed and 
synthesized.  Compounds were intended to investigate the SAR of this scaffold at the 
cannabinoid receptors.  In our quest for novel dual activity compounds with CB1R neutral 
antagonist/CB2R agonist properties, twenty-seven analogues were prepared using step-wise 
molecular investigation of the elements present in the scaffold.  The analogues prepared were 
designed to investigate the SAR at several positions on the scaffold of interest.  Firstly, we 
wanted to examine the necessity of the carbonyl moiety as well as the optimal length of the 
linker from the indole core to the naphthalene ring.  We also sought out to explore the possibility 
for addition of rotational bonds at this position of the molecule.  Secondly, we set to explore the 
requirement of the naphthalene ring through selective introduction of electron withdrawing and 
electron donating groups.  Our initial design strategy was to limit the use of charged species and 
keep steric demands to a minimum.  We also sought out to explore a different substitution at the 
N-atom of the indole core with a substituent with greater pharmacokinetic properties.  Lastly, we 
wanted to investigate the positioning of the hydroxyl moiety around the indole core and its 
necessity for activity at CBRs (Figure 51).  The analogues proposed were synthesized utilizing 
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N-alkylation, Friedel-Crafts like acylation, Suzuki coupling reaction, reduction, and O-
demethylation conditions. 
 
Synthesis 
Synthesis of analogues based on the JWH-073-M4 scaffold began with the use of 
commercially available 7-methoxyindole 433, which was subjected to mild alkylating conditions 
to afford compound 434, an important intermediate in 74-93% yield for the different 
substituents, respectively (Scheme 6).  In addition, commercially available 7-ethylindole was 
also subjected to the aforementioned conditions to yield compound 434 with an ethyl substitution 
at the 7-position of the indole ring in 93% yield.  Intermediate 434 was then subjected to Friedel-
Crafts like acylation conditions, using dimethyaluminum chloride and the appropriate acid 
chloride at 0°C to afford many of the analogues prepared, structurally represented as 
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intermediate 435, in yields ranging from 9-68%.  Compound 435 was shown to be a versatile 
intermediate that can undergo several reactions to yield various scaffolds.  Specifically, it 
undergoes O-demethylation in the presence of BBr3 to afford compound 436 in yields ranging 
from 38%-90% as well as LAH reduction conditions to afford compound 437 in 20% yield.   
 
1-Butyl-5-methoxy-1H-indole, 439 synthesized from N-alkylation of commercially 
available 5-methoxyindole 438, was subjected to Friedel-Crafts like acylation conditions to 
produce compound 440 in 58% yield, which was then O-demethylated using BBr3 to afford 
compound 441 in 90% yield (Scheme 7).  Compound 433 was additionally used in the synthesis 
of intermediate 442 utilizing a one-pot N-alkylation and 3-indole iodination in 69% yield.  
Intermediate 442 was then subjected to Suzuki coupling conditions utilizing different boronic 
acids to afford analogues 443 and 444 in 37% and 50% yield, respectively.   
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 In addition to the analogues synthesized by the methods reported above, analogue 450 
was synthesized as represented in Scheme 8.  Briefly, commercially available 1H-indole-7-
carboxylic acid 445 was subjected to esterification conditions to yield intermediate 446 in 35% 
yield, which was then subjected to similar conditions as other N-alkylated analogues in this 
series to afford compound 447, in 25% yield.  Compound 447 has then subjected to Friedel-
Crafts like conditions to afford aromatic ketone 448 in 71%.  Subjection of intermediate 448 to 
O-ethylation with base afforded compound 449 in 77% yield, which was then exposed to amide 
bond formation with ammonia and peptide coupling reagents to afford analogue 450 in 53% 
yield.  
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 The synthetic methods applied in the production of this series of JWH-073-M4 scaffold 
analogues afforded a group of 27 compounds, structurally represented in Figure 52.  
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Pharmacological Evaluation 
In vitro Binding and Functional Assays 
 Analogues synthesized were then subjected to pharmacological testing for their activity at 
the cannabinoid receptors.  Initial receptor binding screens for both CB1Rs and CB2Rs were 
conducted for all twenty-seven analogues prepared.  These initial binding screens were 
conducted by examining the ability of a single analogue concentration of 1 µM to compete for 
receptor binding with the high affinity CB1R/CB2R agonist [3H]CP-55,940.474, 475  With this 
approach the approximate affinity of all the analogues was quickly attained.  Compounds were 
selected for further assays to determine intrinsic activity at CB1R and CB2Rs if a 1 µM 
concentration produced over 50% displacement of a 0.2 nM concentration of [3H]CP-55,940, 
indicating a relatively high sub-micromolar affinity.  For example, employing the conditions 
used for this screen, it would be predicted by the Cheng-Prusoff equation that the concentration 
of a compound producing 50% displacement of [3H]CP-55,940 from a receptor will estimate the 
compounds affinity for that receptor.476  Data presented in Table 21 shows that a 1µM 
concentration of most analogues examined produced greater than 50% displacement of [3H]CP-
55,940 from both CB1R and CB2Rs.  Out of the twenty-seven analogues that were screened, 
seventeen bind to CB1R and twenty-three bind to CB2R with sub-micromolar affinity.  Several 
analogues exhibited very high affinity for either of the two receptors tested, as seen from their 
near 100% displacement of [3H]CP-55,940 from the receptors.   
 A functional assay to screen for the inhibition of AC-activity by CBRs was selected for 
determination of intrinsic activity of the analogues that demonstrated sub-micromolar affinity for 
CB1R and CB2Rs.475  A 10 µM concentration of all compounds was used to achieve full-
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receptor occupancy.  It is assumed that full-receptor occupancy will produce maximal efficacy.  
The non-selective CB1R/CB2R full agonist CP-55,940 inhibited AC-activity via CB1Rs 
endogenously expressed in Neuro2A cells by 45% and 37% in CHO cells transfected with 
CB2Rs (Table 21).  Most compounds examined exhibited levels of AC-inhibition similar to that 
produced by the full agonist CP-55,940.  However, compounds 451, 461, and 444, produced 
significantly less AC-inhibition via CB1Rs when compared to the full agonist CP-55,940 of -4, 
18, and 16% inhibition, respectively.  Despite little or no AC-inhibition when examined at 
CB1Rs, these compounds exhibited significantly different results when tested for activity at 
CB2Rs.  Specifically, the three compounds 451, 461, and 444 produced levels of AC-inhibition 
that were similar to inhibition resulting from CP-55,940 administration of 22.1, 33.2, and 20.8%, 
respectively.  These data indicate that compounds 451, 461, and 444 display only neutral 
antagonist to weak partial agonist activity at CB1Rs, while exhibiting partial to full agonist 
efficacy at CB2Rs.  Despite the high binding affinities for the CB2Rs seen with analogues 450, 
470 – 474, most of the analogues exhibited very little inhibition of AC-activity at the CB2Rs, 
however compounds 471 and 473 appeared to display inverse agonist activity at these receptors.    
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Table 21.  Binding and activity of aminoalkylindole analogues 443, 444, 450 – 474 
 
% displacement 
of [3H]CP-
55,940 at 
CB1Rs 
% displacement 
of [3H]CP-
55,940 at 
CB2Rs 
% vehicle 
inhibition of 
AC-activity at 
CB1Rs 
% vehicle 
inhibition of 
AC-activity at 
CB2Rs 
Cmpd 
1 µM concentration of compounds 
used 
10 µM concentration of 
compounds used 
CP-55,940 NDa NDa 45 37 
432 99 90 55 38 
450 69 59 18 35 
451 55 80 -4 22 
452 38 64 NDa NDa 
453 93 100 51 52 
454 29 10 NDa NDa 
455 69 91 34 16 
456 21 20 NDa NDa 
457 81 91 34 -40 
458 37 21 NDa NDa 
459 90 90 47 31 
460 97 91 39 37 
461 90 97 18 33 
462 100 100 39 37 
463 10 10 NDa NDa 
444 82 91 16 21 
464 84 99 45 38 
465 84 99 45 1 
466 63 91 NDa NDa 
467 63 88 NDa NDa 
443 98 97 39 37 
468 41 80 NDa NDa 
469 80 97 35 -6 
470 29 62 -6 25 
471 45 89 10 -25 
472 70 92 16 5 
473 5 69 0 -133 
474 0 72 6 25 
aND = not determined 
 
Based on efficacy predicted from the functional experiments examining AC-inhibition, 
together with the initial screen for sub-micromolar receptor affinity, several compounds were 
selected to determine actual Ki values by conducting full concentration effect curves for 
inhibition of [3H]CP-55,940 binding to CBRs.  Even though compound 451 produced minimal 
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AC-inhibition via CB1Rs, it was shown to bind to both CB1R and CB2Rs with a relatively low 
affinity of 387 and 281 nM, respectively (Table 22).  However, analogue 453 demonstrated high 
affinity for CB1R and CB2Rs in the low nanomolar range of 1.7 nM and 0.81 nM, respectively.  
Compounds 461 and 444 displayed similar affinity for both receptors, however binding with 
slightly higher affinity to the CB2R.  Specifically, 461 bound to CB1Rs with a Ki value of 15.4 
nM, while binding to CB2Rs with a Ki value of 10.9 nM.  Compound 444 demonstrated an 
affinity of 37.2 nM and 26.5 nM for CB1R and CB2Rs, respectively.  Compounds 471 and 474 
exhibited higher affinity for the CB2Rs than the CB1Rs, with Ki values of 71 and 148 nM, 
respectively.  Compounds 471 and 474 were 14-fold and 136-fold more selective for the CB2Rs 
than the CB1Rs, respectively.  
 
Table 22.  Affinity of selected analogues for mouse CB1Rs and 
human CB2Rs 
Cmpd 
mCB1R 
Ki ± SEM, nM a 
hCB2R 
Ki ± SEM, nM a 
429 12.9 ± 3.4 9.8 ± 0.9 
432 24.2 ± 17.2 78.3 ± 36.2 
451 387 ± 77.0 281 ± 51.0 
453 1.7 ± 0.3 0.81 ± 0.4 
461 15.4 ± 2.2 10.9 ± 3.1 
444 37.3 ± 11.8 26.5 ± 1.5 
471 970 ± 180 71.4 ± 11.8 
474 20,000 ± 12,800 147.7 ± 19.8 
aValues represent mean ± standard error of mean, experiments 
performed in triplicate.  
 
Compounds 451, 453, 461, and 444 exhibited relatively high affinities as indicated by 
their Ki values were examined together with JWH-073-M4 (432) to determine their potency to 
inhibit AC-activity via CB1R and CB2Rs.  Similar to data reported in the initial screen for AC-
inhibition, 432 and 453 produced 50-60% inhibition of AC-activity via CB1Rs with IC50 values 
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of 225 and 45 nM, respectively.  Conversely, 461 and 444 produced very little inhibition of AC-
activity, which was only observed at very high concentrations of both analogues (Figure 53A).  
In support of the observed functional activity indicating neutral antagonism, the two lead 
compounds and the CB1R antagonist O-2050 (1 µM concentration) significantly antagonized 
AC-inhibition produced by the CB1R full agonist 429 (Figure 53B).  In contrast to neutral 
antagonism at CB1Rs, all of the compounds examined produced 40-50% inhibition of AC-
activity at CB2Rs in CHO-hCB2 cells with potency similar to their rank order of Ki values 
reported in Table 21 (Figure 54A).  To examine if the observed agonist activity in CHO-hCB2 
cells is due to activation of CB2Rs, the AC-inhibition assay was conducted in CHO-WT cells not 
expressing CB2Rs.  As observed in Figure 54B, neither 461 nor 444 significantly modified AC-
activity in CHO-WT cells indicating that the agonist activity observed for both compounds in 
CHO-hCB2 cells is indeed due to their activation of CB2Rs.   
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Figure 53.  Inhibition of AC-activity at CB1Rs for analogues 461 and 444.  Compounds 461 and 
444 produce very little inhibition of AC-activity when tested alone at high concentrations and 
antagonize AC-inhibition produced by CB1R-agonist (black bar in panel B represents inhibition 
of AC-activation of 10-7 M concentration of 429)  
***Lead compounds selected for testing in animals 
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Figure 54.  Inhibition of AC-activity at CB2Rs for analogues 461 and 444.  Compounds 461 and 
444 produce concentration-dependent inhibition of adenylyl cyclase activity by activation of 
CB2Rs 
***Lead compounds selected for testing in animals 
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Letter signifies statistical differences between groups 
 
From these results it can be concluded that the carbonyl moiety is not necessary of 
activity at the CBRs and that introduction of rotational bond at the C-3 position in the scaffold 
retained and improved activity at the CBRs.  Furthermore, exploration of the electronic potential 
of the naphthalene moiety was well tolerated in that electron-withdrawing groups produced 
activity at the CBRs, however analogues containing electron-donating groups at this position 
need to be designed and synthesized in order for a full conclusion to be reached regarding the 
electronic potential of this substituent.  It was also established that no linker or one carbon linker 
between the indole core the C-3 substituent is well tolerated retaining and significantly 
improving the activity at the CBRs.  Additionally, different substitutions at the N-atom are 
tolerated; however N-butyl substituent is optimal of CB1R antagonist activity.  Moreover, 
movement of the hydroxyl substituent around the indole core did not prove fruitful in that those 
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analogues that did not possess a C-7 substitution were not as active at the CBRs.  Additionally, 
substitution of the 7-methoxy moiety with a 7-acetamide moiety was tolerated, however with 
lower activity at the CBRs than those analogues possessing a 7-methoxy substituent. 
 
In vivo animal testing 
The dual CB1R neutral antagonist/CB2R agonist activity displayed by compounds 461 
and 444 in the in vitro assays prompted us to select these analogues for further evaluation in vivo 
using murine subjects in two complementary models relevant to alcohol abuse.  These in vivo 
assay are based on the hypothesis that analogues with dual activity as CB1R neutral 
antagonist/CB2R agonist will reduce both the reinforcing effects of ethanol (EtOH) and the 
conditioned rewarding effects of EtOH in mice.  Thermoregulation assay was used as an initial 
analysis that examines potential cannabinoid receptor antagonist activity.  It is well known that 
cannabinoid agonists produce hypothermic effects, and are blunted by prior treatment with 
CB1R antagonists, allowing us to rapidly determine whether or not our selected compounds 
display in vivo effects consistent with CB1R antagonism.477, 478  The assay was conducted using 
glass-encapsulated radiotelemetry probes surgically implanted into the peritoneal cavity of each 
mouse, which monitored core body temperature in response to drug administration.473  
Intraperitoneal administration of 10 mg/kg of the full CB1R agonist 429, elicited a profound 
hypothermic effect as seen in Figure 55 (black circles).  Importantly, thirty minute pretreatment 
with either 461 (Figure 55, gray triangle) or 444 (Figure 55, white circles), significantly 
decreased the hypothermic effects elicited by subsequent administration of compound 429, 
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confirming the in vivo cannabinoid activity of 461 and 444, and illustrating apparent antagonist 
effects against CB1R agonist-induced hypothermia (Figure 56).   
 
Figure 55.  Thermoregulation assay for analogues 461 and 444.  Compounds 461 and 444 
reduce agonist 429 induced hypothermic effects in rodents 
 
Having established apparent in vivo antagonism, 461 and 444 were further tested in two 
complementary models of alcohol abuse: oral ethanol self-administration (SA) and ethanol 
conditioned place preference (CPP).  Ethanol SA and CPP are important models for the study of 
alcoholism because they capture several aspects of this condition including voluntary EtOH 
drinking (SA) and conditioned EtOH reward (CPP).   
 
197 
	  
The effects of compounds 461 and 444 on voluntary 10% Procedure described by both 
Keane and coworkers and Cunningham and colleagues, where EtOH drinking was studied using 
a two-bottle choice procedure (ethanol vs. water) and where 10 mg/kg rimonabant was used as a 
positive control were employed.479, 480  Across five observations conducted under baseline “no 
injection” conditions it can be observed in Figures 57A, and Figure 57D (black circles) that 
EtOH preference and total fluid consumption (Figure 57B, Figure 57E; black circles) were 
steadily maintained during the entire treatment period.  Consistent with previous reports, daily 
treatment with 10 mg/kg rimonabant decreased EtOH preference (Figure 57A, Figure 57D, 
triangles) without altering total fluid intake (Figure 57B, Figure 57E, triangles).481  However, as 
previously published reports have stated, rimonabant decreased body weight across the treatment 
period (Figure 57C, Figure 57F, triangles).482, 483  After ten day treatment with rimonabant, 
mice were returned to baseline “no injection” conditions where their weights increased and 
voluntary EtOH drinking resumed.  After five such observations, representing a two week drug 
“washout" period, daily treatments with 10 mg/kg of 461 or 444 were initiated.  As previously 
observed with rimonabant, both compounds 461 and 444 reduced EtOH preference (Figure 57A, 
inverted triangles; Figure 57D, gray triangles, respectively) without affecting total fluid 
consumption (Figure 57B, inverted triangles; Figure 57E, gray triangles).  However, unlike 
rimonabant, compounds 461 and 444 did not decrease body weight of mice tested (Figure 57C, 
inverted triangles; Figure 57E, gray triangles).  The last treatment was a daily injection of the 
rimonabant/461/444 vehicle, which was 8% Tween/92% sterile water.  With the exception of the 
first observation period for compound 461 (perhaps representing a persistent effect of 461), 
EtOH preference (Figure 57A, gray circles-compound 461; Figure 57D, gray circles-compound 
444), total fluid consumption (Figure 57B, gray circles-compound 461; Figure 57E, gray 
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circles-compound 444), and mean body weight (Figure 57C, gray circles-compound 461; 
Figure 57F, gray circles-compound 444) were not affected by vehicle injections.  This study 
demonstrates that a JWH-derived compound devoid of inverse agonist activity can replicate the 
effects of rimonabant on alcohol self-administration in mice. 
 
Figure 57.  In vivo ethanols self-administration assay for analogues 461 and 444.  Reduction of 
EtOH self-administration with daily administration of 10 mg/kg rimonabant or compounds 461 
and 444.  Dotted lines represent group means from the 10 “no injection” control periods  
	  
To further explore the in vivo effects of these compounds, an alcohol conditioned place 
preference assay was performed with compounds 461, 444, and rimonabant.  The conditioned 
rewarding effects of ethanol are examine in this assay.  Training of mice involved daily pairings 
of 2 mg/kg EtOH with novel contextual cues within a spatial conditioning chamber, and daily 
pairings of saline with distinct contextual cues within the same chamber.  Following four such 
pairings, an increase in time spent in EtOH-paired chamber was observed, indicating the 
development of conditioned place preference (Figure 58, “No inj” bar).  Separate groups of mice 
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were conditioned as previously described, with the exception that 10 mg/kg 461, 10 mg/kg 444 
or 10 mg/kg rimonabant were administered one hour before each EtOH pairing.  In contrast to 
the ~400 sec preference elicited by EtOH in the absence of cannabinoid administration, mice 
treated with 10 mg/kg rimonabant prior to each EtOH pairing did not exhibit a significant 
preference for the EtOH-paired chamber, which is in agreement with previously reported data 
(Figure 58, “10 RIM” bar).484, 485  Similar to the effects of rimonabant produced in the present 
study, the conditioned rewarding effects of EtOH were also blocked by the administration of 
either 10 mg/kg 461 or 10 mg/kg 444 prior to each EtOH pairing.  In total, these studies 
demonstrate that a novel indole-derived compound with cannabinoid activity lacking inverse 
agonist activity can replicate the effects of rimonabant on alcohol induced CPP in mice.  
 
Figure 58.  In vivo ethanol conditioned place preference for analogues 461 and 444.  Blockage 
of EtOH CPP with rimonabant and compounds 461 and 444  
	  
Conclusions 
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 Analogues of the JWH-073-M4 scaffold were designed and synthesized to gain a better 
understanding for the activity of this scaffold at the cannabinoid receptors.  Analogues 
synthesized were designed to explore several different structural features in the molecule 
including the necessity of the carbonyl moiety, the optimal length of the linker from the indole 
core to the naphthalene ring, the electronic nature of the naphthalene substituent, the introduction 
of a rotatable bond at the C-3 position, the introduction of N-substituents with improved 
pharmacokinetic properties, and explore the optimal position of the substituent on the indole 
ring.   
 Upon synthesis, the designed analogues were subjected to an array of pharmacological 
assays for evaluation.  As seen with the parent compound JWH-073, most of the analogues tested 
exhibited relatively high affinity for both CB1R and CB2Rs.  Of all of the compounds tested, 
two analogues, 461 and 444, appeared to have the most promise with affinities for the 
cannabinoid receptors in the low nanomolar range (Figure 59).  In AC-inhibition assays, both 
compounds produced very little inhibition of AC-activity via CB1Rs, consistent with neutral 
antagonism.  However, 461 and 444 both produced 40-50% inhibition of AC-activity via CB2Rs, 
similar to that of the full agonist CP-55,940 and thus consistent with partial to full agonism. 
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The promising in vitro pharmacological results for these to lead compounds prompted 
further evaluation in in vivo animal assays of alcohol abuse, namely ethanol SA and ethanol 
CPP.  Similar to the actions produced by the CB1R antagonist/inverse agonist rimonabant, both 
461 and 444 were shown to decrease alcohol self-administration, without affecting total fluid 
intake.  Unlike rimonabant, 461 and 444 did not alter body weight during the treatment period.  
Both analogues 461 and 444 interestingly decreased ethanol CPP in a similar manner to 
rimonabant, despite not possessing any apparent inverse agonist activity in vitro.  As previously 
reported for rimonabant, these results demonstrate that both the reinforcing and conditioning 
rewarding effects of alcohol can also be significantly blunted by treatment with novel JWH-
derived cannabinoids, devoid of inverse agonist activity at CB1Rs.486  Compounds with dual 
CB1R neutral antagonist/CB2R agonist activity such as analogues 461 and 444 may indeed 
represent potential leads in an ongoing search for new and improved alcohol abuse therapies.  
  
Future Directions 
 The in vivo pharmacological results that were obtained utilizing murine models of alcohol 
abuse were very promising in the detection of two analogues with dual CB1R antagonists and 
CB2R agonist activities.  A behavioral study completed in non-human primates would assist in 
the collection of behavioral effects that these compounds may have as well as to further examine 
the seen in vivo results of the two lead compounds 461 and 444.   
The positive results that were obtained from the present SAR study of the JWH-073-M4 
scaffold can serve as the base for further SAR exploration of this scaffold at the cannabinoid 
receptors.  Such studies can involve the design and synthesis of a series of analogues that explore 
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different structural features of the two lead compounds 461 and 444.  For example, analogues 
could be designed to explore the necessity of the naphthalene substituent off of the C-3 carbon 
on the indole core as well as explore the electronic potential at this position.  Another series of 
analogues could explore different N-substituents varying in length of the alkyl chain as well as 
substituents with improved pharmacokinetic profiles.  A third series of analogues could examine 
the positioning of the indole ring substituents as well as introduce substituents with different 
electronic profiles at various positions of the indole core.  Lastly, explorations into alkyl 
substituents at the C-2 position as well as conformationaly constrained analogues could give us a 
new insight into the interactions of such molecules with the cannabinoid receptors.   
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CHAPTER 5:  EXPERIMENTAL PROCEDURES FOR JWH-073-M4 ANALOGUES 
 
Chemistry 
 General Procedures.  Unless otherwise indicated, all reagents were purchased from 
commercial sources and were used without further purification.  Melting points were determined 
on a Thomas-Hoover capillary melting apparatus.  NMR spectra were recorded on a Bruker 
DRX-400 with qnp probe or a Bruker AV-500 with cryoprobe using δ values in ppm (TMS as 
internal standard) and J (Hz) assignments of 1H resonance coupling.  High resolution mass 
spectrometry data were collected on either a LCT Premier (Waters Corp., Milford, MA) time of 
flight mass spectrometer or an Agilent 6890 N gas chromatograph in conjunction with a quarto 
Micro GC mass spectrometer (Micromass Ltd, Manchester UK). Thin-layer chromatography 
(TLC) was performed on 0.25 mm plates Analtech GHLF silica gel plates using ethyl acetate/n-
hexanes, in 20%:80% ratio as the solvent unless otherwise noted.  Spots on TLC were visualized 
by UV (254 or 365 nm), or if applicable, phosphomolybdic acid in ethanol.  Column 
chromatography was performed with silica gel (40-63 µ particle size) from Sorbent Technologies 
(Atlanta, GA).  Analytical HPLC was carried out on an Agilent 1100 Series Capillary HPLC 
system with diode array detection at 254 nm on an Agilent Eclipse XDB-C18 column (250 x 10 
mm, 5 µm) with isocratic elution in 80% CH3CN/20% H2O (0.1% formic acid) unless otherwise 
specified.   
General Procedure A: Indole N-alkylation. To a suspension of KOH (5 equiv) in DMF 
(13 mL) was added 5-methoxyindole, 7-methoxyindole or 7-ethylindole (1 equiv).  After stirring 
at 21 °C for an hour, 1-bromobutane (1.375 equiv) was added and the reaction mixture was 
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heated to 50 °C and stirred overnight.  Upon completion, the resulting mixture was poured into 
H2O (15 mL) and extracted with DCM (3 x 15 mL).  Combined organic extracts were washed 
with water, dried over anhydrous Na2SO4, concentrated under reduced pressure and the resulting 
residue was purified by flash column chromatography on silica gel using EtOAc/n-hexanes.  
 
1-Butyl-7-methoxy-1H-indole (434ac).  Compound 434ac was synthesized from 
commercially available 7-methoxyindole using general procedure A and 1-bromobutane to 
afford 0.51 g (74% yield) as a clear oil.  TLC system: 10% EtOAc/90% n-hexanes.  Spectral data 
matched previously reported data.487  
 
1-Butyl-7-ethyl-1H-indole (434bc).  Compound 434bc was synthesized from 
commercially available 7-ethylindole using general procedure A and 1-bromobutane to afford 
0.64 g (93% yield) as a clear oil.  TLC system: 10% EtOAc/90% n-hexanes.  1H NMR (500 
MHz, CDCl3) δ 7.47 (dd, J = 7.6, 1.4 Hz, 1H), 7.05 – 6.95 (m, 3H), 6.47 (d, J = 3.1 Hz, 1H), 
4.31 – 4.21 (m, 2H), 3.03 (q, J = 7.5 Hz, 2H), 1.83 – 1.69 (m, 2H), 1.35 (td, J = 7.6, 2.7 Hz, 5H), 
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0.94 (t, J = 7.4 Hz, 3H).  13C NMR (126 MHz, CDCl3) δ 133.57, 130.09, 129.60, 127.30, 122.42, 
119.49, 119.00, 101.40, 48.75, 34.47, 25.67, 20.04, 16.08, 13.77.  [M+H] calcd for C14H19N, 
202.1590; found 202.1596. 
 
4-(2-(7-Methoxy-1H-indol-1-yl)ethyl)morpholine (434ad).  Compound 434ad was 
synthesized from commercially available 7-methoxyindole using general procedure A and 4-(2-
bromoethyl)morpholine that was made utilizing conditions reported by Cai J., et al.488 to afford 
0.51 g (74% yield) as an oil with a slightly orange tint.  TLC system: 40% EtOAc/60% n-
hexanes.  1H NMR (500 MHz, CDCl3) δ 7.20 (dd, J = 7.9, 0.9 Hz, 1H), 7.01 – 6.99 (m, 1H), 6.97 
(d, J = 7.8 Hz, 1H), 6.61 (dd, J = 7.8, 0.9 Hz, 1H), 6.42 (d, J = 3.1 Hz, 1H), 4.53 – 4.46 (m, 2H), 
3.93 (s, 3H), 3.74 – 3.68 (m, 4H), 2.78 – 2.71 (m, 2H), 2.53 – 2.47 (m, 4H).  13C NMR (126 
MHz, CDCl3) δ 147.33, 130.92, 129.19, 125.48, 119.75, 113.77, 102.14, 101.33, 67.02, 60.15, 
55.15, 53.93, 46.65.  [M+H] calcd for C15H21N2O2, 261.1598; found 261.1603. 
 
206 
	  
1-Butyl-5-methoxy-1H-indole (439).  Compound 439 was synthesized from 
commercially available 5-methoxyindole using general procedure A and 1-bromobutane to 
afford 1.28 g (92% yield) as a clear oil.  TLC system: 10% EtOAc/90% n-hexanes.  1H NMR 
(500 MHz, CDCl3) δ 7.18 (d, J = 8.9, 1H), 7.02 (dd, J = 2.7, 13.3, 2H), 6.81 (dd, J = 2.4, 8.9, 
1H), 6.34 (dd, J = 0.7, 3.0, 1H), 4.02 (t, J = 7.1, 2H), 3.79 (s, 3H), 1.75 (ddd, J = 7.3, 11.2, 14.8, 
2H), 1.32 – 1.23 (m, 2H), 0.87 (t, J = 7.4, 3H).  13C NMR (126 MHz, CDCl3) δ 154.09, 131.56, 
129.06, 128.55, 111.93, 110.35, 102.71, 100.53, 56.12, 46.54, 32.63, 20.43, 13.95.  [M+H] calcd 
for C13H18NO, 204.1383; found 204.1386. 
 
Preparation of 1-butyl-3-iodo-7-methoxy-1H-indole (442).  A round bottom flask 
containing 7-methoxyindole (0.22 mL, 1.70 mmol, 1 equiv) in DMF at 21 °C was stirred with 
KOH (0.10 g, 1.78 mmol, 1.05 equiv) for 15 min and then treated with I2 (0.44g, 1.73 mmol, 
1.02 equiv).  After 30 min, NaH (60% dispersion in mineral oil; 0.082 g, 2.04 mmol, 1.2 equiv) 
was added portion-wise.  After an additional 15 min, 1-bromobutane (0.2 mL, 1.87 mmol, 1.1 
equiv) was added and the reaction mixture was stirred until completion.  Upon completion (TLC 
monitoring), water was added and allowed to stir for 15 min, upon which the mixture was 
extracted with DCM and the layers were separated.  Aqueous layer was washed with DCM (3 x 
15 mL) and the combined organic layers were washed with H2O (2 x 15 mL), dried over 
anhydrous Na2SO4 and concentrated under reduced pressure.  The resulting residue was purified 
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by silica gel column chromatography using EtOAc/n-hexanes to afford 0.45g (80% yield) as an 
clear oil with a yellow tint that was used immediately.  TLC system: 10% EtOAc/90% n-
hexanes.  1H NMR (500 MHz, CDCl3) δ 7.08 (t, J = 3.8, 2H), 7.04 (dd, J = 1.1, 8.0, 1H), 6.68 (d, 
J = 7.5, 1H), 4.38 (t, J = 7.2, 2H), 3.95 (s, 3H), 1.78 (dt, J = 7.5, 12.7, 2H), 1.33 (td, J = 7.5, 
15.0, 2H), 0.94 (t, J = 7.4, 3H).  13C NMR (126 MHz, CDCl3) δ 146.67, 132.31, 131.99, 125.18, 
119.88, 113.27, 102.43, 54.80, 48.90, 33.67, 19.20, 13.13. 
General Procedure B: O-Demethylation procedure.  A solution of BBr3 (1 M in DCM, 
6 equiv) in DCM was added dropwise to a solution of methyl ether (1 equiv) in DCM at -78 °C.  
The mixture was then allowed to warm to 21 °C overnight, and upon completion, NaHCO3 (6 
equiv) was added.  The resulting mixture was then cooled in an ice-bath and MeOH (20 mL) was 
added dropwise and then stirred for 30 min.  The reaction mixture was then warmed up to 21 °C 
and stirred for an additional hour.  The reaction was quenched with H2O and the separated 
aqueous phase was extracted with DCM (3 x 15 mL).  Combined organic extracts were dried 
over anhydrous Na2SO4, and concentrated under reduced pressure.  The resulting residue was 
purified by flash chromatography on silica gel using mixtures of EtOAc/n-hexanes.  
General Procedure C: Acid chloride formation.  The appropriate acid (1 equiv) was 
placed in a round bottom flask and flushed twice with argon (Ar).  Anhydrous DCM (7 mL) was 
then added followed by the dropwise addition of oxalyl chloride (2 M in DCM, 3.1 equiv).  After 
5 min, 3 drops of anhydrous DMF were added to the reaction mixture and once the fizzing 
stopped, the reaction was allowed to stir overnight at 21 °C.  Solvent was then evaporated using 
reduced pressure and the crude residue was used immediately without any further purification.  
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General Procedure D: 3’-indole acylation.  To a solution of the appropriate indole (1 
equiv) in DCM at 0 °C under an Ar atmosphere was added Me2AlCl (1.5 equiv) dropwise and 
the solution was allowed to stir at that temperature for 30 min, after which a solution of the 
appropriate acid chloride (1.2 equiv) in DCM was added dropwise.  Reaction was monitored by 
TLC and upon completion, was carefully poured into an ice-cold 1N HCl solution and then 
extracted with DCM (3 x 15 mL).  Combined organic layers were then washed with NaHCO3 (2 
x 15 mL), brine, and dried over anhydrous Na2SO4.  The solvent was evaporated under reduced 
pressure and the resulting residue was purified by flash column chromatography on silica gel 
using mixtures of EtOAc/n-hexanes to afford the desired product.  
 
1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(4-fluorophenyl)ethanone (451).  Compound 
451 was synthesized from compound 434 using general procedure D and 4-fluorophenylacetyl 
chloride to afford 0.08g (9% yield) isolated as a brown oil.  1H NMR (500 MHz, CDCl3) δ 7.98 
(dd, J = 0.8, 8.1, 1H), 7.64 (s, 1H), 7.29 – 7.25 (m, 2H), 7.16 (t, J = 8.0, 1H), 7.02 – 6.96 (m, 
2H), 6.71 (d, J = 7.5, 1H), 4.39 (t, J = 7.2, 2H), 4.09 (s, 2H), 3.93 (s, 3H), 1.85 – 1.77 (m, 2H), 
1.36 – 1.27 (m, 2H), 0.94 (t, J = 7.4, 3H).  13C NMR (126 MHz, CDCl3) δ 192.32, 162.72, 
160.77, 147.31, 135.78, 131.66 (d, J = 3.2 Hz), 130.95 (d, J = 7.9 Hz), 129.07, 126.33, 123.30, 
115.70 (d, J = 21.4 Hz), 115.21, 115.12, 104.31, 55.36, 50.28, 45.87, 33.81, 19.78, 13.68.  
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HRMS (m/z): [M+K] calcd for C21H22FKNO2, 378.1272; found 378.1315. HPLC tR = 15.031 
min; purity = 95.4% using 70% CH3CN/30% H2O (0.1% formic acid). 
 
1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(4-methoxyphenyl)ethanone (452).  
Compound 452 was synthesized from compound 434 using general procedure D and 4-
methoxyphenylacetyl chloride to afford 0.63 g (59.2% yield) isolated as a reddish solid, mp = 
72-74 °C.  1H NMR (500 MHz, CDCl3) δ 8.00 (dd, J = 0.8, 8.1, 1H), 7.63 (s, 1H), 7.25 – 7.21 
(m, 2H), 7.15 (t, J = 8.0, 1H), 6.87 – 6.81 (m, 2H), 6.70 (d, J = 7.8, 1H), 4.37 (t, J = 7.2, 2H), 
4.06 (s, 2H), 3.92 (s, 3H), 3.77 (s, 3H), 1.84 – 1.76 (m, 2H), 1.35 – 1.26 (m, 2H), 0.93 (t, J = 7.4, 
3H).  13C NMR (126 MHz, CDCl3) δ 193.44, 158.73, 147.69, 136.29, 130.73, 129.59, 128.50, 
126.69, 123.58, 116.22, 115.62, 114.40, 104.62, 55.76, 55.69, 50.63, 46.48, 34.22, 20.19, 14.11.  
HRMS (m/z): [M+Na] calcd for C22H25NNaO3, 374.1732; found 374.1783.  HPLC tR = 7.490 
min; purity = 99.9%.  
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1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(2,3-difluorophenyl)ethanone (453).  
Compound 453 was synthesized from compound 434 using general procedure D and 1-naphthoyl 
chloride to afford 2.00 g (53% yield) isolated as a pale brown solid, mp = 108-110 °C.  1H NMR 
(500 MHz, CDCl3) δ 8.19 (d, J = 8.4, 1H), 8.11 (d, J = 7.4, 1H), 7.96 (d, J = 8.2, 1H), 7.91 (d, J 
= 7.8, 1H), 7.65 (dd, J = 1.1, 7.0, 1H), 7.56 – 7.45 (m, 3H), 7.28 – 7.24 (m, 2H), 7.22 (s, 1H), 
6.79 (d, J = 7.7, 1H), 4.30 (t, J = 7.3, 2H), 3.96 (s, 3H), 1.80 – 1.71 (m, 2H), 1.32 – 1.23 (m, 2H), 
0.89 (t, J = 7.4, 3H).  13C NMR (126 MHz, CDCl3) δ 192.08, 147.45, 139.32, 139.07, 133.81, 
130.89, 129.96, 129.46, 128.22, 126.79, 126.61, 126.34, 126.14, 125.89, 124.65, 123.60, 117.42, 
115.35, 104.66, 55.50, 50.34, 33.86, 19.83, 13.73.  HRMS (m/z): [M+Na+CH3CN] calcd for 
C26H26N2NaO2 421.1892; found 421.1843.  HPLC tR = 14.576; purity = 95.8%. 
 
1-(1-Butyl-7-hydroxy-1H-indol-3-yl)-2-(4-fluorophenyl)ethanone (454).  Compound 
454 was synthesized from 435 using general procedure B to afford 0.10g (38% yield) isolated as 
an off-brown solid, mp = decomposition at 204-206 °C.  1H NMR (500 MHz, DMSO) δ 9.91 (s, 
1H), 8.44 (s, 1H), 7.62 (dd, J = 0.9, 8.0, 1H), 7.39 – 7.33 (m, 2H), 7.12 (ddd, J = 2.6, 5.9, 8.9, 
2H), 6.94 (t, J = 7.8, 1H), 6.61 (dd, J = 0.9, 7.7, 1H), 4.44 (t, J = 7.0, 2H), 4.09 (s, 2H), 1.85 – 
1.75 (m, 2H), 1.31 – 1.21 (m, 2H), 0.90 (t, J = 7.4, 3H).  13C NMR (126 MHz, DMSO) δ 191.61, 
161.72, 159.80, 144.49, 137.94, 132.17 (d, J = 3.1 Hz), 131.05, 130.69 (d, J = 8.0 Hz), 128.73, 
125.46, 122.80, 114.76, 114.59, 114.50, 112.34, 108.26, 48.70, 44.52, 33.29, 18.97, 13.39.  
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HRMS (m/z): [M+Na+CH3CN] calcd for C22H23FN2NaO2, 389.1641; found 389.1711.  HPLC tR 
= 6.491 min; purity = 99.9% using 70% CH3CN/30% H2O (0.1% formic acid). 
 
1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-phenylethanone (455).  Compound 455 was 
synthesized from compound 434 using general procedure D and phenyacetyl chloride to afford 
0.13 g (17% yield) isolated as an off-white solid with a pinkish tint, mp = 65-68 °C.  1H NMR 
(500 MHz, CDCl3) δ 8.03 (dd, J = 0.8, 8.1, 1H), 7.66 (s, 1H), 7.36 – 7.30 (m, 4H), 7.26 – 7.22 
(m, 1H), 7.18 (t, J = 8.0, 1H), 6.72 (d, J = 7.8, 1H), 4.39 (t, J = 7.2, 2H), 4.14 (s, 2H), 3.94 (s, 
3H), 1.87 – 1.77 (m, 2H), 1.32 (dq, J = 7.4, 14.8, 2H), 0.95 (t, J = 7.4, 3H).  13C NMR (126 
MHz, CDCl3) δ 192.72, 147.37, 136.13, 136.06, 129.43, 129.25, 128.62, 126.64, 126.38, 123.30, 
115.96, 115.30, 104.34, 55.44, 50.32, 47.09, 33.88, 19.86, 13.78.  HRMS (m/z): [M+Na] calcd 
for C21H23NNaO2, 344.1626; found 344.1656.  HPLC tR = 8.114 min; purity = 99.9%. 
 
1-(1-Butyl-7-hydroxy-1H-indol-3-yl)-2-phenylethanone (456).  Compound 456 was 
synthesized from compound 435 using general procedure B to afford 0.17 g (68% yield) isolated 
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as a fluffy brown solid, mp = decomposition at 197-200 °C.  1H NMR (500 MHz, DMSO) δ 9.91 
(s, 1H), 8.44 (s, 1H), 7.62 (dd, J = 0.9, 8.0, 1H), 7.36 – 7.31 (m, 2H), 7.28 (dd, J = 4.9, 10.3, 
2H), 7.20 (dd, J = 4.3, 11.6, 1H), 6.93 (t, J = 7.8, 1H), 6.61 (dd, J = 0.9, 7.7, 1H), 4.44 (t, J = 7.0, 
2H), 4.08 (s, 2H), 1.84 – 1.75 (m, 2H), 1.30 – 1.20 (m, 2H), 0.90 (t, J = 7.4, 3H).  13C NMR (126 
MHz, DMSO) δ 191.75, 144.49, 137.99, 136.39, 129.20, 128.76, 128.00, 126.01, 125.46, 122.77, 
114.60, 112.35, 108.24, 48.67, 45.62, 33.28, 18.95, 13.38.  HRMS (m/z): [M+Na] calcd for 
C20H21NNaO2, 330.1470; found 330.1514.  HPLC tR = 6.458 min; purity = 99.8% using 70% 
CH3CN/30% H2O (0.1% formic acid). 
 
1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(naphthalen-1-yl)ethanone (457).  Compound 
457 was synthesized from compound 434 using general procedure D and 1-naphthoylacetyl 
chloride to afford 0.09 g (12% yield) isolated as an amorphous yellow solid, mp = 110-113 °C.  
1H NMR (500 MHz, CDCl3) δ 8.07 – 8.00 (m, 2H), 7.89 – 7.85 (m, 1H), 7.79 (dd, J = 2.4, 7.0, 
1H), 7.72 (s, 1H), 7.51 – 7.46 (m, 2H), 7.46 – 7.43 (m, 2H), 7.18 (t, J = 8.0, 1H), 6.73 (d, J = 7.6, 
1H), 4.61 (s, 2H), 4.38 (t, J = 7.1, 2H), 3.95 (s, 3H), 1.85 – 1.77 (m, 2H), 1.34 – 1.24 (m, 2H), 
0.94 (t, J = 7.4, 3H).  13C NMR (126 MHz, CDCl3) δ 192.76, 147.41, 135.82, 133.97, 132.76, 
132.55, 129.27, 128.76, 127.93, 127.63, 126.32, 126.30, 125.73, 125.57, 124.28, 123.31, 115.99, 
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115.33, 104.33, 55.45, 50.32, 44.80, 33.84, 19.84, 13.77.  HRMS (m/z): [M+K] calcd for 
C25H25KNO2, 410.1522; found 410.1527.  HPLC tR = 11.439 min; purity = 99.8%  
 
1-(1-Butyl-7-hydroxy-1H-indol-3-yl)-2-(naphthalen-1-yl)ethanone (458).  Compound 
458 was synthesized from compound 435 using general procedure B to afford 0.07 g (55% yield) 
isolated as an off brown solid, mp = decomposition at 213-216 °C.  TLC system: 30% 
EtOAc/70% n-hexanes.  1H NMR (500 MHz, DMSO) δ 9.32 (s, 1H), 8.85 (s, 1H), 8.65 – 8.58 
(m, 1H), 8.39 – 8.33 (m, 1H), 8.28 (dt, J = 4.3, 8.6, 2H), 8.00 – 7.88 (m, 4H), 7.42 (t, J = 7.8, 
1H), 7.15 (d, J = 7.6, 1H), 5.13 (s, 2H), 5.02 (t, J = 7.1, 2H), 2.41 – 2.33 (m, 2H), 1.81 (dq, J = 
7.4, 14.9, 2H), 1.40 (t, J = 7.4, 3H).  13C NMR (126 MHz, DMSO) δ 191.47, 144.32, 136.79, 
133.93, 133.52, 132.76, 129.74, 128.34, 128.04, 127.00, 125.69, 125.40, 125.36, 124.74, 122.71, 
115.59, 113.81, 108.35, 49.30, 43.73, 33.85, 19.44, 13.07.  HRMS (m/z): [M+Na+CH3CN] calcd 
for C26H26N2NaO2, 421.1892; found 421.1924.  HPLC tR = 6.458 min; purity = 99.8% using 70% 
CH3CN/30% H2O (0.1% formic acid). 
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(1-Butyl-5-methoxy-1H-indol-3-yl)(naphthalen-1-yl)methanone (459).  Compound 
459 was synthesized from compound 439 using general procedure D and 1-naphthoylacetyl 
chloride to afford 0.36 g (16% yield) isolated as an amorphous yellow oil.  1H NMR (500 MHz, 
CDCl3) δ 8.18 (d, J = 8.5, 1H), 8.01 (d, J = 2.5, 1H), 7.96 (d, J = 8.2, 1H), 7.90 (d, J = 7.6, 1H), 
7.64 (dd, J = 1.2, 7.0, 1H), 7.54 – 7.44 (m, 3H), 7.28 (d, J = 2.2, 1H), 7.25 (s, 1H), 6.98 (dd, J = 
2.6, 8.9, 1H), 4.02 (t, J = 7.2, 2H), 3.92 (s, 3H), 1.81 – 1.71 (m, 2H), 1.32 – 1.22 (m, 2H), 0.88 (t, 
J = 7.4, 3H).  13C NMR (126 MHz, CDCl3) δ 192.12, 156.75, 139.25, 138.00, 133.81, 131.99, 
130.88, 129.96, 128.24, 127.90, 126.80, 126.37, 126.11, 125.83, 124.65, 117.25, 114.28, 110.95, 
103.99, 55.93, 47.23, 31.95, 20.11, 13.65.  HRMS (m/z): [M+Na] calcd for C26H26N2NaO2, 
421.1892; found 421.1930.  HPLC tR = 16.771 min; purity = 99.9% using 70% CH3CN/30% 
H2O (0.1% formic acid). 
 
(1-Butyl-5-hydroxy-1H-indol-3-yl)(naphthalen-1-yl)methanone (460).  Compound 
460 was synthesized from compound 440 using general procedure B to afford 0.59 g (90% yield) 
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isolated as a lightly yellow solid, mp = 209-212 °C.  TLC system: 30% EtOAc/70% n-hexanes.  
1H NMR (500 MHz, DMSO) δ 9.20 (s, 1H), 8.07 (d, J = 7.8, 1H), 8.02 (d, J = 7.9, 1H), 7.98 (d, 
J = 8.5, 1H), 7.74 (d, J = 2.4, 1H), 7.65 – 7.59 (m, 3H), 7.58 – 7.54 (m, 1H), 7.50 (ddd, J = 1.4, 
6.8, 8.2, 1H), 7.41 (d, J = 8.8, 1H), 6.80 (dd, J = 2.4, 8.8, 1H), 4.11 (t, J = 7.2, 2H), 1.69 – 1.61 
(m, 2H), 1.23 – 1.14 (m, 2H), 0.81 (t, J = 7.4, 3H).  13C NMR (126 MHz, DMSO) δ 190.38, 
153.63, 138.93, 138.61, 133.14, 130.83, 129.92, 129.30, 128.09, 127.39, 126.46, 126.06, 125.31, 
125.20, 124.82, 115.24, 112.81, 111.40, 106.01, 45.86, 31.33, 19.16, 13.27.  HRMS (m/z): 
[M+Na+CH3CN] calcd for C25H24N2NaO2, 407.1735; found 407.1777.  HPLC tR = 13.460 min; 
purity = 100.0% using 60% CH3CN/40% H2O (0.1% formic acid). 
 
1-Butyl-7-methoxy-3-(naphthalen-1-ylmethyl)-1H-indole (461).  LiAlH4 (4.9 mL, 4.85 
mmol, 4 equiv) was dissolved in THF (1M) and a solution of AlCl3 (1.94 g, 14.5 mmol, 12 
equiv) in THF (8 mL) was added dropwise at 0 °C.  After 30 min, indole 435 (0.433 g, 1.21 
mmol, 1 equiv) in THF (9 mL) was added to the reaction mixture and allowed to stir at 21 °C for 
48 hrs.  Upon completion, reaction mixture was cooled in an ice-bath and carefully quenched 
with H2O and acidified with 1 N HCl to pH = 3.  The organic phase was then separated and 
washed with NaHCO3, brine, and dried over anhydrous Na2SO4.  The solvent was evaporated 
under reduced pressure and the resulting residue was purified by flash column chromatography 
on silica gel using mixtures of EtOAc/n-hexanes to afford 0.07 g (18% yield) isolated as a 
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pinkish oil.  TLC system: 10% EtOAc/90% n-hexanes.  1H NMR (500 MHz, CDCl3) δ 8.11 (d, J 
= 8.0, 1H), 7.91 – 7.85 (m, 1H), 7.76 (d, J = 8.0, 1H), 7.46 (tt, J = 3.5, 8.3, 2H), 7.42 – 7.34 (m, 
2H), 7.21 (dd, J = 0.8, 8.0, 1H), 7.00 (t, J = 7.8, 1H), 6.65 (d, J = 7.5, 1H), 6.50 (s, 1H), 4.51 (s, 
2H), 4.24 (t, J = 7.2, 2H), 3.94 (s, 3H), 1.70 (dt, J = 7.4, 14.8, 2H), 1.24 (dq, J = 7.4, 14.7, 2H), 
0.87 (t, J = 7.4, 3H).  13C NMR (126 MHz, CDCl3) δ 147.93, 137.47, 134.22, 132.61, 130.65, 
128.93, 128.32, 127.11, 126.92, 126.31, 126.09, 126.05, 125.83, 124.87, 119.55, 113.82, 112.31, 
102.72, 55.68, 49.26, 34.70, 29.37, 20.24, 14.16.  HRMS (m/z): [M+] calcd for C24H25NO, 
343.1936; found 343.1887.  HPLC tR = 12.038 min; purity = 99.9% using 90% CH3CN/10% 
H2O (0.1% formic acid). 
 
(7-Methoxy-1-(2-morpholinoethyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone (462).  
Compound 462 was synthesized from compound 434 using general procedure D and 1-
naphthoylacetyl chloride to afford 0.16 g (16% yield) isolated as a yellow solid, mp = 149-152 
°C.  TLC system: 50% EtOAc/50% n-hexanes.  1H NMR (500 MHz, CDCl3) δ 8.18 – 8.10 (m, 
2H), 7.95 (d, J = 8.2, 1H), 7.89 (d, J = 7.5, 1H), 7.63 (dd, J = 1.2, 7.0, 1H), 7.54 – 7.41 (m, 3H), 
7.27 – 7.23 (m, 3H), 6.77 (d, J = 7.4, 1H), 4.40 (t, J = 6.5, 2H), 3.94 (s, 3H), 3.60 – 3.49 (m, 4H), 
2.67 (t, J = 6.6, 2H), 2.42 – 2.33 (m, 4H).  13C NMR (126 MHz, CDCl3) δ 192.18, 147.29, 
140.00, 139.28, 133.80, 130.86, 130.00, 129.34, 128.26, 126.86, 126.45, 126.38, 126.06, 125.82, 
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124.55, 123.67, 117.60, 115.47, 104.70, 66.99, 59.29, 55.48, 53.77, 47.37.  HRMS (m/z): [M+H] 
calcd for C26H27N2O3+, 415.2016; found 415.1985.  HPLC tR = 7.049 min; purity = 95.0% using 
30% CH3CN/70% H2O (0.1% formic acid). 
 
1-(1-Butyl-7-hydroxy-1H-indol-3-yl)-2-(4-hydroxyphenyl)ethanone (463).  
Compound 463 was synthesized from compound 435 using general procedure B to afford 0.05 g 
(17% yield) isolated as an off-white solid, mp = decomposition at 197-200 °C.  TLC system: 
30% EtOAc/70% n-hexanes.  1H NMR (500 MHz, Acetone) δ 8.86 (s, 1H), 8.23 (s, 1H), 8.16 (s, 
1H), 7.86 (dd, J = 0.9, 8.0, 1H), 7.21 (d, J = 8.6, 2H), 6.98 (t, J = 7.8, 1H), 6.80 – 6.73 (m, 2H), 
6.68 (dd, J = 0.9, 7.6, 1H), 4.54 (t, J = 7.1, 2H), 4.01 (s, 2H), 1.94 – 1.85 (m, 2H), 1.39 – 1.29 
(m, 2H), 0.94 (t, J = 7.4, 3H).  13C NMR (126 MHz, Acetone) δ 193.14, 156.81, 145.21, 137.93, 
131.20, 130.75, 128.46, 126.87, 123.57, 116.43, 115.91, 115.82, 114.76, 109.25, 50.17, 46.31, 
34.79, 20.37, 13.99.  HRMS (m/z): [M+Na] calcd for C22H24N2NaO3, 387.1685; found 387.1658.  
HPLC tR = 4.998 min; purity = 99.4% using 60% CH3CN/40% H2O (0.1% formic acid). 
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1-Butyl-7-methoxy-3-(naphthalen-2-yl)-1H-indole (444).  Pd(OAc)2 (2 mg, 0.01 mmol, 
0.01 equiv), SPhos (7.4 mg, 0.02 mmol, 0.02 equiv), K3PO4 (379 mg, 1.79 mmol, 2 equiv), and 
2-naphthaleneboronic acid (230 mg, 1.34 mmol, 1.5 equiv) were placed into a round bottom 
pressure flask and flushed with Ar.  Intermediate 442 (294 mg, 0.89 mmol, 1 equiv) in toluene (1 
mL) was then added and the reaction mixture was allowed to stir at 100 °C overnight.  Reaction 
was monitored via TLC and upon completion, it was allowed to cool to 21 °C and diluted with 
Et2O (10mL).  Mixture was then filtered through a pad of Celite and concentrated under reduced 
pressure.  The resulting residue was purified by flash column chromatography on silica gel using 
mixtures of DCM/n-hexanes, to afford 0.15 g (50% yield) isolated as a clear amorphous oil,  
TLC system: 15% DCM/85% n-hexanes.  1H NMR (500 MHz, CDCl3) δ 8.10 (s, 1H), 7.93 – 
7.84 (m, 4H), 7.80 (dd, J = 1.8, 8.4, 1H), 7.65 (dt, J = 3.2, 6.3, 1H), 7.47 (dddd, J = 1.3, 6.9, 8.0, 
16.2, 2H), 7.29 (s, 1H), 7.12 (t, J = 7.9, 1H), 6.72 (d, J = 7.7, 1H), 4.46 (t, J = 7.2, 2H), 3.99 (s, 
3H), 1.92 – 1.83 (m, 2H), 1.45 – 1.36 (m, 2H), 0.98 (t, J = 7.4, 3H).  13C NMR (126 MHz, 
CDCl3) δ 147.84, 134.10, 133.46, 131.93, 128.72, 128.20, 127.80, 127.75, 127.51, 126.71, 
126.56, 126.12, 125.11, 125.07, 120.43, 116.57, 112.74, 102.83, 55.45, 49.49, 34.43, 20.06, 
13.91.  HRMS (m/z): [M+] calcd for C23H23NO, 329.1780; found 329.1747.  HPLC tR = 12.570 
min; purity = 96.7% using 90% CH3CN/10% H2O (0.1% formic acid). 
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(1-Butyl-7-methoxy-1H-indol-3-yl)(4-fluorophenyl)methanone (464).  Compound 464 
was synthesized from compound 434 using general procedure D and 4-fluorobenzoyl chloride to 
afford 0.28 g (49% yield) isolated as a pinkish solid, mp = 91-94 °C.  1H NMR (500 MHz, 
CDCl3) δ 8.02 (dd, J = 0.8, 8.0, 1H), 7.89 – 7.84 (m, 2H), 7.45 (s, 1H), 7.26 (t, J = 8.0, 1H), 7.22 
– 7.17 (m, 2H), 6.80 (d, J = 7.4, 1H), 4.44 (t, J = 7.2, 2H), 4.00 (s, 3H), 1.91 – 1.81 (m, 2H), 1.43 
– 1.32 (m, 2H), 0.98 (t, J = 7.4, 3H).  13C NMR (126 MHz, CDCl3) δ 189.45, 165.64, 163.64, 
147.43, 137.73, 137.64 (d, J = 3.1 Hz), 131.45 (d, J = 8.7 Hz), 129.80, 126.50, 123.39, 116.08 
(d, J = 21.9 Hz), 115.28, 115.13, 104.57, 55.49, 50.37, 33.97, 19.90, 13.79.  HRMS (m/z): 
[M+Na+CH3CN] calcd for C22H23FN2NaO2, 389.1641; found 389.1608.  HPLC tR = 8.765 min; 
purity = 99.8%. 
 
1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(2-fluorophenyl)ethanone (465).  Compound 
465 was synthesized from compound 434 using general procedure D and an acid chloride made 
in situ from 2-(2-fluorophenyl)acetic acid489 to afford 0.30 g (35% yield) isolated as a darker 
yellow solid, mp = 86-88 °C.  1H NMR (500 MHz, CDCl3) δ 8.04 (dd, J = 0.8, 8.1, 1H), 7.78 (s, 
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1H), 7.41 (td, J = 1.7, 7.6, 1H), 7.29 – 7.23 (m, 1H), 7.21 (t, J = 8.0, 1H), 7.16 – 7.07 (m, 2H), 
6.75 (d, J = 7.4, 1H), 4.44 (t, J = 7.2, 2H), 4.20 (s, 2H), 3.97 (s, 3H), 1.91 – 1.82 (m, 2H), 1.42 – 
1.32 (m, 2H), 0.99 (t, J = 7.4, 3H).  13C NMR (126 MHz, CDCl3) δ 190.37, 160.78, 158.83, 
146.34, 135.03 (d, J = 1.9 Hz), 130.69 (d, J = 4.2 Hz), 128.14, 127.51 (d, J = 8.2 Hz), 125.39, 
123.21 (d, J = 3.5 Hz), 122.30, 122.07 (d, J = 15.8 Hz), 114.61, 114.37, 114.19, 114.17, 103.31, 
54.40, 49.30, 38.49, 38.48, 32.82, 18.80, 12.73.  [M+Na] calcd for C21H22FNNaO2, 362.1532; 
found 362.1513.  HPLC tR = 8.732 min; purity = 99.6%. 
 
1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(3-fluorophenyl)ethanone (466).  Compound 
466 was synthesized from compound 434 using general procedure D and an acid chloride made 
in situ from 2-(3-fluorophenyl)acetic acid489 to afford 0.21 g (27% yield) isolated as a yellow oil.  
1H NMR (500 MHz, CDCl3) δ 7.98 (dd, J = 0.8, 8.1, 1H), 7.63 (s, 1H), 7.28 – 7.21 (m, 2H), 7.16 
(t, J = 8.0, 1H), 7.08 (d, J = 8.1, 1H), 7.03 (d, J = 9.8, 1H), 6.91 (td, J = 1.8, 8.3, 1H), 6.71 (d, J = 
7.5, 1H), 4.38 (t, J = 7.2, 2H), 4.10 (s, 2H), 3.92 (s, 3H), 1.85 – 1.75 (m, 2H), 1.36 – 1.25 (m, 
2H), 0.93 (t, J = 7.4, 3H).  13C NMR (126 MHz, CDCl3) δ 191.85, 163.92, 161.97, 147.41, 
138.39 (d, J = 7.7 Hz), 138.36, 135.97, 129.97 (d, J = 8.3 Hz), 129.16, 126.44, 125.17 (d, J = 2.9 
Hz), 123.45, 116.54, 116.37, 115.86, 115.21, 113.69, 113.52, 104.46, 55.46, 50.40, 46.55, 46.54, 
33.88, 19.87, 13.77.  HRMS (m/z): [M+Na] calcd for C21H22FNNaO2, 362.1532; found 
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362.1503.  HPLC tR = 13.931 min; purity = 99.9% using 50% CH3CN/50% H2O (0.1% formic 
acid). 
 
1-(1-Butyl-7-ethyl-1H-indol-3-yl)-2-(4-fluorophenyl)ethanone (467).  Compound 467 
was synthesized from compound 467 using general procedure D and 4-fluorophenylacetyl 
chloride to afford 0.34 g (39% yield) isolated as an white powder, mp = 67-70 °C.  1H NMR 
(500 MHz, CDCl3) δ 8.34 (dd, J = 1.2, 8.0, 1H), 7.72 (s, 1H), 7.32 – 7.27 (m, 2H), 7.25 – 7.20 
(m, 1H), 7.10 (d, J = 6.5, 1H), 7.04 – 6.98 (m, 2H), 4.35 – 4.28 (m, 2H), 4.12 (s, 2H), 3.02 (q, J 
= 7.5, 2H), 1.87 – 1.78 (m, 2H), 1.42 – 1.32 (m, 5H), 0.98 (t, J = 7.4, 3H).  13C NMR (126 MHz, 
CDCl3) δ 192.35, 162.81, 160.87, 136.80, 134.58, 132.03 (d, J = 3.2 Hz), 131.23 (d, J = 7.9 Hz), 
128.22, 127.79, 124.78, 123.06, 120.82, 115.82, 115.50, 115.33, 49.80, 46.00, 34.07, 25.52, 
20.01, 16.28, 13.75.  HRMS (m/z): [M+Na+CH3CN] calcd for C24H27FN2NaO, 401.2005; found 
401.1976.  HPLC tR = 9.645 min; purity = 99.9%. 
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1-Butyl-7-methoxy-3-(naphthalen-1-yl)-1H-indole (443).  Intermediate 443 (512 mg, 
1.56 mmol, 1 equiv) and Pd(PPh3)4 (54 mg, 0.05 mmol, 0.03 equiv) were placed into a round 
bottom flask and flushed with Ar.  Solvent (DME, 6 mL) was then added and allowed to stir for 
10 min upon which the solution was degassed by bubbling with Ar for 15 min.  Sodium 
carbonate (2M [1.06 g in 5 mL H2O, 1.6 ml], 3.11mmol, 2 equiv) and 1-naphthaleboronic acid 
(401 mg, 2.33 mmol, 1.5 equiv) in EtOH (1 mL) were added and the reaction mixture was 
refluxed.  Reaction was monitored via TLC and upon completion, it was allowed to cool to 21 °C 
and EtOAc was added.  Mixture was then filtered through a pad of Celite and concentrated under 
reduced pressure.  The resulting residue was purified by flash column chromatography on silica 
gel using 3% DCM/97% n-hexanes to afford 0.17 g (37% yield) isolated as a yellow solid, mp = 
74-76 °C.  TLC system: 10% DCM/90% n-hexanes.  1H NMR (500 MHz, CDCl3) δ 8.10 (d, J = 
8.2, 1H), 7.92 (d, J = 8.2, 1H), 7.85 (d, J = 8.0, 1H), 7.53 (dddd, J = 1.3, 6.9, 8.1, 23.6, 3H), 7.41 
(ddd, J = 1.3, 6.8, 8.2, 1H), 7.19 (s, 1H), 7.09 (dd, J = 0.9, 8.0, 1H), 7.00 (t, J = 7.8, 1H), 6.70 (d, 
J = 7.3, 1H), 4.50 (t, J = 7.1, 2H), 4.01 (s, 3H), 1.95 – 1.86 (m, 2H), 1.47 – 1.37 (m, 2H), 0.99 (t, 
J = 7.4, 3H).  13C NMR (126 MHz, CDCl3) δ 147.75, 134.08, 133.36, 132.64, 130.54, 128.76, 
128.28, 127.75, 126.92, 126.80, 125.90, 125.70, 125.67, 125.65, 119.90, 114.86, 113.25, 102.56, 
55.47, 49.36, 34.47, 20.08, 13.93.  HRMS (m/z): [M+] calcd for C23H23NO, 329.1780; found 
329.1747.  HPLC tR = 11.727 min; purity = 95.4% using 90% CH3CN/10% H2O (0.1% formic 
acid).  
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1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(3,4-difluorophenyl)ethanone (468).  
Compound 468 was synthesized from compound 434 using general procedure D and an acid 
chloride made in situ from 2-(3,4-difluorophenyl)acetic acid489 to afford 0.07 g (8% yield) 
isolated as an off-white solid, mp = 88-90 °C.  1H NMR (500 MHz, CDCl3) δ 8.01 (dd, J = 0.8, 
8.1, 1H), 7.68 (s, 1H), 7.21 (t, J = 8.0, 1H), 7.19 – 7.14 (m, 1H), 7.14 – 7.09 (m, 1H), 7.06 (d, J = 
2.2, 1H), 6.76 (d, J = 7.8, 1H), 4.44 (t, J = 7.2, 2H), 4.11 (s, 2H), 3.97 (s, 3H), 1.92 – 1.79 (m, 
2H), 1.37 (dq, J = 7.4, 14.8, 2H), 0.99 (t, J = 7.4, 3H).  13C NMR (126 MHz, CDCl3) δ 191.44 , 
150.14 (dd, J = 247.8, 12.8 Hz), 149.30 (dd, J = 246.7, 12.6 Hz), 147.32 , 135.70 , 132.64 (dd, J 
= 6.0, 4.0 Hz), 128.98 , 126.38 , 125.38 (dd, J = 6.1, 3.6 Hz), 123.43 , 118.36 (d, J = 17.3 Hz), 
117.08 (d, J = 17.1 Hz), 115.66 , 115.02 , 104.41 , 55.37 , 50.34 , 46.07 – 44.76 (m), 33.81 , 
19.80 , 13.68 .  HRMS (m/z): [M+Na+CH3CN] calcd for C23H24F2N2NaO2, 421.1704; found 
421.1678.  HPLC tR = 8.678 min; purity = 100.0%.  
 
1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(2,3-difluorophenyl)ethanone (469).  
Compound 469 was synthesized from compound 434 using general procedure D and an acid 
chloride made in situ from 2-(2,3-difluorophenyl)acetic acid489 to afford 0.23 g (24% yield) 
isolated as a yellow oil.  1H NMR (500 MHz, CDCl3) δ 8.02 (dd, J = 0.8, 8.1, 1H), 7.78 (s, 1H), 
7.21 (t, J = 8.0, 1H), 7.16 (t, J = 6.7, 1H), 7.13 – 7.03 (m, 2H), 6.76 (d, J = 7.4, 1H), 4.45 (t, J = 
7.2, 2H), 4.23 (d, J = 1.3, 2H), 3.98 (s, 3H), 1.92 – 1.83 (m, 2H), 1.43 – 1.33 (m, 2H), 0.99 (t, J = 
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7.4, 3H).  13C NMR (126 MHz, CDCl3) δ 190.40 , 150.68 (dd, J = 222.0, 13.0 Hz), 148.72 (dd, J 
= 220.5, 13.1 Hz), 147.32 , 135.89 (d, J = 1.6 Hz), 129.00 , 126.37 , 126.29 (t, J = 3.2 Hz), 
125.38 (d, J = 12.6 Hz), 123.91 (dd, J = 6.9, 4.6 Hz), 123.37 , 115.65 (d, J = 17.1 Hz), 115.44 , 
115.03 , 104.36 , 55.36 , 50.32 , 39.10 (t, J = 1.8 Hz), 33.78 , 19.76 , 13.67 . HRMS (m/z): 
[M+Na+CH3CN] calcd for C23H24F2N2NaO2, 421.1704; found 421.1687.  HPLC tR = 8.827 min; 
purity = 100.0%.  
 
1-(1-butyl-7-methoxy-1H-indol-3-yl)-2-(4-nitrophenyl)ethanone (470).  Compound 
470 was synthesized from compound 434 using general procedure D and an acid chloride made 
in situ from 2-(4-nitrophenyl)acetic acid489 to afford 0.41 g (46% yield) isolated as an off-brown 
solid.  mp = 96-98 °C.  1H NMR (500 MHz, CDCl3) δ 8.22 – 8.15 (m, 2H), 7.96 (dd, J = 8.0, 0.9 
Hz, 1H), 7.69 (s, 1H), 7.51 – 7.45 (m, 2H), 7.19 (t, J = 8.0 Hz, 1H), 6.74 (dd, J = 7.9, 0.9 Hz, 
1H), 4.42 (t, J = 7.2 Hz, 2H), 4.25 (s, 2H), 3.94 (s, 3H), 1.89 – 1.78 (m, 2H), 1.39 – 1.29 (m, 
2H), 0.96 (t, J = 7.4 Hz, 3H).  13C NMR (126 MHz, CDCl3) δ 190.44, 147.36, 146.81, 143.38, 
135.73, 130.42, 128.90, 126.43, 123.63, 123.59, 115.70, 114.94, 104.53, 55.39, 50.41, 46.20, 
33.82, 19.81, 13.69.HRMS (m/z): [2M+Na] calcd for C42H44N4NaO8, 755.3057; found 755.3074.  
HPLC tR = 14.342 min; purity = 98.4% using 70% CH3CN/30% H2O.  
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1-(1-butyl-7-methoxy-1H-indol-3-yl)-2-(2,4-difluorophenyl)ethanone (471).  
Compound 471 was synthesized from compound 434 using general procedure D and an acid 
chloride made in situ from 2,4-difluorophenyl acetic acid489 to afford 0.21 g (23% yield) isolated 
as a pinkish solid.  mp = 113-115 °C.  1H NMR (500 MHz, CDCl3) δ 7.97 (dd, J = 8.0, 0.9 Hz, 
1H), 7.73 (s, 1H), 7.33 (td, J = 8.4, 6.4 Hz, 1H), 7.17 (t, J = 8.0 Hz, 1H), 6.87 – 6.79 (m, 2H), 
6.72 (dd, J = 7.9, 0.9 Hz, 1H), 4.41 (t, J = 7.2 Hz, 2H), 4.12 (d, J = 1.3 Hz, 2H), 3.94 (s, 3H), 
1.88 – 1.79 (m, 2H), 1.39 – 1.29 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H).  13C NMR (126 MHz, CDCl3) 
δ 190.91 , 161.95 (dd, J = 247.3, 12.1 Hz), 160.68 (dd, J = 247.2, 11.9 Hz), 147.31 , 135.81 (d, J 
= 1.7 Hz), 132.28 (dd, J = 9.5, 5.9 Hz), 129.00 , 126.36 , 123.34 , 118.79 (dd, J = 16.0, 3.9 Hz), 
115.47 , 115.04 , 111.25 (dd, J = 21.1, 3.7 Hz), 104.32 , 103.62 (t, J = 25.8 Hz), 55.36 , 50.30 , 
38.75 (d, J = 1.6 Hz), 33.79 , 19.77 , 13.68.  HRMS (m/z): [M+Na+CH3CN] calcd for 
C23H24F2N2NaO2, 421.1704; found 421.1714.  HPLC tR = 9.087 min; purity = 99.9%.  
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1-(1-butyl-7-methoxy-1H-indol-3-yl)-2-(thiophen-3-yl)ethanone (472).  Compound 
472 was synthesized from compound 434 using general procedure D and an acid chloride made 
in situ from 3-thiopheneacetic acid489 to afford 0.21 g (38% yield) isolated as a brown-yellow 
solid.  mp= 70-73 °C.  1H NMR (500 MHz, CDCl3) δ 8.01 (dd, J = 8.0, 0.9 Hz, 1H), 7.63 (s, 1H), 
7.28 – 7.26 (m, 1H), 7.17 (t, J = 8.0 Hz, 1H), 7.14 (dq, J = 3.0, 1.0 Hz, 1H), 7.07 (dd, J = 4.9, 1.3 
Hz, 1H), 6.71 (dd, J = 7.9, 0.9 Hz, 1H), 4.38 (t, J = 7.2 Hz, 2H), 4.15 – 4.13 (m, 2H), 3.93 (s, 
3H), 1.81 (ddd, J = 8.7, 6.7, 1.4 Hz, 2H), 1.37 – 1.27 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H).  13C NMR 
(126 MHz, CDCl3) δ 192.08, 147.28, 135.86, 135.76, 129.10, 128.72, 126.27, 125.50, 123.23, 
122.21, 115.68, 115.13, 104.25, 55.35, 50.24, 41.54, 33.80, 19.77, 13.69.  HRMS (m/z): 
[2M+Na] calcd for C38H42N2NaO4S2, 677.2484; found 677.2466.  HPLC tR = 7.554 min; purity = 
99.9%. 
 
1-(1-butyl-7-methoxy-1H-indol-3-yl)-2-(perfluorophenyl)ethanone (473).  Compound 
473 was synthesized from compound 434 using general procedure D and an acid chloride made 
in situ from 2,3,4,5,6-pentafluororphenyl acetic acid489 to afford 0.14 g (29% yield) isolated as a 
light brown solid.  mp = 106-108 °C.  1H NMR (500 MHz, CDCl3) δ 7.90 (dd, J = 8.0, 0.9 Hz, 
0H), 7.77 (s, 0H), 7.19 (t, J = 8.0 Hz, 0H), 6.74 (dd, J = 8.0, 0.9 Hz, 0H), 4.44 (t, J = 7.2 Hz, 
1H), 4.28 (t, J = 1.5 Hz, 1H), 3.95 (s, 1H), 1.92 – 1.82 (m, 1H), 1.44 – 1.33 (m, 1H), 0.98 (t, J = 
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7.4 Hz, 1H).  13C NMR (126 MHz, CDCl3) δ 138.92 – 137.71 (m), 136.92 – 135.80 (m), 187.32 , 
138.74 – 138.04 (m), 147.40 , 146.39 (t, J = 7.6 Hz), 144.41 (d, J = 11.3 Hz), 141.24 , 139.23 , 
138.44 , 139.62 – 138.76 (m), 136.44 , 135.47 , 128.77 , 126.37 , 123.61 , 115.04 , 114.80 , 
104.49 , 55.40 , 50.46 , 33.87 , 33.09 , 145.09 – 143.69 (m), 19.84 , 13.71 , 141.69 – 140.57 (m), 
146.92 – 145.69 (m).  HRMS (m/z): [M+Na+CH3CN] calcd for C23H21F5N2NaO2, 475.1421; 
found 475.1444.  HPLC tR = 12.530 min; purity = 99.2%.   
 
2-(4-fluorophenyl)-1-(7-methoxy-1-(2-morpholinoethyl)-1H-indol-3-yl)ethanone 
(474).  Compound 474 was synthesized from compound 434 using general procedure D and an 
acid chloride made in situ from 4-fluorophenylacetic acid489 to afford 0.11 g (14% yield) isolated 
as a brown oil.  1H NMR (500 MHz, CDCl3) δ 8.00 (dd, J = 8.1, 0.9 Hz, 1H), 7.72 (s, 1H), 7.30 – 
7.26 (m, 2H), 7.18 (t, J = 8.0 Hz, 1H), 7.04 – 6.97 (m, 2H), 6.73 (dd, J = 7.9, 0.9 Hz, 1H), 4.53 
(t, J = 6.7 Hz, 2H), 4.10 (s, 2H), 3.94 (s, 3H), 3.71 – 3.66 (m, 4H), 2.78 (t, J = 6.7 Hz, 2H), 2.53 
– 2.46 (m, 4H).  13C NMR (126 MHz, CDCl3) δ 192.36, 162.73, 160.79, 147.08, 136.32, 131.43 
(d, J = 3.2 Hz), 130.84, 130.77, 129.01, 126.14, 123.41, 116.04, 115.48 (d, J = 21.8 Hz), 115.25, 
104.36, 66.88, 59.39, 55.33, 53.79, 47.53, 45.86. 
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HRMS (m/z): [M+Na] calcd for C23H25FN2NaO3, 419.1747; found 419.1757.  HPLC tR = 1.650 
min; purity = 96.5% using 50% CH3CN/50% H2O (0.1% formic acid).  
 
3-(1-naphthoyl)-1-butyl-1H-indole-7-carboxamide (450).  To a solution of 3-(1-
naphthoyl)-1-butyl-1H-indole-7-carboxylic acid (0.047 g, 0.127 mmol, 1 equiv) in DCM at 
ambient temperature were added EDCI (0.029 g, 0.152 mmol, 1.2 equiv), HOBt (0.021 g, 0.152 
mmol, 1.2 equiv) and NH3 (2.0 M in MeOH, 0.25 mL, 0.51 mmol, 4 equiv).  The reaction 
mixture was allowed to stir at ambient temperature for 16 hours.  Upon completion, the solvent 
was evaporated and the residue partitioned between EtOac (10 mL) and H2O (10 mL).  The 
aqueous layer was then washed with EtOAc (2x) and the combined organic extracts were dried 
over Na2SO4, filtered, and concentrated under reduced pressure.  The resulting residue was 
purified by flash column chromatography on silica gel using of 50% EtOAc/50% n-hexanes, to 
afford 0.025 g (53% yield) isolated as a white solid, mp = 176-179 °C.  TLC system: 40% 
EtOAc/60% n-hexanes.  1H NMR (500 MHz, CDCl3) δ 8.72 (dd, J = 8.0, 1.2 Hz, 1H), 8.17 (ddt, 
J = 8.4, 1.4, 0.8 Hz, 1H), 7.99 (dt, J = 8.4, 1.0 Hz, 1H), 7.95 – 7.89 (m, 1H), 7.65 (dd, J = 7.0, 
1.3 Hz, 1H), 7.54 (ddd, J = 8.1, 6.8, 5.3 Hz, 2H), 7.51 – 7.46 (m, 2H), 7.37 – 7.35 (m, 2H), 6.12 
– 6.04 (m, 1H), 5.81 (s, 1H), 4.33 – 4.25 (m, 2H), 1.70 – 1.61 (m, 2H), 1.25 – 1.17 (m, 2H), 0.85 
(t, J = 7.4 Hz, 3H).  13C NMR (126 MHz, CDCl3) δ 192.05, 170.44, 140.61, 138.73, 133.73, 
132.57, 130.73, 130.23, 129.32, 128.21, 126.86, 126.35, 126.06, 125.86, 125.79, 124.55, 123.23, 
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121.98, 121.07, 117.20, 49.75, 32.48, 19.80, 13.63.  HRMS (m/z): [M+Na+CH3CN] calcd for 
C26H25N3NaO2, 434.1844; found 434.1855.  HPLC tR = 8.227 min; purity = 100.0% using 60% 
CH3CN/40% H2O (0.1 % formic acid).  
Binding and Efficacy Studies 
Membrane preparation.474  Mouse brain homogenates for in vitro assays were prepared 
as previously described.474  Briefly, whole brains were harvested from B6SJL mice, snap-frozen 
in liquid nitrogen and stored at -80 °C.  On the day membrane homogenates were to be prepared, 
brains were thawed on ice, then pooled in a 40 mL Dounce glass homogenizer and suspended in 
5 volumes of ice-cold homogenization buffer (50mM HEPES, pH 7.4, 3 mM MgCl2, and 1 mM 
EGTA).  Brains were then subjected to 10 complete strokes with an A pestle, followed by 
centrifugation at 40,000 x g for 10 min at +4 °C.  Resulting supernatants were discarded, and the 
pellet was resuspended, homogenized and centrifuged similarly twice more, with supernatants 
being discarded.  For the final resuspension and homogenization with a B pestle, ice-cold 50 mM 
HEPES was used in place of homogenization buffer and homogenates were aliquoted and stored 
at -80 °C.  Protein concentrations of homogenates were determined using the BCATM Protein 
Assay (Thermo Scientific, Rockford, IL).  
Competition receptor binding assay.475  Competition receptor binding was performed 
as previously described.475  Briefly, 50 µg of mouse brain homogenates were incubated for 90 
min to attain equilibrium binding at room temperature with 0.2 nM [3H]CP-55,940, 5 mM 
MgCl2, and either increasing cannabinoid concentrations (0.1 nM to 10 µM), 10 µM WIN-
55,212-2 (for non-specific binding) or vehicle (for total binding), in triplicate, in a volume of 1 
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mL of buffer containing 50 mM Tris, 0.05% bovine serum albumin (BSA) and 0.1% ethanol 
vehicle.  Reactions were terminated by rapid vacuum filtration through Whatman GF/B glass 
fiber filters, followed by five washes with ice-cold buffer (50 mM Tris, 0.05% BSA).  Filters 
were immediately placed into 7 mL scintillation vials to which 4 mL of ScintiVerseTM BD 
Cocktail scintillation fluid (Fisher Scientific, Fair Lawn, NJ) was added.  Bound radioactivity 
was determined after overnight incubation at room temperature and shaking, by liquid 
scintillation spectrophotometry with an efficiency of 44% (TriCarb 2100 TR Liquid Scintilation 
Analyzer, Packard Instrument Company, Meriden, CT).  Specific binding is expressed as total 
binding minus non-specific binding, and is graphed for each data point as a percentage of 
specific binding occurring in the absence of any competitor.  
Adenylyl cyclase assay.475  Four million Neuro2AWT or CHO-hCB2 cells were plated 
into a 24-well plate and allowed to attach overnight.  At 80-90% confluency (the following 
morning), 0.5 mL of warm incubation media composed of DMEM with 0.9g/L NaCl, 2.5 
µCi/mL [3H]Adenine and 0.5 mM IBMX was added to the cells.  After a 4-hour incubation 
period at 37°C in a 5% CO2 incubator, the media was removed and the plate was briefly floated 
on an ice-water bath while 0.5 mL of an assay mix was quickly added to the cells in triplicate.  
The assay mix consisted of a Krebs Ringer HEPES buffered saline solution containing 0.5 mM 
IBMX, 10 µM forskolin and either vehicle (0.2% ethanol) or at least 6 concentrations (0.1 nM to 
10 µM) of each test compound.  The plate was then transferred to a 37°C water bath for a 15 
minute incubation and the reaction was terminated by addition of 50 µL of 2.2 N HCl.  
Intracellular [3H]cAMP was separated by column chromatography employing acidic alumina.  
Four mL of the final eluent was added to 10 mL of ScintiVerse™ BD Cocktail Scintillation Fluid 
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(Fisher Scientific, Fair Lawn, NJ) and radioactivity was immediately measured employing liquid 
scintillation spectrophotometry (Tri Carb 2100 TR Liquid Scintillation Analyzer, Packard 
Instrument Company, Meriden, CT).  Data are expressed as the percent of intracellular 
[3H]cAMP relative to that observed in vehicle samples.  In experiments where agonists and 
antagonists were co-incubated, antagonists were added 5 minutes prior to addition of agonists.  
Statistical comparison of mean IC50 and IMAX values (± SEM) for test compounds was 
accomplished using one-way ANOVA followed by a Tukey’s post- test. 
In vivo mouse studies 
Animal care and use.  Prior to surgery (see below), male NIH Swiss mice (Harlan 
Sprague Dawley Inc., Indianapolis, IN), weighing approximately 25-30 g, were housed 3 animals 
per Plexiglass cage (15.24 x 25.40 x 12.70 cm) in a temperature-controlled room at the 
University of Arkansas for Medical Sciences, Little Rock, AR.  Room conditions were 
maintained at an ambient temperature of 22 ± 2 °C at 45-50% humidity.  Lights were set to a 12 
h light/dark cycle.  Animals were fed Lab Diet rodent chow (laboratory rodent Diet #5001, PMI 
Feeds, Inc., St. Louis, MO) and water ad libitum until immediately before testing.  Animals were 
acclimated to the laboratory environment 2 days prior to experiments and were tested in groups 
of 4-8 mice per condition.  All studies were carried out in accordance with the Declaration of 
Helsinki and with the Guide for Care and Use of Laboratory animals as adopted and promulgated 
by the National Institutes of Health.  Experimental protocols were approved by the Animal care 
and Use Committee at the University of Arkansas for Medicinal Sciences.  
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Core temperature measurements.  Following appropriate anesthetization with inhaled 
isoflurane, the abdominal area of each mouse was shaved and sanitized with iodine swabs.  A 
rostral-caudal cut approximately 1.5 cm in length was made with skin scissors, providing access 
to the intraperitoneal cavity.  A cylindrical glass encapsulated radiotelemetry probe (model ER-
4000 E-Mitter, Mini Mitter, Bend, OR) was then inserted, and then incision was closed using 
absorbable 5-0 chromic gut suture material.  At least 7 days were imposed between surgery and 
experimental observation of drug effects to allow incision to heal and mice to recover normal 
body weights.  Following surgery, implanted mice were individually housed in Plexiglass mouse 
cages (15.24 x 25.40 x 12.70 cm) for the duration of all temperature experiments.  Implanted 
transmitters produced temperature-modulated signals that were transmitted to a receiver (model 
ER-4000 receiver, Mini Mitter Co., Inc) underneath each mouse cage.  Receivers were housed in 
light- and sound attenuating cubicles (med Associates model ENV-022MD, St. Albans, VT) 
equipped with exhaust fans, which further masked ambient laboratory noise.  On experimental 
days, mice were weighted, marked, and returned to their individual cages for at least 1 hr of 
baseline data collection.  Cannabinoid doses were then calculated and drugs were prepared for 
injection.  Animals were subsequently removed from their cage and injected with various doses 
of drug or an equivalent volume of vehicle.  Temperature data were collected at regular 5-min 
intervals and processed simultaneously by the Vital View data acquisition system (Mini Mitter 
Co., Inc.) for at least 8 hrs.  
Oral EtOH self-administration (two-bottle EtOH choice).490  The standard two-bottle 
EtOH choice protocol is a widely used oral self-administration model of ongoing EtOH drinking 
that captures aspects of voluntary alcohol consumption in humans.  In our procedure, each home 
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cage contained two 25 mL Pyrex glass bottles, capped with rubber stoppers fitted with stainless 
steel tips.  One bottle contained water while the other bottle contained a 10% ethanol solution 
(diluted with tap water).  Volumetric consumption data were recorded from both drinking bottles 
every Monday and Thursday at approximately the same time.  After recording consumption data, 
bottles were emptied, cleaned, refilled to 25 ml, and switched to eliminate a position preference.  
All animals were given unrestricted food access (Purina rodent lab diet) during testing, and all 
mice had 24 h access to 10% (v/v) EtOH and water for the duration of the study.  Drinking 
preference was assessed as the amount of EtOH consumed divided by total fluid consumed × 
100.  Baseline drinking was established and considered stable when EtOH drinking varied by 
<10% for three consecutive days.  After baseline criterion drinking was achieved, mice were 
injected (i.p.) with 10 mg/kg of the CB1 antagonist rimonabant for 10 consecutive days.  After a 
two week drug “washout” period, mice were injected with 10 mg/kg 461 or 10 mg/kg 444.  After 
10 days of treatment with either 461 or 444 was conducted, mice were injected with the drug 
vehicle solution for 10 consecutive days. Solutions were prepared fresh weekly with 8%tween 
and 92% distilled water. 
Conditioned place preference.491  Conditioned place preference (CPP) is one of the 
most popular models to study the motivational effects of drugs and non-drug treatments in 
experimental animals, and has been widely used to evaluate the appetitive effects of abused 
drugs in mice.491  Our procedure for establishing CPP involved 3 distinct phases, using Panlab 3-
compartment spatial discrimination chambers.  Briefly, these chambers consist of a box with two 
equally-sized conditioning compartments connected by a rectangular corridor.  The 
compartments are differentiated by visual pattern on the walls (dots vs. stripes), color (distinct 
234 
	  
shades of grey), floor texture (smooth grid vs. rough), and shape (square vs. multi-angled), 
providing the subjects with multiple contextual dimensions across sensory modalities with which 
to differentiate the distinct compartments.  During the pre-conditioning preference test, mice 
were allowed to explore the chamber for 30 min while their behavior was recorded and scored.  
These tests occurred on Friday afternoons, and on the next two days mice were housed in the 
colony room and not used experimentally.  During this time, mice were assigned to receive 
EtOH pairings (see below) on their non-preferred side, and saline in their preferred compartment.  
On Monday, the conditioning phase began with all mice receiving a saline injection, then being 
placed in their preferred compartment for 30 min.  During saline conditioning, the hallway was 
blocked so that mice could not leave the conditioning compartment.  After the saline 
conditioning trial, mice were removed from the chamber and placed back in their home cage.  
Approximately 4 hours later, mice were injected with 2 g/kg EtOH, and then placed into their 
non-preferred compartment for 30 min.  In this manner, mice were conditioned with both saline 
and drug each day, and these conditioning trials occurred Monday through Thursday.  On Friday 
morning, the post-conditioning preference test was conducted in a manner identical to the pre-
conditioning preference test.  For studies involving CBR antagonists, mice were injected with 10 
mg/kg rimonabant, 10 mg/kg 461, or 10mg/kg 444 one hour before each EtOH pairing.  To 
calculate a preference (or aversion) score, the time spent in the drug-paired side during the pre-
conditioning test is subtracted from the time spent in that compartment during the post-
conditioning test.   
Statistical analysis.  Curve fitting and statistical analyses for in vitro experiments were 
performed using GraphPad Prism version 5.0b (GraphPad Software, Inc., San Diego, CA).  The 
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Cheng-Prusoff equation was used to convert the experimental IC50 values obtained from 
competition receptor binding experiments to Ki values, a quantitative measure of receptor 
binding.476  Non-linear regression for one-site competition was used to determine the IC50 for 
competition binding.  Data are expressed as mean ± SEM.  A one-way ANOVA, followed by 
Tukey’s Multiple Comparison post-hoc test, was used to determine statistical significance 
(P<0.05) between three or more groups.  For core body temperature experiments, the area under 
the curve (AUC) was calculated using a trapezoidal rule from 0-10 hr.  For temperature data, 
statistical significance (P<0.05) was determined using a one-way ANOVA, followed by Tukey’s 
HSD post-hoc Test.  All in vivo statistical calculations were performed using SigmaStat 3 (Systat 
Software, Inc., San Jose, CA). 
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CHAPTER 6:  DISSERTATION CONCLUSIONS 
 It has been estimated that approximately 1.5 billion people worldwide are affected by 
CNS disorders, which accounts for a third of the global disease burden.1  It has been estimated 
that by year 2050, the population of people older than 65 years will significantly increase 
yielding an additional 1 billion of elderly persons, thus increasing the need for CNS 
pharmaceuticals for the treatment of various CNS disorders.2  In the United States and many 
countries around the world, CNS disorders will affect numerous people in years to come 
affecting health care systems and families of those in need.  Aside from the overwhelming 
burden that neurological CNS disorders cause society, substance abuse and addiction are not to 
be forgotten as part of CNS disorders.  Globally, the WHO estimated that in 2010, between 
99,000 and 253,000 deaths were attributed to illicit drug use, accounting for 0.5 to 1.3% of all 
deaths affecting people aged 15-64 years.492  Additionally, approximately 2.5 million people die 
of alcohol abuse each year among which 320,000 young adults between the ages of 15 and 29 die 
from alcohol-related causes.460   
Treatments for most CNS disorders including substance addiction are currently available; 
however their use is hampered because of the increased appearance of unwanted side effects.  
The need for the discovery and development of novel CNS active ligands that have potential as 
CNS therapeutics continues to rise.  In search for such agents, several studies were conducted.   
 The principal active component of S. divinorum, the neoclerodane diterpene salvinorin A 
(83), was investigated as a novel opioid receptor ligand.  Salvinorin A was shown to be the first 
non-nitrogenous opioid ligand acting as potent and selective KOP receptor agonist.124  
Modification of the furan ring in order to gain additional knowledge of the interactions of the 
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furan ring binding pocket within the KOP receptor was the primary goal of this study.  
Analogues synthesized were designed to explore the changes at the C-13 position of the 
molecule and their effect on the activity at the KOP receptors.  These modifications were 
designed to attain the optimal distance between the furan ring and the salvinorin A core and the 
steric requirements necessary for binding and activity at this position; the necessity of an 
aromatic substituent at the C-13 position; and the preferred orientation of the furan ring oxygen 
atom.  Pharmacological evaluation of the synthesized analogues indicated that there is a 
preferred O-atom orientation in the salvinorin A-KOP receptor binding pocket in that the cis 
conformer (236) exhibited higher binding affinity than the trans conformer (235).  Despite its 
similar affinity for the KOP receptor as salvinorin A, the cis –alkene analogue proved to be 34-
fold less active at the KOP receptors than the parent molecule.  The activity of the C-13 two 
carbon homologue of salvinorin A at the KOP receptors indicates that such modification is well 
tolerated, however additional studies need to be completed in order to determine the optimal 
distance between the furan ring and the diterpene core.  Furthermore, it was also determined that 
an aromatic substituent at the C-13 position is not required for activity at the KOP receptors.  
Lastly, two carbon furan and tetrahydrofran homologs of salvinorin A were also well tolerated at 
the KOP receptor; nonetheless additional analogues need to be designed to determine the definite 
steric requirements at this position.   
 Further exploration of the salvinorin A core and investigation into the possibility to 
change the biological activity of salvinorin A was conducted.  As basis for such studies, several 
quinone containing analogues of salvinorin A were designed and synthesized utilizing the 
structural similarity between the diterpene family of nakijiquinone marine natural products, the 
first naturally occurring Her-2/Neu kinase inhibitors and the neoclerodane diterpene salvinorin 
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A, whose BBB penetrating abilities have been well demonstrated.279, 327  Such salvinorin A 
analogues would be interesting biological probes that could serve as diagnostic tool in various 
brain cancers.  As expected, pharmacological evaluation of the quinone containing analogues of 
salvinorin A demonstrated that these analogues did not exhibit any significant opioid receptor 
activity.  However, these analogues exhibited moderate antiproliferative activity in two breast 
cancer cell lines, representing the first report of salvinorin A analogues that exhibit 
antiproliferative activity.  
 The therapeutic potential of Cannabis has been known and well utilized throughout many 
centuries.  The widespread distribution of the cannabinoid receptors within the CNS as well as in 
the periphery, may be the reason for the involvement of the endocannabinoid system in various 
physiological processes.398  The recent discovery of the neutral antagonistic activity of a JWH-
073 metabolite and the widely demonstrated therapeutic potential of CB1R antagonists, it was 
hypothesized that SAR modifications of the JWH-073-M4 scaffold would identify novel indole-
based analogues with dual CB1R antagonist/CB2R agonist properties and  potential as alcohol 
abuse therapies.  Twenty-seven analogues were prepared using step-wise molecular investigation 
of the elements present in our lead scaffold JWH-073-M4.  Analogues synthesized were 
designed to explore several positions in the JWH-073-M4 scaffold: (a) examine the necessity of 
the carbonyl moiety and the optimal length of the linker from the indole core to the naphthalene 
ring; (b) explore the possibility for addition of rotational bonds at this position of the molecule; 
(c) explore the requirement of the naphthalene ring through selective introduction of electron 
withdrawing and electron donating groups; (d) explore different substitution at the N-atom of the 
indole core; and (e) investigate the positioning of the hydroxyl moiety around the indole core and 
its necessity for activity at CBRs.   
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The designed analogues were subjected to an array of pharmacological assays for 
evaluation, where most of the analogues tested exhibited relatively high affinity for both CB1R 
and CB2Rs.  From all the analogues tested, analogues 461 and 444, showed the most promise 
with affinities for the cannabinoid receptors in the low nanomolar range.  From the functional 
assay of inhibition of AC-activity, it was observed that both analogues exhibit very little 
inhibition of AC-activity via CB1Rs, which is consistent with neutral antagonism.  Despite the 
seen antagonistic activity at the CB1Rs, both 461 and 444 produced 40-50% inhibition of AC-
activity via CB2Rs, consistent with partial to full agonism.   
The promising in vitro pharmacological results for these two lead compounds prompted 
further evaluation in in vivo animal assays of alcohol abuse, namely ethanol SA and ethanol 
CPP.  Both analogues 461 and 444 exhibited similar actions to those seen with the CB1Rs 
antagonist rimonabant in that they both were shown to decrease ethanol self-administration, 
without affecting total fluid intake.  However, unlike rimonabant, 461 and 444 did not alter body 
weight during the treatment period.  Both analogues 461 and 444 interestingly decreased ethanol 
CPP in a similar manner to rimonabant, despite not possessing any apparent inverse agonist 
activity in vitro.  In agreement with previous rimonabant reports, these results demonstrate that 
both the reinforcing and conditioning rewarding effects of ethanol can also be significantly 
blunted by treatment with novel JWH-derived cannabinoids, devoid of inverse agonist activity at 
CB1Rs.486  Compounds with dual CB1R neutral antagonist/CB2R agonist activity such as 
analogues 461 and 444 may indeed represent potential leads in an ongoing search for new and 
improved alcohol abuse therapies.   
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 Collectively, these studies emphasize the importance of the continuous search for novel 
CNS active ligands.  The SAR of the furan ring of salvinorin A completed in this study can be 
used as the starting point in further SAR experiments that will allow for greater understating of 
the interaction between salvinorin A and the KOP receptor, as well as for further development of 
the salvinorin A scaffold as an useful biological tool.  Furthermore, the dual activity CB1R 
antagonist/CB2R agonist ligands based on the JWH-073-M4 scaffold have the potential as 
alcohol abuse therapy, whose development is ongoing.   The results from these studies confirm 
the utility and the use of novel scaffolds as CNS active agents. 
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APPENDIX A:  1H NMR SPECTRA 
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